Immune Checkpoint Targeting in Cancer Therapy: Tow
Curative Potential

Cell

161, 205-214

DOI: 10.1016/j.cell.2015.03.030

Citation Report

#	Article	IF	Citations
1	Immune Cell Identity: Perspective from a Palimpsest. Perspectives in Biology and Medicine, 2015, 58, 205-228.	0.3	1
2	Special Review. Cancer Journal (Sudbury, Mass), 2015, 21, 441-447.	1.0	13
3	Tumor neoantigens: building a framework for personalized cancer immunotherapy. Journal of Clinical Investigation, 2015, 125, 3413-3421.	3.9	502
4	Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine. Vaccines, 2015, 3, 490-502.	2.1	43
5	Progress in Adaptive Immunotherapy for Cancer in Companion Animals: Success on the Path to a Cure. Veterinary Sciences, 2015, 2, 363-387.	0.6	24
6	Using MRI to evaluate and predict therapeutic success from depot-based cancer vaccines. Molecular Therapy - Methods and Clinical Development, 2015, 2, 15048.	1.8	7
7	Getting Tumor Dendritic Cells to Engage the Dead. Cancer Cell, 2015, 28, 685-687.	7.7	1
8	Immunotherapy: the next step in the treatment of myeloma. Lancet Haematology,the, 2015, 2, e504-e505.	2.2	2
9	Current and Emerging Perspectives on Immunotherapy for Melanoma. Seminars in Oncology, 2015, 42, S3-S11.	0.8	19
10	Strategies to Target Tumor Immunosuppression. , 2015, , 73-86.		0
11	From Scientific Discovery to Cures: Bright Stars within a Galaxy. Cell, 2015, 163, 21-23.	13.5	38
12	Lung cancer nanomedicine: potentials and pitfalls. Nanomedicine, 2015, 10, 3203-3212.	1.7	53
13	Antiviral Monoclonal Antibodies: Can They Be More Than Simple Neutralizing Agents?. Trends in Microbiology, 2015, 23, 653-665.	3.5	97
14	CD47 blockade as another immune checkpoint therapy for cancer. Nature Medicine, 2015, 21, 1122-1123.	15.2	96
15	Immune Response to Cancer Therapy: Mounting an Effective Antitumor Response and Mechanisms of Resistance. Trends in Cancer, 2015, 1, 66-75.	3.8	101
16	Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?. OncoImmunology, 2015, 4, e1058597.	2.1	62
17	Immune Checkpoint Blockade in Cancer Therapy. JAMA - Journal of the American Medical Association, 2015, 314, 1113.	3.8	75
18	A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy. Journal of the American Chemical Society, 2015, 137, 14854-14857.	6.6	149

#	Article	IF	Citations
19	Immunotherapy Combinations With Checkpoint Inhibitors in Metastatic Melanoma: Current Approaches and Future Directions. Seminars in Oncology, 2015, 42, S12-S19.	0.8	24
20	Immuno-oncology combinations: raising the tail of the survival curve. Cancer Biology and Medicine, 2016, 13, 171-193.	1.4	98
21	Tremelimumab: research and clinical development. OncoTargets and Therapy, 2016, 9, 1767.	1.0	51
22	CD8 T Cellâ€"Independent Antitumor Response and Its Potential for Treatment of Malignant Gliomas. Cancers, 2016, 8, 71.	1.7	8
23	In Vitro Antileukemia Activity of ZSTK474 on K562 and Multidrug Resistant K562/A02 Cells. International Journal of Biological Sciences, 2016, 12, 631-638.	2.6	22
24	Growth and Metastasis of Intraocular Tumors in Aged Mice. , 2016, 57, 2366.		9
25	Improving the clinical impact of biomaterials in cancer immunotherapy. Oncotarget, 2016, 7, 15421-15443.	0.8	56
26	Current State of Immune-Based Therapies for Glioblastoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e132-e139.	1.8	13
27	Regulation of Natural Killer Cell Function by STAT3. Frontiers in Immunology, 2016, 7, 128.	2.2	64
28	Immunogenic FEAT protein circulates in the bloodstream of cancer patients. Journal of Translational Medicine, 2016, 14, 275.	1.8	8
30	Combined Immune Therapy for the Treatment of Visceral Leishmaniasis. PLoS Neglected Tropical Diseases, 2016, 10, e0004415.	1.3	33
31	Immunostimulatory Effects of Melphalan and Usefulness in Adoptive Cell Therapy with Antitumor CD4+ T Cells. Critical Reviews in Immunology, 2016, 36, 179-191.	1.0	23
32	The State of Immune Checkpoint Inhibition in Urothelial Carcinoma. Cancer Journal (Sudbury, Mass), 2016, 22, 96-100.	1.0	5
33	Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies. Immunotherapy, 2016, 8, 809-819.	1.0	44
34	Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas. Immunotherapy, 2016, 8, 907-921.	1.0	20
35	Immune Checkpoint Therapy and the Search for Predictive Biomarkers. Cancer Journal (Sudbury, Mass) Tj ETQq1 1 0.784314 rgBT /Ov	1.0	31
36	IL-8â€"Positive Tumor-Infiltrating Inflammatory Cells Are a Novel Prognostic Marker in Pancreatic Ductal Adenocarcinoma Patients. Pancreas, 2016, 45, 671-678.	0.5	14
37	Computational genomics tools for dissecting tumourâ€"immune cell interactions. Nature Reviews Genetics, 2016, 17, 441-458.	7.7	233

#	Article	IF	Citations
38	The Impact of Established Immunoregulatory Networks on Vaccine Efficacy and the Development of Immunity to Malaria. Journal of Immunology, 2016, 197, 4518-4526.	0.4	23
39	The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer and Metastasis Reviews, 2016, 35, 575-588.	2.7	237
40	The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity. Cell, 2016, 167, 1525-1539.e17.	13.5	318
41	Challenges and opportunitiesÂfor checkpoint blockade in T-cell lymphoproliferative disorders. , 2016, 4, 95.		18
42	Immunomodulatory and Antitumor Effects of a Novel TLR7 Agonist Combined with Lapatinib. Scientific Reports, 2016, 6, 39598.	1.6	6
43	The use of dendritic cell vaccinations in melanoma: where are we now?. Melanoma Management, 2016, 3, 247-250.	0.1	3
44	A Novel PD-L1-targeting Antagonistic DNA Aptamer With Antitumor Effects. Molecular Therapy - Nucleic Acids, 2016, 5, e397.	2.3	114
45	Targeting the Microenvironment in Advanced Colorectal Cancer. Trends in Cancer, 2016, 2, 495-504.	3.8	80
46	Checkpoint inhibition in myeloma. Hematology American Society of Hematology Education Program, 2016, 2016, 528-533.	0.9	10
47	Challenges in the Delivery of Therapies to Melanoma Brain Metastases. Current Pharmacology Reports, 2016, 2, 309-325.	1.5	18
48	Advances in RNAi therapeutic delivery to leukocytes using lipid nanoparticles. Journal of Drug Targeting, 2016, 24, 780-786.	2.1	28
49	Immunological off-target effects of imatinib. Nature Reviews Clinical Oncology, 2016, 13, 431-446.	12.5	120
50	Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. Journal of Hematology and Oncology, 2016, 9, 47.	6.9	271
51	CSF-1Râ€“Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy. Journal of Immunology, 2016, 197, 179-187.	0.4	48
52	Reducing prostaglandin E₂production to raise cancer immunogenicity. OncoImmunology, 2016, 5, e1123370.	2.1	14
53	Microbiome and Anticancer Immunosurveillance. Cell, 2016, 165, 276-287.	13.5	366
54	Cancer Immunotherapy Booster. Cell, 2016, 165, 253-255.	13.5	4
55	Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. Immunity, 2016, 44, 924-938.	6.6	857

#	Article	IF	Citations
56	Revving Up Dendritic Cells while Braking PD-L1 to Jump-Start the Cancer-Immunity Cycle Motor. Immunity, 2016, 44, 722-724.	6.6	10
57	Cancer immunotherapy: the beginning of the end of cancer?. BMC Medicine, 2016, 14, 73.	2.3	908
58	Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumab. Immunotherapy, 2016, 8, 687-692.	1.0	7
59	T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines. Cancer Research, 2016, 76, 3496-3506.	0.4	33
60	Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Nonâ€“small Cell Lung Cancer. Journal of Histochemistry and Cytochemistry, 2016, 64, 587-600.	1.3	30
61	A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment. Journal of Biomedical Science, 2016, 23, 64.	2.6	21
62	Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors. ACS Nano, 2016, 10, 8956-8963.	7.3	275
63	Homing Improvement: Boosting T Cell Trafficking for Cancer Immunotherapy. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 127-161.	0.1	0
64	SHP-1: the next checkpoint target for cancer immunotherapy?. Biochemical Society Transactions, 2016, 44, 356-362.	1.6	60
65	Radiotherapy: Changing the Game in Immunotherapy. Trends in Cancer, 2016, 2, 286-294.	3.8	270
66	Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncology, The, 2016, 17, 1590-1598.	5.1	594
67	Advances in PET Detection of the Antitumor T Cell Response. Advances in Immunology, 2016, 131, 187-231.	1.1	39
68	Emerging roles of p53 and other tumour-suppressor genes in immune regulation. Nature Reviews Immunology, 2016, 16, 741-750.	10.6	262
69	Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors. Cell, 2016, 167, 419-432.e16.	13.5	485
70	Single-cell RNA-seq identifies a PD-1hi ILC progenitor and defines its development pathway. Nature, 2016, 539, 102-106.	13.7	257
71	Mouse models in oncoimmunology. Nature Reviews Cancer, 2016, 16, 759-773.	12.8	267
72	Checkpointâ€Inhibitoren in der Immuntherapie: Ein Meilenstein in der Behandlung des malignen Melanoms. JDDG - Journal of the German Society of Dermatology, 2016, 14, 685-697.	0.4	6
73	Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. OncoImmunology, 2016, 5, e1240859.	2.1	75

#	Article	IF	Citations
74	Combining Immune Checkpoint Inhibitors and Kinase-Inhibiting Supramolecular Therapeutics for Enhanced Anticancer Efficacy. ACS Nano, 2016, 10, 9227-9242.	7.3	36
75	Heterodinuclear Pt(‹scp›iv‹/scp›)â€“Ru(‹scp›ii‹/scp›) anticancer prodrugs to combat both drug resistance and tumor metastasis. Chemical Communications, 2016, 52, 10735-10738.	2.2	70
76	Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors. JAMA Oncology, 2016, 2, 1490.	3.4	68
77	Fundamentally low reproducibility in molecular genetic cancer research. Russian Journal of Genetics, 2016, 52, 650-663.	0.2	5
78	Immunotherapy to Treat Cancer. Clinical Pharmacology and Therapeutics, 2016, 100, 198-203.	2.3	13
79	PDâ€1 Pathway Inhibitors: Immunoâ€Oncology Agents for Restoring Antitumor Immune Responses. Pharmacotherapy, 2016, 36, 317-334.	1.2	82
80	Converting monoclonal antibody-based immunotherapies from passive to active: bringing immune complexes into play. Emerging Microbes and Infections, 2016, 5, 1-9.	3.0	36
82	Defects in T Cell Trafficking and Resistance to Cancer Immunotherapy. Resistance To Targeted Anti-cancer Therapeutics, 2016, , .	0.1	2
83	Methods to Evaluate the Antitumor Activity of Immune Checkpoint Inhibitors in Preclinical Studies. Methods in Molecular Biology, 2016, 1458, 159-177.	0.4	7
84	Targeted Programming of the Lymph Node Environment Causes Evolution of Local and Systemic Immunity. Cellular and Molecular Bioengineering, 2016, 9, 418-432.	1.0	13
85	Inflammationâ€Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Antiâ€PD1 Antibody. Advanced Materials, 2016, 28, 8912-8920.	11.1	286
86	Regulation of neutrophil functions through inhibitory receptors: an emerging paradigm in health and disease. Immunological Reviews, 2016, 273, 140-155.	2.8	62
87	The broken â€œOffâ€•switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance. BBA Clinical, 2016, 6, 87-99.	4.1	133
88	Towards precision medicine. Nature Reviews Genetics, 2016, 17, 507-522.	7.7	651
89	Critical care of patients with cancer. Ca-A Cancer Journal for Clinicians, 2016, 66, 496-517.	157.7	102
90	Looking beyond the cancer cell for effective drug combinations. Genome Medicine, 2016, 8, 125.	3.6	31
91	Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells. Immunity, 2016, 45, 1135-1147.	6.6	510
92	Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cellâ€Rich Tumor. Cancer Research, 2016, 76, 6266-6277.	0.4	74

#	Article	IF	Citations
93	Disruption of Anti-tumor T Cell Responses by Cancer-Associated Fibroblasts. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 77-98.	0.1	1
94	Targeting the cancer epigenome for therapy. Nature Reviews Genetics, 2016, 17, 630-641.	7.7	888
95	Loss of IFN-Î³ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell, 2016, 167, 397-404.e9.	13.5	1,009
96	Presurgical window of opportunity trial design as a platform for testing anticancer drugs: Pros, cons and a focus on breast cancer. Critical Reviews in Oncology/Hematology, 2016, 106, 132-142.	2.0	9
97	Autophagy, Inflammation, and Immunity: A Troika Governing Cancer and Its Treatment. Cell, 2016, 166, 288-298.	13.5	508
98	HDAC inhibitors with PD-1 blockade: a promising strategy for treatment of multiple cancer types?. Epigenomics, 2016, 8, 1015-1017.	1.0	22
99	IL-2, IL-7, and IL-15: Multistage regulators of CD4+ T helper cell differentiation. Experimental Hematology, 2016, 44, 799-808.	0.2	57
100	Immune checkpoint inhibitors: a milestone in the treatment of melanoma. JDDG - Journal of the German Society of Dermatology, 2016, 14, 685-695.	0.4	15
101	Human Î³Î´ T cells: From a neglected lymphocyte population to cellular immunotherapy: A personal reflection of 30years of Î³Î´ T cell research. Clinical Immunology, 2016, 172, 90-97.	1.4	17
102	Recent advances in the preparation and application of multifunctional iron oxide and liposome-based nanosystems for multimodal diagnosis and therapy. Interface Focus, 2016, 6, 20160055.	1.5	26
103	Emerging role of immunotherapy in urothelial carcinomaâ€"Immunobiology/biomarkers. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 556-565.	0.8	23
104	Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells. Journal of Hematology and Oncology, 2016, 9, 101.	6.9	96
105	Bypassing STAT3-mediated inhibition of the transcriptional regulator ID2 improves the antitumor efficacy of dendritic cells. Science Signaling, 2016, 9, ra94.	1.6	18
106	Cell-Intrinsic Barriers of T Cell-Based Immunotherapy. Trends in Molecular Medicine, 2016, 22, 1000-1011.	3.5	60
107	Progress in Cancer Immunotherapy. Advances in Experimental Medicine and Biology, 2016, , .	0.8	6
108	Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. Immunity, 2016, 44, 1255-1269.	6.6	797
109	Driving CARs into Sweet Roads: Targeting Glycosylated Antigens in Cancer. Immunity, 2016, 44, 1248-1250.	6.6	9
110	Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies. British Journal of Cancer, 2016, 115, 145-155.	2.9	50

#	Article	IF	Citations
111	Molecular assessment of disease states in kidney transplant biopsy samples. Nature Reviews Nephrology, 2016, 12, 534-548.	4.1	129
112	Cell population heterogeneity and evolution towards drug resistance in cancer: Biological and mathematical assessment, theoretical treatment optimisation. Biochimica Et Biophysica Acta - General Subjects, 2016, 1860, 2627-2645.	1.1	69
113	Adoptive Cellular Therapy (ACT) for Cancer Treatment. Advances in Experimental Medicine and Biology, 2016, 909, 169-239.	0.8	14
114	Immune Checkpoint inhibitors: An introduction to the nextâ€generation cancer immunotherapy. Journal of Clinical Pharmacology, 2016, 56, 157-169.	1.0	102
115	Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer. OncoImmunology, 2016, 5, e1139275.	2.1	21
116	Anticancer metal drugs and immunogenic cell death. Journal of Inorganic Biochemistry, 2016, 165, 71-79.	1.5	107
117	Cancer immunoprevention. Current Opinion in Immunology, 2016, 39, 52-58.	2.4	50
118	Metastatic colonization by circulating tumour cells. Nature, 2016, 529, 298-306.	13.7	1,498
119	Adeno-associated virus (AAV) vectors in cancer gene therapy. Journal of Controlled Release, 2016, 240, 287-301.	4.8	137
120	Regulation of Immunity by Butyrophilins. Annual Review of Immunology, 2016, 34, 151-172.	9.5	129
121	Re-examining the Nature and Function of Self-Reactive T cells. Trends in Immunology, 2016, 37, 114-125.	2.9	68
122	Inhibitory leukocyte immunoglobulin-like receptors: Immune checkpoint proteins and tumor sustaining factors. Cell Cycle, 2016, 15, 25-40.	1.3	150
123	Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody. Nano Letters, 2016, 16, 2334-2340.	4.5	609
124	Cancer vaccines for hepatocellular carcinoma: future directions. Immunotherapy, 2016, 8, 391-393.	1.0	3
125	Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell, 2016, 165, 35-44.	13.5	2,437
126	Combining Epigenetic and Immunotherapy to Combat Cancer. Cancer Research, 2016, 76, 1683-1689.	0.4	251
127	The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. Advances in Immunology, 2016, 130, 25-74.	1.1	181
128	Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer. Lung Cancer, 2016, 93, 59-68.	0.9	103

#	Article	IF	Citations
129	Genetics and biology of pancreatic ductal adenocarcinoma. Genes and Development, 2016, 30, 355-385.	2.7	416
130	Plasma cells in primary melanoma. Prognostic significance and possible role of IgA. Modern Pathology, 2016, 29, 347-358.	2.9	43
131	Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints. Targeted Oncology, 2016, 11, 469-477.	1.7	34
132	Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer. Molecular Diagnosis and Therapy, 2016, 20, 175-181.	1.6	30
133	Biomaterials for enhancing anti-cancer immunity. Current Opinion in Biotechnology, 2016, 40, 1-8.	3.3	115
134	Autologous Tumor Cell Lysate-Loaded Dendritic Cell Vaccine Inhibited Tumor Progression in an Orthotopic Murine Model for Hepatocellular Carcinoma. Annals of Surgical Oncology, 2016, 23, 574-582.	0.7	13
136	Combinatorial immunotherapy strategies for hepatocellular carcinoma. Current Opinion in Immunology, 2016, 39, 103-113.	2.4	52
137	Tumor Immunology. , 2016, , 329-339.		1
138	The Future of Immunology. , 2016, , 365-371.		0
139	Anti-CD137 monoclonal antibodies and adoptive T cell therapy: a perfect marriage?. Cancer Immunology, Immunotherapy, 2016, 65, 493-497.	2.0	15
140	AIRE expands: new roles in immune tolerance and beyond. Nature Reviews Immunology, 2016, 16, 247-258.	10.6	220
141	Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Antiâ€“PD-1 and Anti-CD137 Monoclonal Antibodies. Journal of Thoracic Oncology, 2016, 11, 524-536.	0.5	48
142	Development of immuno-oncology drugs â€” from CTLA4 to PD1 to the next generations. Nature Reviews Drug Discovery, 2016, 15, 235-247.	21.5	503
143	Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy. OncoImmunology, 2016, 5, e1149673.	2.1	136
144	MYC regulates the antitumor immune response through CD47 and PD-L1. Science, 2016, 352, 227-231.	6.0	989
145	Trial Watchâ€”Small molecules targeting the immunological tumor microenvironment for cancer therapy. OncoImmunology, 2016, 5, e1149674.	2.1	46
146	HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma. Clinical Cancer Research, 2016, 22, 4119-4132.	3.2	266
147	Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation. Journal of Controlled Release, 2016, 231, 17-28.	4.8	171

#	Article	IF	Citations
148	Introduction to tumor microenvironment regulation of cancer cell survival, metastasis, inflammation, and immune surveillance. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 379-381.	1.9	27
149	Primary analysis for clinical efficacy of immunotherapy in patients with pancreatic cancer. Immunotherapy, 2016, 8, 223-234.	1.0	13
150	Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins. Leukemia and Lymphoma, 2016, 57, 537-556.	0.6	17
151	Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant. Leukemia, 2017, 31, 177-185.	3.3	40
152	Elements of cancer immunity and the cancerâ€“immune set point. Nature, 2017, 541, 321-330.	13.7	3,558
153	Chronic lymphocytic leukaemia. Nature Reviews Disease Primers, 2017, 3, 16096.	18.1	363
154	Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science, 2017, 355, .	6.0	988
155	Tâ€cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer. Molecular Oncology, 2017, 11, 235-247.	2.1	65
156	Repurposing Antiestrogens for Tumor Immunotherapy. Cancer Discovery, 2017, 7, 17-19.	7.7	19
157	Management of Prostate Cancer. , 2017, , .		5
158	Targeting the Lung Cancer Microenvironment: Harnessing Host Responses. , 2017, , 309-327.		1
159	Host controls of <scp>HIV</scp> broadly neutralizing antibody development. Immunological Reviews, 2017, 275, 79-88.	2.8	65
160	Novel immune check point inhibiting antibodies in cancer therapyâ€”Opportunities and challenges. Drug Resistance Updates, 2017, 30, 39-47.	6.5	98
161	Review: Immuneâ€Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer. Arthritis and Rheumatology, 2017, 69, 687-699.	2.9	101
162	Galectins: emerging regulatory checkpoints linking tumor immunity and angiogenesis. Current Opinion in Immunology, 2017, 45, 8-15.	2.4	141
163	Radiation-Induced Enhancement of Antitumor T-cell Immunity by VEGF-Targeted 4-1BB Costimulation. Cancer Research, 2017, 77, 1310-1321.	0.4	32
164	Synergistic effects of host B7-H4 deficiency and gemcitabine treatment on tumor regression and anti-tumor T cell immunity in a mouse model. Cancer Immunology, Immunotherapy, 2017, 66, 491-502.	2.0	7
165	PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective. Journal of Hematology and Oncology, 2017, 10, 34.	6.9	82

#	Article	IF	Citations
166	The impact of melanoma genetics on treatment response and resistance in clinical and experimental studies. Cancer and Metastasis Reviews, 2017, 36, 53-75.	2.7	30
167	Dendritic cell rehab: new strategies to unleash therapeutic immunity in ovarian cancer. Cancer Immunology, Immunotherapy, 2017, 66, 969-977.	2.0	22
168	Editorial overview: Viral immunology: Dealing with bad news. Current Opinion in Virology, 2017, 22, viii-x.	2.6	0
169	Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy. EBioMedicine, 2017, 17, 30-44.	2.7	52
170	Phosphinophosphonates and Their Tris-pivaloyloxymethyl Prodrugs Reveal a Negatively Cooperative Butyrophilin Activation Mechanism. Journal of Medicinal Chemistry, 2017, 60, 2373-2382.	2.9	28
171	Neutrophil-to-lymphocyte ratio as an independent predictor for survival in patients with localized clear cell renal cell carcinoma after radiofrequency ablation: a propensity score matching analysis. International Urology and Nephrology, 2017, 49, 967-974.	0.6	16
172	Calciumâ€“NFAT transcriptional signalling in T cell activation and T cell exhaustion. Cell Calcium, 2017, 63, 66-69.	1.1	119
173	Emerging Biological Principles of Metastasis. Cell, 2017, 168, 670-691.	13.5	2,208
174	Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell, 2017, 168, 707-723.	13.5	3,483
175	Interplay between Immune Checkpoint Proteins and Cellular Metabolism. Cancer Research, 2017, 77, 1245-1249.	0.4	82
176	Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer. Breast Cancer Research and Treatment, 2017, 163, 255-262.	1.1	3
177	Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model. Molecular Imaging and Biology, 2017, 19, 903-914.	1.3	91
178	HLA-A24 ligandome analysis of colon and lung cancer cells identifies a novel cancer-testis antigen and a neoantigen that elicits specific and strong CTL responses. OncoImmunology, 2017, 6, e1293214.	2.1	23
179	The expanding role of immunotherapy. Cancer Treatment Reviews, 2017, 54, 74-86.	3.4	100
180	Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma. Nature Communications, 2017, 8, .	5.8	103
181	Exploiting the p53 Pathway for Therapy. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a026310.	2.9	41
182	Exploiting tumor-associated dendritic cell heterogeneity for novel cancer therapies. Journal of Leukocyte Biology, 2017, 102, 317-324.	1.5	32
183	T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature, 2017, 545, 60-65.	13.7	1,280

#	Article	IF	Citations
184	Resistance to immunotherapy: clouds in a bright sky. Investigational New Drugs, 2017, 35, 649-654.	1.2	8
185	Combined antiangiogenic and antiâ€“PD-L1 therapy stimulates tumor immunity through HEV formation. Science Translational Medicine, 2017, 9, .	5.8	541
186	Nanotechnology based therapeutic modality to boost anti-tumor immunity and collapse tumor defense. Journal of Controlled Release, 2017, 256, 26-45.	4.8	41
187	Global survey of the immunomodulatory potential of common drugs. Nature Chemical Biology, 2017, 13, 681-690.	3.9	53
188	Mind the immuno-connection gap. Nature Chemical Biology, 2017, 13, 572-573.	3.9	0
189	A STING-activating nanovaccine for cancer immunotherapy. Nature Nanotechnology, 2017, 12, 648-654.	15.6	649
190	Novel immune checkpoint blocker to treat Merkel cell carcinoma. OncoImmunology, 2017, 6, e1315496.	2.1	1
192	Phenformin Inhibits Myeloid-Derived Suppressor Cells and Enhances theÂAnti-Tumor Activity of PD-1 Blockade inÂMelanoma. Journal of Investigative Dermatology, 2017, 137, 1740-1748.	0.3	107
193	SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin. Nature, 2017, 544, 493-497.	13.7	188
194	CD47 receptor as a primary target for cancer therapy. Molecular Biology, 2017, 51, 216-225.	0.4	9
195	Platelets subvert T cell immunity against cancer via GARP-TGFÎ² axis. Science Immunology, 2017, 2, .	5.6	237
196	YAP-1 Promotes Tregs Differentiation in Hepatocellular Carcinoma by Enhancing TGFBR2 Transcription. Cellular Physiology and Biochemistry, 2017, 41, 1189-1198.	1.1	43
197	Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future. Immunotherapy, 2017, 9, 507-520.	1.0	12
198	In silico polypharmacology of natural products. Briefings in Bioinformatics, 2018, 19, 1153-1171.	3.2	95
199	Mutation patterns in genes encoding interferon signaling and antigen presentation: A panâ€cancer survey with implications for the use of immune checkpoint inhibitors. Genes Chromosomes and Cancer, 2017, 56, 651-659.	1.5	35
200	Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses. Journal of Experimental Medicine, 2017, 214, 1679-1690.	4.2	41
201	FKBP51s signature in peripheral blood mononuclear cells of melanoma patients as a possible predictive factor for immunotherapy. Cancer Immunology, Immunotherapy, 2017, 66, 1143-1151.	2.0	12
202	Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities. Annual Review of Immunology, 2017, 35, 229-253.	9.5	96

#	Article	IF	Citations
203	Landscape of Combination Immunotherapy and Targeted Therapy to Improve Cancer Management. Cancer Research, 2017, 77, 3666-3671.	0.4	93
204	Immunotherapy for the treatment of breast cancer. Expert Opinion on Biological Therapy, 2017, 17, 797-812.	1.4	12
205	Tumor Static Concentration Curves in Combination Therapy. AAPS Journal, 2017, 19, 456-467.	2.2	15
206	Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast Cancer. Journal of Biological Chemistry, 2017, 292, 748-759.	1.6	28
207	Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing. Cell, 2017, 169, 1342-1356.e16.	13.5	1,540
208	Cancer therapies in HIV cure research. Current Opinion in HIV and AIDS, 2017, 12, 96-104.	1.5	19
210	Combinatorial immunotherapy and nanoparticle mediated hyperthermia. Advanced Drug Delivery Reviews, 2017, 114, 175-183.	6.6	91
211	Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer. Nature Immunology, 2017, 18, 940-950.	7.0	407
212	Molecular Communication and Nanonetwork for Targeted Drug Delivery: A Survey. IEEE Communications Surveys and Tutorials, 2017, 19, 3046-3096.	24.8	127
213	Immunotherapeutic approaches of IL-1 neutralization in the tumor microenvironment. Journal of Leukocyte Biology, 2017, 102, 293-306.	1.5	40
214	The multiple pathways to autoimmunity. Nature Immunology, 2017, 18, 716-724.	7.0	429
215	De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation. Cell, 2017, 170, 142-157.e19.	13.5	536
216	Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook. Advanced Materials, 2017, 29, 1606036.	11.1	220
217	Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, N-glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma. Molecular and Cellular Proteomics, 2017, 16, 1705-1717.	2.5	56
218	A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy. Cell Reports, 2017, 19, 1874-1887.	2.9	104
219	Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition. Molecular and Cellular Endocrinology, 2017, 451, 1-14.	1.6	228
220	Tumor-derived factors affecting immune cells. Cytokine and Growth Factor Reviews, 2017, 36, 79-87.	3.2	25
221	Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1. Journal of Medicinal Chemistry, 2017, 60, 5857-5867.	2.9	242

#	Article	IF	Citations
222	Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature, 2017, 544, 250-254.	13.7	555
223	Immune Therapy for Sarcomas. Advances in Experimental Medicine and Biology, 2017, 995, 127-140.	0.8	9
224	Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment. International Immunopharmacology, 2017, 46, 210-219.	1.7	102
225	VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nature Medicine, 2017, 23, 551-555.	15.2	467
226	An Anti-Programmed Death-1 Antibody (Î±PD-1) Fusion Protein That Self-Assembles into a Multivalent and Functional Iâ±PD-1 Nanoparticle. Molecular Pharmaceutics, 2017, 14, 1494-1500.	2.3	26
227	Immunotherapy for gastric cancers: emerging role and future perspectives. Expert Review of Clinical Pharmacology, 2017, 10, 609-619.	1.3	33
228	Antibodies and associates: Partners in targeted drug delivery. , 2017, 177, 129-145.		52
229	Molecular dynamics simulations elucidate conformational selection and induced fit mechanisms in the binding of PD-1 and PD-L1. Molecular BioSystems, 2017, 13, 892-900.	2.9	35
230	Recent advances in genitourinary tumors: A review focused on biology and systemic treatment. Critical Reviews in Oncology/Hematology, 2017, 113, 171-190.	2.0	22
231	The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. Journal of Hepatology, 2017, 67, 173-183.	1.8	165
233	Ex Vivo Engineering of the Tumor Microenvironment. Cancer Drug Discovery and Development, 2017, , .	0.2	4
234	Microfluidics and Future of Cancer Diagnostics. Cancer Drug Discovery and Development, 2017, , 55-70.	0.2	1
235	The synergy between ionizing radiation and immunotherapy in the treatment of prostate cancer. Immunotherapy, 2017, 9, 1005-1018.	1.0	2
236	Future cancer research priorities in the USA: a Lancet Oncology Commission. Lancet Oncology, The, 2017, 18, e653-e706.	5.1	153
237	Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer. Molecular Therapy, 2017, 25, 2440-2451.	3.7	151
238	Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics. OncoImmunology, 2017, 6, e1386829.	2.1	209
239	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2017, 390, 2461-2471.	6.3	1,749
240	Hypothesis: stimulation of trained immunity as adjunctive immunotherapy in cancer. Journal of Leukocyte Biology, 2017, 102, 1323-1332.	1.5	35

#	Article	IF	Citations
241	Immunotherapy for Breast Cancer: Current and Future Strategies. Current Surgery Reports, 2017, 5, 1.	0.4	31
242	Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance. Immunological Reviews, 2017, 280, 165-174.	2.8	82
243	Prolonged IKKÎ² Inhibition Improves Ongoing CTL Antitumor Responses by Incapacitating Regulatory T Cells. Cell Reports, 2017, 21, 578-586.	2.9	22
244	The efficacy of Apaziquone in the treatment of bladder cancer. Expert Opinion on Pharmacotherapy, 2017, 18, 1781-1788.	0.9	12
245	Nanotechnology for Multimodal Synergistic Cancer Therapy. Chemical Reviews, 2017, 117, 13566-13638.	23.0	1,392
246	A Synthetic CD8Î±:MyD88 Coreceptor Enhances CD8+ T-cell Responses to Weakly Immunogenic and Lowly Expressed Tumor Antigens. Cancer Research, 2017, 77, 7049-7058.	0.4	10
247	Avelumab and other recent advances in Merkel cell carcinoma. Future Oncology, 2017, 13, 2771-2783.	1.1	11
248	Cutting Edge: Antiâ€“TIM-3 Treatment Exacerbates Pulmonary Inflammation and Fibrosis in Mice. Journal of Immunology, 2017, 199, 3733-3737.	0.4	21
249	Insights into immune tolerance from AIRE deficiency. Current Opinion in Immunology, 2017, 49, 71-78.	2.4	52
250	A bifunctional nanomodulator for boosting CpG-mediated cancer immunotherapy. Nanoscale, 2017, 9, 14236-14247.	2.8	48
251	Prospects and progress of immunotherapy for bladder cancer. Expert Opinion on Biological Therapy, 2017, 17, 1-15.	1.4	29
252	PD-1/PD-L1 and immunotherapy for pancreatic cancer. Cancer Letters, 2017, 407, 57-65.	3.2	235
253	The potential and promise of IL-15 in immuno-oncogenic therapies. Immunology Letters, 2017, 190, 159-168.	1.1	152
254	Learning the Roles of the Hepatic Adaptive Immune System in Hepatocellular Carcinomaâ€”Nature's Guide for Successful Cancer Immunotherapy. Seminars in Liver Disease, 2017, 37, 210-218.	1.8	3
255	PML degradation fosters an immunosuppressive and pro-metastatic tumor microenvironment. Molecular and Cellular Oncology, 2017, 4, e1364212.	0.3	2
256	Immunology of Solid Tumors Beyond Tumor-Infiltrating Lymphocytes: The Role of Tertiary Lymphoid Structures. , 2017, , 259-280.		0
257	Prognostic value of tumor PD-L1 expression combined with CD8 + tumor infiltrating lymphocytes in high grade serous ovarian cancer. International Immunopharmacology, 2017, 52, 7-14.	1.7	68
258	Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications. OncoImmunology, 2017, 6, e1371896.	2.1	36

#	Article	IF	Citations
259	Trial watch: Immune checkpoint blockers for cancer therapy. OncoImmunology, 2017, 6, e1373237.	2.1	62
260	Nanomaterials for cancer immunotherapy. Biomaterials, 2017, 148, 16-30.	5.7	226
261	Bacterial outer membrane vesicles suppress tumor by interferon-Î³-mediated antitumor response. Nature Communications, 2017, 8, 626.	5.8	329
262	Two faces of Hippo. Anti-Cancer Drugs, 2017, 28, 1079-1085.	0.7	13
263	Gene Modified T Cell Therapies for Hematological Malignancies. Hematology/Oncology Clinics of North America, 2017, 31, 913-926.	0.9	4
264	Two is better than one: advances in pathogen-boosted immunotherapy and adoptive T-cell therapy. Immunotherapy, 2017, 9, 837-849.	1.0	1
265	A CTLA-4 Antagonizing DNA Aptamer with Antitumor Effect. Molecular Therapy - Nucleic Acids, 2017, 8, 520-528.	2.3	46
266	Contrasting effects of cyclophosphamide on antiâ€<scp>CTL</scp>â€associated protein 4 blockade therapy in two mouse tumor models. Cancer Science, 2017, 108, 1974-1984.	1.7	35
267	NF-ÎºB c-Rel Is Crucial for the Regulatory T Cell Immune Checkpoint in Cancer. Cell, 2017, 170, 1096-1108.e13.	13.5	222
268	Nutrition, inflammation and cancer. Nature Immunology, 2017, 18, 843-850.	7.0	313
269	The immune contexture in cancer prognosis and treatment. Nature Reviews Clinical Oncology, 2017, 14, 717-734.	12.5	1,590
270	pH-Responsive prodrug nanoparticles based on a sodium alginate derivative for selective co-release of doxorubicin and curcumin into tumor cells. Nanoscale, 2017, 9, 12533-12542.	2.8	102
271	Evasion of immunosurveillance by genomic alterations of PPARÎ³/RXRÎ± in bladder cancer. Nature Communications, 2017, 8, 103.	5.8	107
272	Blinatumomab bridges the gap between leukemia and immunity. OncoImmunology, 2017, 6, e1358335.	2.1	5
273	Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade. Cancer Cell, 2017, 32, 253-267.e5.	7.7	430
274	CD103⁺ cells at the forefront of anticancer immunity. OncoImmunology, 2017, 6, e1356154.	2.1	3
275	Cancer Chemoprevention: What Have we Learned?. Current Pharmacology Reports, 2017, 3, 409-422.	1.5	1
276	Trial watch: DNA-based vaccines for oncological indications. OncoImmunology, 2017, 6, e1398878.	2.1	30

#	Article	IF	Citations
277	Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives. Nature Reviews Neurology, 2017, 13, 755-763.	4.9	139
278	Cardiotoxicity of immune checkpoint inhibitors. ESMO Open, 2017, 2, e000247.	2.0	186
279	CD4+ T Cell and NK Cell Interplay Key to Regression of MHC Class Ilow Tumors upon TLR7/8 Agonist Therapy. Cancer Immunology Research, 2017, 5, 642-653.	1.6	37
280	Expression and Clinical Significance of Herpes Virus Entry Mediator (HVEM) in Breast Cancer. Annals of Surgical Oncology, 2017, 24, 4042-4050.	0.7	30
281	Molecular Dissection of CD8 + T-Cell Dysfunction. Trends in Immunology, 2017, 38, 567-576.	2.9	51
282	Ebola Virus Disease in Humans: Pathophysiology and Immunity. Current Topics in Microbiology and Immunology, 2017, 411, 141-169.	0.7	31
283	Soluble NKG2D ligands limit the efficacy of immune checkpoint blockade. OncoImmunology, 2017, 6, e1346766.	2.1	21
284	Exercise protects from cancer through regulation of immune function and inflammation. Biochemical Society Transactions, 2017, 45, 905-911.	1.6	105
285	Goals and objectives of the Italian Network for Tumor Biotherapy (NIBIT). Cytokine and Growth Factor Reviews, 2017, 36, 1-3.	3.2	1
286	Immunotherapy-based combinations: current status and perspectives. Current Opinion in Oncology, 2017, 29, 382-394.	1.1	7
287	Checkpoint inhibition for advanced mucosal melanoma. European Journal of Dermatology, 2017, 27, 160-165.	0.3	17
288	Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy. Clinical Epigenetics, 2017, 9, 59.	1.8	118
289	Tissue-resident lymphocytes: sentinel of the transformed tissue. , 2017, 5, 41.		15
290	Immune therapy in colorectal cancer. Colorectal Cancer, 2017, 6, 1-10.	0.8	3
291	Genomes of early onset prostate cancer. Current Opinion in Urology, 2017, 27, 481-487.	0.9	9
293	Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy. Nature Reviews Clinical Oncology, 2017, 14, 247-258.	12.5	261
294	Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC). Seminars in Cancer Biology, 2017, 45, 36-49.	4.3	11
295	Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy. Journal of Pathology, 2017, 241, 10-24.	2.1	55

#	Article	IF	Citations
296	DPP8 and DPP9 inhibition induces pro-caspase-1-dependent monocyte and macrophage pyroptosis. Nature Chemical Biology, 2017, 13, 46-53.	3.9	208
297	Thermal and mechanical high-intensity focused ultrasound: perspectives on tumor ablation, immune effects and combination strategies. Cancer Immunology, Immunotherapy, 2017, 66, 247-258.	2.0	186
298	CD137â€CRDI is not necessary in the role of contacting its natural ligand. Immunology and Cell Biology, 2017, 95, 24-32.	1.0	4
299	PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia, 2017, 31, 697-704.	3.3	90
300	Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation. Cancer Immunology, Immunotherapy, 2017, 66, 1-7.	2.0	33
301	Immune and inflammatory responses to DNA damage in cancer and aging. Mechanisms of Ageing and Development, 2017, 165, 10-16.	2.2	32
302	Personalized cancer vaccines: Targeting the cancer mutanome. Vaccine, 2017, 35, 1094-1100.	1.7	63
303	Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer. Expert Review of Clinical Pharmacology, 2017, 10, 31-38.	1.3	23
304	Regulatory T Cells. , 2017, , 1377-1422.		0
305	Immune Checkpoint Blockade in Breast Cancer Therapy. Advances in Experimental Medicine and Biology, 2017, 1026, 383-402.	0.8	24
306	Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update. Oncology, 2017, 93, 147-159.	0.9	83
307	Targeting sialic acidâ€“Siglec interactions to reverse immune suppression in cancer. Glycobiology, 2018, 28, 640-647.	1.3	115
308	Informatics for cancer immunotherapy. Annals of Oncology, 2017, 28, xii56-xii73.	0.6	19
309	Marburg- and Ebolaviruses. Current Topics in Microbiology and Immunology, 2017, , .	0.7	4
310	Bioinformatics Approaches to Profile the Tumor Microenvironment for Immunotherapeutic Discovery. Current Pharmaceutical Design, 2017, 23, 4716-4725.	0.9	11
314	Tumor Microenvironment and Metabolism. International Journal of Molecular Sciences, 2017, 18, 2729.	1.8	35
315	Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality. International Journal of Molecular Sciences, 2017, 18, 2291.	1.8	40
316	Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies. Frontiers in Cell and Developmental Biology, 2017, 5, 101.	1.8	65

#	Article	IF	Citations
317	PD-L1 Promotes Self-Renewal and Tumorigenicity of Malignant Melanoma Initiating Cells. BioMed Research International, 2017, 2017, 1-8.	0.9	13
318	Are Mast Cells MASTers in Cancer?. Frontiers in Immunology, 2017, 8, 424.	2.2	243
319	Two Distinct Myeloid Subsets at the Term Human Fetalâ€“Maternal Interface. Frontiers in Immunology, 2017, 8, 1357.	2.2	12
320	Toll-Like Receptor 3 Signal in Dendritic Cells Benefits Cancer Immunotherapy. Frontiers in Immunology, 2017, 8, 1897.	2.2	55
321	Humanized Immunoglobulin Mice. Advances in Immunology, 2017, 134, 235-352.	1.1	14
322	Immunotherapy as a Promising Treatment for Prostate Cancer: A Systematic Review. Journal of Immunology Research, 2017, 2017, 1-6.	0.9	45
323	Identification of new MUC1 epitopes using HLA-transgenic animals: implication for immunomonitoring. Journal of Translational Medicine, 2017, 15, 154.	1.8	4
324	Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients. Biomarker Research, 2017, 5, 32.	2.8	33
325	PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed. Oncotarget, 2017, 8, 66293-66304.	0.8	11
326	Mesenchymal traits at the convergence of tumor-intrinsic and -extrinsic mechanisms of resistance to immune checkpoint blockers. Emerging Topics in Life Sciences, 2017, 1, 471-486.	1.1	5
327	Immune Checkpoint Blockade and Adaptive Immune Resistance in Cancer. , 0, , .		3
328	Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells. Oncotarget, 2017, 8, 72167-72181.	0.8	221
329	First-line treatment of metastatic melanoma: role of nivolumab. ImmunoTargets and Therapy, 2017, Volume 6, 1-10.	2.7	26
330	Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma. JCI Insight, 2017, 2, .	2.3	257
331	Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of Nivolumab. Journal of Blood Medicine, 2017, Volume 8, 41-54.	0.7	5
332	The large tumor suppressor family: friend or foe?. Journal of Thoracic Disease, 2017, 9, 1748-1751.	0.6	3
333	In situ formed reactive oxygen speciesâ€“responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy. Science Translational Medicine, 2018, 10, .	5.8	439
334	Immune landscape of papillary thyroid cancer and immunotherapeutic implications. Endocrine-Related Cancer, 2018, 25, 523-531.	1.6	74

#	Article	IF	Citations
335	Cancer-associated fibroblasts induce antigen-specific deletion of CD8 + T Cells to protect tumour cells. Nature Communications, 2018, 9, 948.	5.8	369
336	The autophagic network and cancer. Nature Cell Biology, 2018, 20, 243-251.	4.6	233
337	Necroptotic cancer cells-mimicry nanovaccine boosts anti-tumor immunity with tailored immune-stimulatory modality. Biomaterials, 2018, 164, 80-97.	5.7	78
338	Considerations for Developing Targeted Therapies in Lowâ€Frequency Molecular Subsets of a Disease. Clinical Pharmacology and Therapeutics, 2018, 104, 282-289.	2.3	12
339	Combination Cancer Immunotherapy in Hepatocellular Carcinoma. Liver Cancer, 2018, 7, 20-27.	4.2	55
340	Heating it up: Oncolytic viruses make tumors â€˜hotâ€™ and suitable for checkpoint blockade immunotherapies. OncoImmunology, 2018, 7, e1442169.	2.1	85
341	The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models. Cancer Immunology, Immunotherapy, 2018, 67, 815-824.	2.0	42
342	The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies. Annals of Surgical Oncology, 2018, 25, 1814-1827.	0.7	45
343	Data-DrivenÂMethods for Advancing Precision Oncology. Current Pharmacology Reports, 2018, 4, 145-156.	1.5	6
344	Design and synthesis of triple inhibitors of janus kinase (JAK), histone deacetylase (HDAC) and Heat Shock Protein 90 (HSP90). Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1357-1362.	1.0	21
345	CTGF/VEGFA-activated Fibroblasts Promote Tumor Migration Through Micro-environmental Modulation. Molecular and Cellular Proteomics, 2018, 17, 1502-1514.	2.5	12
346	Combination Therapy and the Evolution of Resistance: The Theoretical Merits of Synergism and Antagonism in Cancer. Cancer Research, 2018, 78, 2419-2431.	0.4	58
347	NFATc1 Promotes Antitumoral Effector Functions and Memory CD8+ T-cell Differentiation during Nonâ€“Small Cell Lung Cancer Development. Cancer Research, 2018, 78, 3619-3633.	0.4	37
348	Immunotherapy for Glioblastoma: Playing Chess, Not Checkers. Clinical Cancer Research, 2018, 24, 4059-4061.	3.2	14
349	Emerging roles of Hippo signaling in inflammation and YAP-driven tumor immunity. Cancer Letters, 2018, 426, 73-79.	3.2	29
350	miR-216a-5p acts as an oncogene in renal cell carcinoma. Experimental and Therapeutic Medicine, 2018, 15, 4039-4046.	0.8	18
351	Precision medicine based on surgical oncology in the era of genomeâ€scale analysis and genome editing technology. Annals of Gastroenterological Surgery, 2018, 2, 106-115.	1.2	5
352	Quercetin: A functional dietary flavonoid with potential chemoâ€preventive properties in colorectal cancer. Journal of Cellular Physiology, 2018, 233, 6544-6560.	2.0	135

#	Article	IF	Citations
353	Targeting Wnt/Î²-Catenin Signaling for Cancer Immunotherapy. Trends in Pharmacological Sciences, 2018, 39, 648-658.	4.0	159
354	Next generation antibody drugs: pursuit of the 'high-hanging fruit'. Nature Reviews Drug Discovery, 2018, 17, 197-223.	21.5	595
355	Tissueâ€resident memory T cells in tissue homeostasis, persistent infection, and cancer surveillance. Immunological Reviews, 2018, 283, 54-76.	2.8	142
356	A new era of proactive melanoma therapy: hit hard, hit early. British Journal of Dermatology, 2018, 178, 817-820.	1.4	7
357	Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors. OncoImmunology, 2018, 7, e1457596.	2.1	31
358	The mesenchymal and myeloid regulation of immunity: Power is nothing without control. Seminars in Immunology, 2018, 35, 1-2.	2.7	1
360	The gut microbiota influences anticancer immunosurveillance and general health. Nature Reviews Clinical Oncology, 2018, 15, 382-396.	12.5	389
361	Factors Associated with Early Referral to Palliative Care in Outpatients with Advanced Cancer. Journal of Palliative Medicine, 2018, 21, 1322-1328.	0.6	22
362	Macrophages: The Road Less Traveled, Changing Anticancer Therapy. Trends in Molecular Medicine, 2018, 24, 472-489.	3.5	219
363	PDâ€1 Blockade Cellular Vesicles for Cancer Immunotherapy. Advanced Materials, 2018, 30, e1707112.	11.1	196
364	Chemokines beyond chemo-attraction: CXCL10 and its significant role in cancer and autoimmunity. Cytokine, 2018, 109, 24-28.	1.4	153
365	Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. OncoImmunology, 2018, 7, e1433982.	2.1	38
366	Mechanisms of autophagy and relevant small-molecule compounds for targeted cancer therapy. Cellular and Molecular Life Sciences, 2018, 75, 1803-1826.	2.4	46
367	Myeloid cell heterogeneity in cancer: not a single cell alike. Cellular Immunology, 2018, 330, 188-201.	1.4	127
368	Potentiating prostate cancer immunotherapy with oncolytic viruses. Nature Reviews Urology, 2018, 15, 235-250.	1.9	46
369	Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity. Journal of Experimental Medicine, 2018, 215, 859-876.	4.2	150
370	Human mast cells and basophilsâ€"How are they similar how are they different?. Immunological Reviews, 2018, 282, 8-34.	2.8	124
371	IL-2 and Beyond in Cancer Immunotherapy. Journal of Interferon and Cytokine Research, 2018, 38, 45-68.	0.5	83

#	Article	IF	Citations
372	The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation. Cellular and Molecular Immunology, 2018, 15, 438-446.	4.8	88
373	A potential biomarker for anti-PD-1 immunotherapy. Nature Medicine, 2018, 24, 123-124.	15.2	23
374	PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer. OncoImmunology, 2018, 7, e1433981.	2.1	167
375	14-3-3Î¶ delivered by hepatocellular carcinoma-derived exosomes impaired anti-tumor function of tumor-infiltrating TÂlymphocytes. Cell Death and Disease, 2018, 9, 159.	2.7	96
378	eIF2Î± phosphorylation is pathognomonic for immunogenic cell death. Cell Death and Differentiation, 2018, 25, 1375-1393.	5.0	162
379	Mechanisms of Resistance to PD-1 and PD-L1 Blockade. Cancer Journal (Sudbury, Mass), 2018, 24, 47-53.	1.0	287
380	Targeting tumorâ€infiltrating Ly6G⁺ myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma. International Journal of Cancer, 2018, 142, 1878-1889.	2.3	46
381	Resolving the dark side of therapy-driven cancer cell death. Journal of Experimental Medicine, 2018, 215, 9-11.	4.2	9
382	Prediction of response to targeted and immune checkpoint therapies. Personalized Medicine, 2018, 15, 45-56.	0.8	0
383	Cancer Associated Fibroblasts: The Architects of Stroma Remodeling. Proteomics, 2018, 18, e1700167.	1.3	169
384	Single-Cell Genomics: A Stepping Stone for Future Immunology Discoveries. Cell, 2018, 172, 14-21.	13.5	214
385	Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers. Seminars in Cancer Biology, 2018, 52, 125-134.	4.3	51
386	Innate Immune Receptors in the Regulation of Tumor Immunity. , 2018, , 407-427.		0
387	Synergy Between Radiotherapy and Immunotherapy. , 2018, , 507-524.		0
388	Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies. Clinical Cancer Research, 2018, 24, 1011-1018.	3.2	31
389	Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis by CXCL16-mediated Effects. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1164-1176.	2.5	77
390	Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome. OncoImmunology, 2018, 7, e1423184.	2.1	38
391	Immunotherapy for brain tumors: understanding early successes and limitations. Expert Review of Neurotherapeutics, 2018, 18, 251-259.	1.4	22

#	Article	IF	Citations
392	The Immune Checkpoint Modulator OX40 and Its Ligand OX40L in NK-Cell Immunosurveillance and Acute Myeloid Leukemia. Cancer Immunology Research, 2018, 6, 209-221.	1.6	49
393	The significance of intertumor and intratumor heterogeneity in liver cancer. Experimental and Molecular Medicine, 2018, 50, e416-e416.	3.2	158
394	A Believerâ€™s Overview of Cancer Immunosurveillance and Immunotherapy. Journal of Immunology, 2018, 200, 385-391.	0.4	103
395	Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. Journal of Hematology and Oncology, 2018, 11, 31.	6.9	256
396	Next generation of immune checkpoint therapy in cancer: new developments and challenges. Journal of Hematology and Oncology, 2018, 11, 39.	6.9	597
397	Understanding the structural and energetic basis of PD-1 and monoclonal antibodies bound to PD-L1: A molecular modeling perspective. Biochimica Et Biophysica Acta - General Subjects, 2018, 1862, 576-588.	1.1	21
398	Correlates of immune and clinical activity of novel cancer vaccines. Seminars in Immunology, 2018, 39, 119-136.	2.7	54
399	Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. Current Opinion in Immunology, 2018, 51, 146-153.	2.4	178
400	B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity. Clinical Cancer Research, 2018, 24, 2653-2664.	3.2	109
401	Loss of the Immune Checkpoint CD85j/LILRB1 on Malignant Plasma Cells Contributes to Immune Escape in Multiple Myeloma. Journal of Immunology, 2018, 200, 2581-2591.	0.4	19
402	Immunotherapy in Advanced Renal Cancer â€" Is Cure Possible?. New England Journal of Medicine, 2018, 378, 1344-1345.	13.9	10
403	Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies. Cancer Cell, 2018, 33, 664-675.e4.	7.7	78
404	Chemokines and cancer: new immune checkpoints for cancer therapy. Current Opinion in Immunology, 2018, 51, 140-145.	2.4	109
405	Single-cell technologies for profiling T cells to enable monitoring of immunotherapies. Current Opinion in Chemical Engineering, 2018, 19, 142-152.	3.8	11
406	Rapid Advances in Immunotherapy to Treat Cancer. Clinical Pharmacology and Therapeutics, 2018, 103, 540-544.	2.3	64
407	Safety of Combined Treatment With Monoclonal Antibodies and Viscum album L Preparations. Integrative Cancer Therapies, 2018, 17, 41-51.	0.8	16
408	Metaâ€Analysis of the Risk of Immuneâ€Related Adverse Events With Anticytotoxic Tâ€Lymphocyteâ€Associated Antigen 4 and Antiprogrammed Death 1 Therapies. Clinical Pharmacology and Therapeutics, 2018, 103, 318-331.	2.3	22
409	Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms. OncoImmunology, 2018, 7, e1341032.	2.1	11

#	Article	IF	Citations
410	Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers. Clinical Cancer Research, 2018, 24, 259-265.	3.2	137
411	Genetic variation in <scp>IRF</scp>4 expression modulates growth characteristics, tyrosinase expression and interferonâ€gamma response in melanocytic cells. Pigment Cell and Melanoma Research, 2018, 31, 51-63.	1.5	19
412	Oncogenic pathways that affect antitumor immune response and immune checkpoint blockade therapy. , 2018, 181, 76-84.		49
413	Molecular Mechanisms Linking Exercise to Cancer Prevention and Treatment. Cell Metabolism, 2018, 27, 10-21.	7.2	333
414	Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors. Journal of Molecular Diagnostics, 2018, 20, 95-109.	1.2	50
415	Eosinophils: The unsung heroes in cancer?. OncoImmunology, 2018, 7, e1393134.	2.1	184
416	Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment. Seminars in Cancer Biology, 2018, 52, 216-227.	4.3	14
417	Immune Modulation Therapy and Imaging: Workshop Report. Journal of Nuclear Medicine, 2018, 59, 410-417.	2.8	23
418	Interleukin-27 Exerts Its Antitumor Effects by Promoting Differentiation of Hematopoietic Stem Cells to M1 Macrophages. Cancer Research, 2018, 78, 182-194.	0.4	25
419	Triple negative breast cancer â€“ prognostic role of immune-related factors: a systematic review. Acta OncolÃ³gica, 2018, 57, 74-82.	0.8	93
420	Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses. MAbs, 2018, 10, 315-324.	2.6	72
421	Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells. Cancer Immunology Research, 2018, 6, 139-150.	1.6	172
422	Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nature Reviews Immunology, 2018, 18, 168-182.	10.6	736
423	Using <scp>MRI</scp> cell tracking to monitor immune cell recruitment in response to a peptideâ€based cancer vaccine. Magnetic Resonance in Medicine, 2018, 80, 304-316.	1.9	30
424	Recent discovery of indoleamine-2,3-dioxygenase 1 inhibitors targeting cancer immunotherapy. European Journal of Medicinal Chemistry, 2018, 143, 656-669.	2.6	47
425	Drug development in the era of precision medicine. Nature Reviews Drug Discovery, 2018, 17, 183-196.	21.5	294
426	CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discovery, 2018, 8, 216-233.	7.7	503
427	Deregulation and Therapeutic Potential of the Hippo Pathway in Cancer. Annual Review of Cancer Biology, 2018, 2, 59-79.	2.3	14

#	Article	IF	Citations
428	Management of Immune-mediated Cytopenias in the Era of Cancer Immunotherapy: A Report of 4 Cases. Journal of Immunotherapy, 2018, 41, 32-34.	1.2	26
429	Small-Molecule Sigma1 Modulator Induces Autophagic Degradation of PD-L1. Molecular Cancer Research, 2018, 16, 243-255.	1.5	117
431	Primer on Cancer Immunotherapy and the Targeting of Native Proteins. Current Cancer Research, 2018, , 1-28.	0.2	0
432	Melanoma Immunotherapy. Current Cancer Research, 2018, , 307-331.	0.2	0
433	Humanized mice in studying efficacy and mechanisms of PDâ€1â€targeted cancer immunotherapy. FASEB Journal, 2018, 32, 1537-1549.	0.2	260
434	PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab. OncoImmunology, 2018, 7, e1405206.	2.1	43
435	Impact of Clinicopathologic Features on the Efficacy of PD-1/PD-L1 Inhibitors in Patients With Previously Treated Nonâ€“small-cell Lung Cancer. Clinical Lung Cancer, 2018, 19, e177-e184.	1.1	6
436	Aligning digital CD8⁺ scoring and targeted nextâ€generation sequencing with programmed death ligand 1 expression: a pragmatic approach in earlyâ€stage squamous cell lung carcinoma. Histopathology, 2018, 72, 270-284.	1.6	17
437	Monoclonal antibodies: technologies for early discovery and engineering. Critical Reviews in Biotechnology, 2018, 38, 394-408.	5.1	61
438	Harnessing the immune system in the battle against breast cancer. Drugs in Context, 2018, 7, 1-21.	1.0	19
439	Novel targeting approaches and signaling pathways of colorectal cancer: An insight. World Journal of Gastroenterology, 2018, 24, 4428-4435.	1.4	64
442	Ganoderma lucidum Polysaccharides as An Anti-cancer Agent. Anti-Cancer Agents in Medicinal Chemistry, 2018, 18, 667-674.	0.9	116
443	Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 157-172.	0.7	40
444	Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to singleâ€agent checkpoint blockade. Clinical and Translational Medicine, 2018, 7, 32.	1.7	29
445	Immune Checkpoints of CD8+ T Cells in Acute Myeloid Leukemia. Journal of Molecular and Genetic Medicine: an International Journal of Biomedical Research, 2018, 12, .	0.1	0
446	Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for Cancer. IScience, 2018, 9, 258-277.	1.9	83
447	Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells. Cell, 2018, 175, 1731-1743.e13.	13.5	812
448	Harnessing immune checkpoints for cancer therapy. Immunotherapy, 2018, 10, 1265-1284.	1.0	9

#	Article	IF	Citations
449	The efficacy and safety of immune checkpoint inhibitor combination therapy in lung cancer: a systematic review and meta-analysis. OncoTargets and Therapy, 2018, Volume 11, 7369-7383.	1.0	19
450	Novel Immunotherapeutic Approaches for Neuroblastoma and Malignant Melanoma. Journal of Immunology Research, 2018, 2018, 1-12.	0.9	11
452	Transforming of the Tumor Microenvironment: Implications for TGF-<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mrow><mml:mi>Î²</mml:mi></mml:mrow></mml:math>Inhibition in the Context of Immune-Checkpoint Therapy. Journal of Oncology, 2018, 2018, 1-9.	0.6	35
453	Radiotherapy and immune response: the systemic effects of a local treatment. Clinics, 2018, 73, e557s.	0.6	154
454	Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer. Clinics, 2018, 73, e479s.	0.6	7
455	Artificial T Cell Mimetics to Combat Melanoma Tumor Growth. American Journal of Advanced Drug Delivery, 2018, 06, .	0.1	2
456	Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity. Cell Reports, 2018, 25, 3074-3085.e5.	2.9	266
457	Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing. Journal of Hematology and Oncology, 2018, 11, 142.	6.9	95
458	Immune-Related Adverse Events: Pneumonitis. Advances in Experimental Medicine and Biology, 2018, 995, 131-149.	0.8	19
460	Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours. Nature Communications, 2018, 9, 5097.	5.8	21
461	Functional Heterogeneity of CD4+ Tumor-Infiltrating Lymphocytes With a Resident Memory Phenotype in NSCLC. Frontiers in Immunology, 2018, 9, 2654.	2.2	85
462	Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma. OncoImmunology, 2018, 7, e1468956.	2.1	88
463	The role of CCR5 in directing the mobilization and biological function of CD11b+Gr1+Ly6Clow polymorphonuclear myeloid cells in cancer. Cancer Immunology, Immunotherapy, 2018, 67, 1949-1953.	2.0	18
464	PDL1 is expressed in the islets of people with type 1 diabetes and is up-regulated by interferons-Î± and-Î³ via IRF1 induction. EBioMedicine, 2018, 36, 367-375.	2.7	138
465	Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences. Frontiers in Pharmacology, 2018, 9, 1050.	1.6	48
466	Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages. Cell, 2018, 175, 442-457.e23.	13.5	198
467	Multifunctional Cargo-Free Nanomedicine for Cancer Therapy. International Journal of Molecular Sciences, 2018, 19, 2963.	1.8	21
468	Improved Cancer Immunochemotherapy via Optimal Co-delivery of Chemotherapeutic and Immunomodulatory Agents. Molecular Pharmaceutics, 2018, 15, 5162-5173.	2.3	20

#	Article	IF	Citations
469	A novel dual-cytokineâ€“antibody fusion protein for the treatment of CD38-positive malignancies. Protein Engineering, Design and Selection, 2018, 31, 173-179.	1.0	9
470	On the Road to Immunotherapyâ€”Prospects for Treating Head and Neck Cancers With Checkpoint Inhibitor Antibodies. Frontiers in Immunology, 2018, 9, 2182.	2.2	15
471	Checkpoint Blockade Reverses Anergy in IL-13RÎ±2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas. Molecular Therapy - Oncolytics, 2018, 11, 20-38.	2.0	123
472	Degradationâ€Regulatable Architectured Implantable Macroporous Scaffold for the Spatiotemporal Modulation of Immunosuppressive Microenvironment and Enhanced Combination Cancer Immunotherapy. Advanced Functional Materials, 2018, 28, 1804490.	7.8	36
473	Microvascular Mural Cells in Cancer. Trends in Cancer, 2018, 4, 838-848.	3.8	16
474	Trapping of Lipopolysaccharide to Promote Immunotherapy against Colorectal Cancer and Attenuate Liver Metastasis. Advanced Materials, 2018, 30, e1805007.	11.1	125
475	Statins: A New Approach to Combat Temozolomide Chemoresistance in Glioblastoma. Journal of Investigative Medicine, 2018, 66, 1083-1087.	0.7	27
476	Defective transcription elongation in a subset of cancers confers immunotherapy resistance. Nature Communications, 2018, 9, 4410.	5.8	17
477	Multi-Omics Profiling of the Tumor Microenvironment: Paving the Way to Precision Immuno-Oncology. Frontiers in Oncology, 2018, 8, 430.	1.3	57
478	Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical Considerations. Journal of Thoracic Oncology, 2018, 13, 1625-1637.	0.5	10
479	Targeting macrophages: therapeutic approaches in cancer. Nature Reviews Drug Discovery, 2018, 17, 887-904.	21.5	1,246
480	Emerging Role and Future Directions of Immunotherapy in Advanced Ovarian Cancer. Hematology/Oncology Clinics of North America, 2018, 32, 1025-1039.	0.9	11
481	Assessment of biotechnologies: a therapeutic monoclonal antibody emerging score. , 2018, , .		1
482	Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer. OncoTargets and Therapy, 2018, Volume 11, 6505-6524.	1.0	47
483	Translational Potential of Therapeutics Targeting Regulatory Myeloid Cells in Tuberculosis. Frontiers in Cellular and Infection Microbiology, 2018, 8, 332.	1.8	22
484	Successful treatment of liver metastases arising from early gastric cancer achieved clinical complete response by nivolumab. Surgical Case Reports, 2018, 4, 71.	0.2	17
485	Valproic acid attenuates immunosuppressive function of myeloid-derived suppressor cells. Journal of Pharmacological Sciences, 2018, 137, 359-365.	1.1	31
486	Immune checkpoint inhibitors for urothelial carcinoma. Investigative and Clinical Urology, 2018, 59, 285.	1.0	94

#	Article	IF	Citations
487	Natural killer cells induce distinct modes of cancer cell death: Discrimination, quantification, and modulation of apoptosis, necrosis, and mixed forms. Journal of Biological Chemistry, 2018, 293, 16348-16363.	1.6	78
488	Trial watch: Peptide-based vaccines in anticancer therapy. OncoImmunology, 2018, 7, e1511506.	2.1	121
489	Immune Checkpoint Molecules, Personalized Immunotherapy, and Autoimmune Diabetes. Trends in Molecular Medicine, 2018, 24, 931-941.	3.5	34
490	Roles of the RANKLâ€“RANK axis in antitumour immunity â€” implications for therapy. Nature Reviews Clinical Oncology, 2018, 15, 676-693.	12.5	77
491	The hallmarks of successful anticancer immunotherapy. Science Translational Medicine, 2018, 10, .	5.8	419
492	Recent updates on cancer immunotherapy. Precision Clinical Medicine, 2018, 1, 65-74.	1.3	95
493	Translational Biomarkers: Application in the Clinical Development of Combination Therapies. , 2018, , 223-248.		0
494	Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors. Current Rheumatology Reports, 2018, 20, 65.	2.1	39
495	Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia. Blood Advances, 2018, 2, 1187-1190.	2.5	8
496	Disease-Associated Microglia: A Universal Immune Sensor of Neurodegeneration. Cell, 2018, 173, 1073-1081.	13.5	765
497	Combination targeted therapy in chronic lymphocytic leukaemia â€“ can preâ€clinical studies translate to the clinic?. British Journal of Haematology, 2018, 182, 315-316.	1.2	0
498	Nature of tumour rejection antigens in ovarian cancer. Immunology, 2018, 155, 202-210.	2.0	12
499	Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. Oncogene, 2018, 37, 4639-4661.	2.6	219
500	Potentiation of PD-L1 blockade with a potency-matched dual cytokineâ€“antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains. Cancer Immunology, Immunotherapy, 2018, 67, 1381-1391.	2.0	25
501	Delivery Strategies for Immune Checkpoint Blockade. Advanced Healthcare Materials, 2018, 7, e1800424.	3.9	76
502	T Lymphocyteâ€“Based Cancer Immunotherapeutics. International Review of Cell and Molecular Biology, 2018, 341, 201-276.	1.6	22
503	VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML. OncoImmunology, 2018, 7, e1469594.	2.1	107
504	Novel therapeutic strategy for cancer and autoimmune conditions: Modulating cell metabolism and redox capacity. , 2018, 191, 148-161.		24

#	Article	IF	Citations
505	Systemically Administered Sindbis Virus in Combination with Immune Checkpoint Blockade Induces Curative Anti-tumor Immunity. Molecular Therapy - Oncolytics, 2018, 9, 51-63.	2.0	22
506	Oxygenated lipid signaling in tumor-associated macrophagesâ€"focus on colon cancer. Cancer and Metastasis Reviews, 2018, 37, 289-315.	2.7	10
507	Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non-MSI-H Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, 258-273.	1.0	41
508	Precision medicine and drug targeting. , 2018, , 155-166.		1
509	Macrophage targeting: opening new possibilities for cancer immunotherapy. Immunology, 2018, 155, 285-293.	2.0	123
510	Endocrine, Sexual Function, and Infertility Side Effects of Immune Checkpoint Inhibitor Therapy for Genitourinary Cancers. Current Urology Reports, 2018, 19, 68.	1.0	12
511	Induction of oligoclonal CD8 T cell responses against pulmonary metastatic cancer by a phospholipid-conjugated TLR7 agonist. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E6836-E6844.	3.3	17
512	Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events. , 2018, 6, 40.		110
513	Engineering PD-1-Presenting Platelets for Cancer Immunotherapy. Nano Letters, 2018, 18, 5716-5725.	4.5	172
514	Notch Signaling as a Regulator of the Tumor Immune Response: To Target or Not To Target?. Frontiers in Immunology, 2018, 9, 1649.	2.2	85
515	Immunotherapy for Gastric Cancer: Time for a Personalized Approach?. International Journal of Molecular Sciences, 2018, 19, 1602.	1.8	48
516	Potentiating cancer vaccine efficacy in liver cancer. OncoImmunology, 2018, 7, e1488564.	2.1	26
517	Monoclonal antibody therapy in cancer: When two is better (and considerably more expensive) than one. Journal of Clinical Pharmacy and Therapeutics, 2018, 43, 925-930.	0.7	5
519	Characterizing parathyroid carcinomas and atypical neoplasms based on the expression of programmed death-ligand 1 expression and the presence of tumor-infiltrating lymphocytes and macrophages. Surgery, 2018, 164, 960-964.	1.0	15
520	Lymphatic vessel density is associated with CD8⁺ T cell infiltration and immunosuppressive factors in human melanoma. OncoImmunology, 2018, 7, e1462878.	2.1	47
521	Pathways in melanoma development. Italian Journal of Dermatology and Venereology, 2018, 153, 68-76.	0.1	4
522	Oncostatin M treatment increases the responsiveness toward cisplatinâ€'based chemoradiotherapy in cervical cancer cells in a STAT3â€'dependent manner. Oncology Letters, 2018, 16, 3351-3358.	0.8	6
523	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. Molecular and Cellular Proteomics, 2018, 17, 2132-2145.	2.5	41

#	Article	IF	Citations
524	Immunological Approaches Towards Cancer and Inflammation: A Cross Talk. Frontiers in Immunology, 2018, 9, 563.	2.2	227
525	Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors. Frontiers in Immunology, 2018, 9, 1104.	2.2	95
526	The Prognostic Value of Immune Factors in the Tumor Microenvironment of Penile Squamous Cell Carcinoma. Frontiers in Immunology, 2018, 9, 1253.	2.2	61
527	A Cartography of Siglecs and Sialyltransferases in Gynecologic Malignancies: Is There a Road Towards a Sweet Future?. Frontiers in Oncology, 2018, 8, 68.	1.3	14
528	Multistage Carcinogenesis: Cell and Animal Models. , 2018, , 11-35.		2
529	Tune Up In Situ Autovaccination against Solid Tumors with Oncolytic Viruses. Cancers, 2018, 10, 171.	1.7	11
530	Identification and functional analysis of heterogeneous FOXP3+ Treg cell subpopulations in human pancreatic ductal adenocarcinoma. Science Bulletin, 2018, 63, 972-981.	4.3	16
531	CCL5-deficiency enhances intratumoral infiltration of CD8+ T cells in colorectal cancer. Cell Death and Disease, 2018, 9, 766.	2.7	51
532	Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect. Trends in Immunology, 2018, 39, 644-655.	2.9	312
533	Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice. Future Oncology, 2018, 14, 41-60.	1.1	12
534	Structureâ€"Function Analysis of Immune Checkpoint Receptors to Guide Emerging Anticancer Immunotherapy. Journal of Medicinal Chemistry, 2018, 61, 10957-10975.	2.9	30
535	Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi. Frontiers in Oncology, 2018, 8, 92.	1.3	506
536	Clinical Interventions in HIV Cure Research. Advances in Experimental Medicine and Biology, 2018, 1075, 285-318.	0.8	16
537	Targeting Tumor-Associated Macrophages as a Potential Strategy to Enhance the Response to Immune Checkpoint Inhibitors. Frontiers in Cell and Developmental Biology, 2018, 6, 38.	1.8	171
538	Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment. Frontiers in Cell and Developmental Biology, 2018, 6, 56.	1.8	54
539	Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors. Molecular Cancer, 2018, 17, 7.	7.9	63
541	Invasive lobular and ductal breast carcinoma differ in immune response, protein translation efficiency and metabolism. Scientific Reports, 2018, 8, 7205.	1.6	71
542	Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities. Expert Opinion on Biological Therapy, 2018, 18, 653-664.	1.4	26

#	Article	IF	Citations
543	Big Data Approaches for Modeling Response and Resistance to Cancer Drugs. Annual Review of Biomedical Data Science, 2018, 1, 1-27.	2.8	27
544	New Directions in the Study and Treatment of Metastatic Cancer. Frontiers in Oncology, 2018, 8, 258.	1.3	14
545	Endogenous glucocorticoids control host resistance to viral infection through the tissue-specific regulation of PD-1 expression on NK cells. Nature Immunology, 2018, 19, 954-962.	7.0	125
546	Immune Checkpoint Ligand PD-L1 Is Upregulated in Pulmonary Lymphangioleiomyomatosis. American Journal of Respiratory Cell and Molecular Biology, 2018, 59, 723-732.	1.4	37
547	Diagnostic value of peripheral blood immune profiling in colorectal cancer. Annals of Surgical Treatment and Research, 2018, 94, 312.	0.4	26
548	Next Generation Cancer Vaccinesâ€"Make It Personal!. Vaccines, 2018, 6, 52.	2.1	20
549	CD103⁺ Cell Growth Factor Flt3L Enhances the Efficacy of Immune Checkpoint Blockades in Murine Glioblastoma Model. Oncology Research, 2018, 26, 173-182.	0.6	9
550	BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Nonâ€"Small Cell Lung Cancer. Cancer Immunology Research, 2018, 6, 1234-1245.	1.6	80
551	Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids. Cell, 2018, 174, 1586-1598.e12.	13.5	644
552	The Protein Corona as a Confounding Variable of Nanoparticle-Mediated Targeted Vaccine Delivery. Frontiers in Immunology, 2018, 9, 1760.	2.2	63
553	Cancer vaccine: learning lessons from immune checkpoint inhibitors. Journal of Cancer, 2018, 9, 263-268.	1.2	38
554	Personalized cancer neoantigen vaccines come of age. Theranostics, 2018, 8, 4238-4246.	4.6	51
555	PDâ€1 Blockade for Improving the Antitumor Efficiency of Polymerâ€"Doxorubicin Nanoprodrug. Small, 2018, 14, e1802403.	5.2	57
556	Development of a new highâ€affinity human antibody with antitumor activity against solid and blood malignancies. FASEB Journal, 2018, 32, 5063-5077.	0.2	7
557	Critically dysregulated signaling pathways and clinical utility of theÂpathway biomarkers in lymphoid malignancies. Chronic Diseases and Translational Medicine, 2018, 4, 29-44.	0.9	10
558	Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs. Cancer Immunology Research, 2018, 6, 910-920.	1.6	245
559	Synthetic vaccine particles for durable cytolytic T lymphocyte responses and anti-tumor immunotherapy. PLoS ONE, 2018, 13, e0197694.	1.1	17
561	Tumor Challenges in Immunotoxicity Testing. Methods in Molecular Biology, 2018, 1803, 169-180.	0.4	1

#	Article	IF	Citations
562	Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nature Immunology, 2018, 19, 723-732.	7.0	716
563	Immune Checkpoint Blockade across the Cancer Care Continuum. Immunity, 2018, 48, 1077-1080.	6.6	33
564	Adverse Effects of Immune Checkpoint Therapy in Cancer Patients Visiting the Emergency Department of a Comprehensive Cancer Center. Annals of Emergency Medicine, 2019, 73, 79-87.	0.3	68
565	Cytotoxic T Lymphocytes and Natural Killer Cells. , 2019, , 247-259.e1.		12
566	Epsteinâ˜'Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas. Leukemia, 2019, 33, 132-147.	3.3	126
567	Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 485-495.	1.4	3
568	Role of protein phosphatases in the cancer microenvironment. Biochimica Et Biophysica Acta - Molecular Cell Research, 2019, 1866, 144-152.	1.9	39
569	Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy. Cellular and Molecular Immunology, 2019, 16, 28-39.	4.8	57
570	Obesity and Breast Cancer: Role of Leptin. Frontiers in Oncology, 2019, 9, 596.	1.3	175
571	O₂-Cu/ZIF-8@Ce6/ZIF-8@F127 Composite as a Tumor Microenvironment-Responsive Nanoplatform with Enhanced Photo-/Chemodynamic Antitumor Efficacy. ACS Applied Materials & Interfaces, 2019, 11, 31671-31680.	4.0	131
572	Proteogenomic discovery of cancer antigens: Neoantigens and beyond. Pathology International, 2019, 69, 511-518.	0.6	9
573	The Role of the Lymphocyte Functional Crosstalk and Regulation in the Context of Checkpoint Inhibitor Treatmentâ€"Review. Frontiers in Immunology, 2019, 10, 2043.	2.2	7
574	A Three-in-One Immunotherapy Nanoweapon via Cascade-Amplifying Cancer-Immunity Cycle against Tumor Metastasis, Relapse, and Postsurgical Regrowth. Nano Letters, 2019, 19, 6647-6657.	4.5	92
575	USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity. Cancer Immunology Research, 2019, 7, 1580-1590.	1.6	94
576	Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition. , 2019, 7, 216.		56
577	Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study. Frontiers in Immunology, 2019, 10, 1848.	2.2	56
578	Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials. Liver Cancer, 2019, 8, 221-238.	4.2	51
579	Current state of melanoma diagnosis and treatment. Cancer Biology and Therapy, 2019, 20, 1366-1379.	1.5	462

#	Article	IF	Citations
580	Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy. Cancer Cell, 2019, 36, 168-178.e4.	7.7	240
581	Cas9-edited immune checkpoint blockade PD-1 DNA polyaptamer hydrogel for cancer immunotherapy. Biomaterials, 2019, 218, 119359.	5.7	64
582	Bioresponsive Protein Complex of aPD1 and aCD47 Antibodies for Enhanced Immunotherapy. Nano Letters, 2019, 19, 4879-4889.	4.5	103
583	Design, Synthesis, Evaluation, and Structural Studies of C₂-Symmetric Small Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Proteinâ€“Protein Interaction. Journal of Medicinal Chemistry, 2019, 62, 7250-7263.	2.9	71
584	Japan oncology market overview: Current and future perspectives. Journal of Generic Medicines, 2019, 15, 104-114.	0.0	1
585	Prognostic Significance of 18F-FDG PET/CT Metabolic Parameters and Tumor Galectin-1 Expression in Patients With Surgically Resected Lung Adenocarcinoma. Clinical Lung Cancer, 2019, 20, 420-428.	1.1	7
586	Influence of mutagenic versus non-mutagenic pre-operative chemotherapy on the immune infiltration of residual breast cancer. Acta OncolÃ³gica, 2019, 58, 1603-1611.	0.8	4
587	Toward Personalized Cancer Treatment: From Diagnostics to Therapy Monitoring in Miniaturized Electrohydrodynamic Systems. Accounts of Chemical Research, 2019, 52, 2113-2123.	7.6	32
588	Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing. Frontiers in Immunology, 2019, 10, 1505.	2.2	34
589	Head and Neck Cancer Immunotherapy beyond the Checkpoint Blockade. Journal of Dental Research, 2019, 98, 1073-1080.	2.5	9
590	Structural insights and binding analysis for determining the molecular bases for programmed cell death protein ligand-1 inhibition. MedChemComm, 2019, 10, 1810-1818.	3.5	5
591	Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights. Journal of Oncology, 2019, 2019, 1-9.	0.6	5
592	Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer. , 2019, 7, 199.		27
593	Tumor Targeting Strategies of Smart Fluorescent Nanoparticles and Their Applications in Cancer Diagnosis and Treatment. Advanced Materials, 2019, 31, e1902409.	11.1	173
594	Remodeling the Tumor Microenvironment Sensitizes Breast Tumors to Anti-Programmed Death-Ligand 1 Immunotherapy. Cancer Research, 2019, 79, 4149-4159.	0.4	44
595	Cancer Immunoediting and Hijacking of the Immune System. Learning Materials in Biosciences, 2019, , 117-139.	0.2	0
596	Rationally designed peptide-conjugated gold/platinum nanosystem with active tumor-targeting for enhancing tumor photothermal-immunotherapy. Journal of Controlled Release, 2019, 308, 29-43.	4.8	82
597	åšè‚½è•ç‰©åŠ¨æ€…ä½“åœ¨ç™Œç—‡å…ç–«æ²»ç–—ä¸šš„åº”ç”¨. Science China Materials, 2019, 62, 1759-1783.	3.5	19

#	Article	IF	Citations
598	Major fundamental factors hindering immune system in defense against tumor cells: The link between insufficiency of innate immune responses, metabolism, and neurotransmitters with effector immune cells disability. Immunology Letters, 2019, 212, 81-87.	1.1	7
599	Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPÎ±. MAbs, 2019, 11, 1036-1052.	2.6	38
600	The relationship between KLK3 rs17632542 and PRNCR1 rs16901979 polymorphisms with susceptibility to prostate cancer. Meta Gene, 2019, 21, 100595.	0.3	0
601	Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. Cell Research, 2019, 29, 725-738.	5.7	661
602	Quantitative assessment of microenvironment characteristics and metabolic activity in glioma via multiphoton microscopy. Journal of Biophotonics, 2019, 12, e201900136.	1.1	9
603	Application of immune repertoire sequencing in cancer immunotherapy. International Immunopharmacology, 2019, 74, 105688.	1.7	7
604	Bodyâ€™s Own Epitopes among Foreign Ones: T Cells and Autoantigens. Molecular Biology, 2019, 53, 748-757.	0.4	0
605	Nanomedicineâ€Based Immunotherapy for the Treatment of Cancer Metastasis. Advanced Materials, 2019, 31, e1904156.	11.1	120
606	NK Cell-Fc Receptors Advance Tumor Immunotherapy. Journal of Clinical Medicine, 2019, 8, 1667.	1.0	17
607	Clinicopathologic significance of human leukocyte antigen class I expression in patients with stage II and III gastric cancer. Cancer Immunology, Immunotherapy, 2019, 68, 1779-1790.	2.0	10
608	Monalizumab: inhibiting the novel immune checkpoint NKG2A. , 2019, 7, 263.		182
609	Lyophilizable and Multifaceted Toll-like Receptor 7/8 Agonist-Loaded Nanoemulsion for the Reprogramming of Tumor Microenvironments and Enhanced Cancer Immunotherapy. ACS Nano, 2019, 13, 12671-12686.	7.3	86
610	Local biomaterials-assisted cancer immunotherapy to trigger systemic antitumor responses. Chemical Society Reviews, 2019, 48, 5506-5526.	18.7	209
612	Understanding tumor-infiltrating lymphocytes by single cell RNA sequencing. Advances in Immunology, 2019, 144, 217-245.	1.1	21
613	Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers. Critical Reviews in Oncology/Hematology, 2019, 144, 102812.	2.0	7
614	Cancer Nanomedicine: A New Era of Successful Targeted Therapy. Journal of Nanomaterials, 2019, 2019, 1-13.	1.5	52
615	Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma. EBioMedicine, 2019, 49, 96-105.	2.7	47
617	Beta-Adrenergic Signaling in Tumor Immunology and Immunotherapy. Critical Reviews in Immunology, 2019, 39, 93-103.	1.0	16

#	Article	IF	Citations
618	Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma. Frontiers in Genetics, 2019, 10, 986.	1.1	22
619	Magnetic Nanomedicine. , 2019, , 269-313.		0
620	Fluorescence quenching study on the interaction of Lycium barbarum polysaccharide with bovine serum albumin. Applied Physics Express, 2019, 12, 092007.	1.1	4
621	Interplay between dendritic cells and cancer cells. International Review of Cell and Molecular Biology, 2019, 348, 179-215.	1.6	37
622	Computational Insight Into the Small Molecule Intervening PD-L1 Dimerization and the Potential Structure-Activity Relationship. Frontiers in Chemistry, 2019, 7, 764.	1.8	33
623	Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 22246-22251.	3.3	142
624	Targeting Angiogenesis With Peptide Vaccines. Frontiers in Immunology, 2019, 10, 1924.	2.2	15
625	Potential applications of nanoparticles for tumor microenvironment remodeling to ameliorate cancer immunotherapy. International Journal of Pharmaceutics, 2019, 570, 118636.	2.6	24
626	Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. Cell Research, 2019, 29, 846-861.	5.7	160
627	Can Allosteric Receptor-Protein Interactions in Receptor Complexes Be a Molecular Mechanism Involved in Cancer Immune Therapy?. Frontiers in Endocrinology, 2019, 10, 574.	1.5	1
628	Innate lymphoid cells and cancer at border surfaces with the environment. Seminars in Immunology, 2019, 41, 101278.	2.7	11
629	Principles of Cancer Treatment and Anticancer Drug Development. , 2019, , .		10
630	Mapping the Binding Hot Spots on Human Programmed Cell Death 1 and Its Ligand with Free-Energy Simulations. Journal of Chemical Information and Modeling, 2019, 59, 4339-4349.	2.5	4
631	A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control. OncoImmunology, 2019, 8, 1652539.	2.1	45
632	Clinical and immune profiling for cancer of unknown primary site. , 2019, 7, 251.		26
633	Utility of the RIG-I Agonist Triphosphate RNA for Melanoma Therapy. Molecular Cancer Therapeutics, 2019, 18, 2343-2356.	1.9	12
634	Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging. Nature Protocols, 2019, 14, 2900-2930.	5.5	92
635	Suppression of tumor antigen presentation during aneuploid tumor evolution contributes to immune evasion. OncoImmunology, 2019, 8, 1657374.	2.1	36

#	Article	IF	Citations
636	One-Step Microfluidic Purification of White Blood Cells from Whole Blood for Immunophenotyping. Analytical Chemistry, 2019, 91, 13230-13236.	3.2	16
637	Molecular Modeling Studies on the Binding Mode of the PD-1/PD-L1 Complex Inhibitors. International Journal of Molecular Sciences, 2019, 20, 4654.	1.8	29
638	Targeted co-delivery of Trp-2 polypeptide and monophosphoryl lipid A by pH-sensitive poly (Î²-amino) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 102092.	1.7	9
639	[Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the antiâ€“CTLA-4 antibody in a mouse model. PLoS ONE, 2019, 14, e0222280.	1.1	23
640	Trends and Challenges in Tumor Anti-Angiogenic Therapies. Cells, 2019, 8, 1102.	1.8	150
641	Delivery of 5â€²-triphosphate RNA with endosomolytic nanoparticles potently activates RIG-I to improve cancer immunotherapy. Biomaterials Science, 2019, 7, 547-559.	2.6	49
642	Recent advances in musculoskeletal local drug delivery. Acta Biomaterialia, 2019, 93, 135-151.	4.1	22
643	Eomes+T-betlow CD8+ T Cells Are Functionally Impaired and Are Associated with Poor Clinical Outcome in Patients with Acute Myeloid Leukemia. Cancer Research, 2019, 79, 1635-1645.	0.4	42
644	Multiscale Agent-Based and Hybrid Modeling of the Tumor Immune Microenvironment. Processes, 2019, 7, 37.	1.3	115
645	Pseudomonas Exotoxin Immunotoxins and Anti-Tumor Immunity: From Observations at the Patientâ€™s Bedside to Evaluation in Preclinical Models. Toxins, 2019, 11, 20.	1.5	37
646	Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs). Clinical Cancer Research, 2019, 25, 2644-2655.	3.2	56
647	Combination Cancer Immunotherapy with Molecular Targeted Agents/Anti-CTLA-4 Antibody for Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 1-11.	4.2	48
648	SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal degradation of PD-L1. EBioMedicine, 2019, 40, 151-162.	2.7	53
649	Identification of Sex-Specific Transcriptome Responses to Polychlorinated Biphenyls (PCBs). Scientific Reports, 2019, 9, 746.	1.6	8
650	Clonal Deletion of Tumor-Specific T Cells by Interferon-Î³ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. Immunity, 2019, 50, 477-492.e8.	6.6	93
651	PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+ T-cell Function. Cancer Immunology Research, 2019, 7, 257-268.	1.6	108
652	Recent advances in the clinical development of immune checkpoint blockade therapy. Cellular Oncology (Dordrecht), 2019, 42, 609-626.	2.1	76
653	Mesothelin-targeted CAR-T cells for adoptive cell therapy of solid tumors. Archives of Medical Science, 2019, 17, 1213-1220.	0.4	2

#	Article	IF	Citations
654	Novel TCR-based biologics: mobilising T cells to warm â€˜coldâ€™ tumours. Cancer Treatment Reviews, 2019, 77, 35-43.	3.4	57
655	Nanotechnology is an important strategy for combinational innovative chemo-immunotherapies against colorectal cancer. Journal of Controlled Release, 2019, 307, 108-138.	4.8	49
656	Multifunctional Nanoregulator Reshapes Immune Microenvironment and Enhances Immune Memory for Tumor Immunotherapy. Advanced Science, 2019, 6, 1900037.	5.6	94
657	Editing the immunopeptidome of melanoma cells using a potent inhibitor of endoplasmic reticulum aminopeptidase 1 (ERAP1). Cancer Immunology, Immunotherapy, 2019, 68, 1245-1261.	2.0	49
658	IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell. Cancer Immunology Research, 2019, 7, 1258-1266.	1.6	56
659	Molecular and Cell Biology of Cancer. Learning Materials in Biosciences, 2019, , .	0.2	3
660	The road map of cancer precision medicine with the innovation of advanced cancer detection technology and personalized immunotherapy. Japanese Journal of Clinical Oncology, 2019, 49, 596-603.	0.6	10
661	MicroRNAs aid the assessment of programmed death ligandï¿½1 expression in patients with nonâ€‘small cell lung cancer. Oncology Letters, 2019, 17, 5193-5200.	0.8	14
662	Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity. Cell, 2019, 177, 1701-1713.e16.	13.5	280
663	Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy. Cancers, 2019, 11, 714.	1.7	79
664	TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8 ⁺ T cell exhaustion. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 12410-12415.	3.3	481
665	An efficient or methodical review of immunotherapy against breast cancer. Journal of Biochemical and Molecular Toxicology, 2019, 33, e22339.	1.4	14
666	Solid Tumors Challenges and New Insights of CAR T Cell Engineering. Stem Cell Reviews and Reports, 2019, 15, 619-636.	1.7	71
667	Vascular Disrupting Agents in cancer treatment: Cardiovascular toxicity and implications for co-administration with other cancer chemotherapeutics. , 2019, 202, 18-31.		37
668	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. Molecular and Cellular Proteomics, 2019, 18, 1255-1268.	2.5	45
669	The Novel Combination of Nitroxoline and PD-1 Blockade, Exerts a Potent Antitumor Effect in a Mouse Model of Prostate Cancer. International Journal of Biological Sciences, 2019, 15, 919-928.	2.6	21
670	Clinicopathological implications of TIM3+ tumor-infiltrating lymphocytes and the miR-455-5p/Galectin-9 axis in skull base chordoma patients. Cancer Immunology, Immunotherapy, 2019, 68, 1157-1169.	2.0	26
671	Monitoring Patient Response to Pembrolizumab With Peripheral Blood Exhaustion Marker Profiles. Frontiers in Medicine, 2019, 6, 113.	1.2	25

#	Article	IF	Citations
672	Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies. Cell Reports, 2019, 27, 2411-2425.e9.	2.9	274
673	Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches. Journal of the National Cancer Institute, 2019, 111, 1131-1141.	3.0	116
674	Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies. , 2019, 7, 132.		46
675	Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer. Cell Reports, 2019, 27, 1781-1793.e4.	2.9	102
676	Immunomodulation and Immunotherapy for Gastric Cancer. Current Clinical Pathology, 2019, , 189-212.	0.0	1
677	Helper-like innate lymphoid cells and cancer immunotherapy. Seminars in Immunology, 2019, 41, 101274.	2.7	25
678	TLR1/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletion. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 10453-10462.	3.3	53
679	NK cells to cure cancer. Seminars in Immunology, 2019, 41, 101272.	2.7	70
680	Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome Activation. Cancer Cell, 2019, 35, 767-781.e6.	7.7	91
681	Macrophages in Colorectal Cancer Liver Metastases. Cancers, 2019, 11, 633.	1.7	47
682	Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRÎ² diversity. Cancer Immunology, Immunotherapy, 2019, 68, 1095-1106.	2.0	5
683	Therapy-Induced MHC I Ligands Shape Neo-Antitumor CD8 T Cell Responses during Oncolytic Virus-Based Cancer Immunotherapy. Journal of Proteome Research, 2019, 18, 2666-2675.	1.8	22
684	A Metabolism Toolbox for CAR T Therapy. Frontiers in Oncology, 2019, 9, 322.	1.3	54
685	Prognostic significance of PD-L1 and TLR5 expression in peripheral T-cell lymphomas. Leukemia and Lymphoma, 2019, 60, 2599-2601.	0.6	0
686	Challenges and solutions in patient treatment strategies for stage II colon cancer. Gastroenterology Report, 2019, 7, 151-161.	0.6	41
687	Antigen Priming with Enantiospecific Cationic Lipid Nanoparticles Induces Potent Antitumor CTL Responses through Novel Induction of a Type I IFN Response. Journal of Immunology, 2019, 202, 3524-3536.	0.4	34
688	Gastric Cancer In The Precision Medicine Era. Current Clinical Pathology, 2019, , .	0.0	2
689	The Expression of ILT4 in Myeloid Dendritic Cells in Patients with Hepatocellular Carcinoma. Immunological Investigations, 2019, 48, 704-718.	1.0	9

#	Article	IF	Citations
690	Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities. Trends in Immunology, 2019, 40, 511-523.	2.9	180
691	Polyphenols as Immunomodulatory Compounds in the Tumor Microenvironment: Friends or Foes?. International Journal of Molecular Sciences, 2019, 20, 1714.	1.8	54
692	Siglec-9 Regulates an Effector Memory CD8+ T-cell Subset That Congregates in the Melanoma Tumor Microenvironment. Cancer Immunology Research, 2019, 7, 707-718.	1.6	94
693	Cancer nanomedicine for combination cancer immunotherapy. Nature Reviews Materials, 2019, 4, 398-414.	23.3	658
694	Cancer Treatment in the Genomic Era. Annual Review of Biochemistry, 2019, 88, 247-280.	5.0	24
695	Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors. Frontiers in Oncology, 2019, 9, 52.	1.3	36
696	Multifunctional platinum(IV) complexes as immunostimulatory agents to promote cancer immunochemotherapy by inhibiting tryptophan-2,3-dioxygenase. European Journal of Medicinal Chemistry, 2019, 169, 29-41.	2.6	25
697	Targeting natural killer cells in solid tumors. Cellular and Molecular Immunology, 2019, 16, 415-422.	4.8	166
698	MIF family proteins in genitourinary cancer: tumorigenic roles and therapeutic potential. Nature Reviews Urology, 2019, 16, 318-328.	1.9	54
700	The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 7278-7287.	3.3	186
701	Angiogenesis in Pancreatic Cancer: Pre-Clinical and Clinical Studies. Cancers, 2019, 11, 381.	1.7	66
702	Development of an Interleukin-12 Fusion Protein That Is Activated by Cleavage with Matrix Metalloproteinase 9. Journal of Interferon and Cytokine Research, 2019, 39, 233-245.	0.5	21
703	Nivolumab-induced interstitial lung disease in a patient with gastric cancer. Oxford Medical Case Reports, 2019, 2019, omz007.	0.2	3
704	Roles of NKT cells in cancer immunotherapy. Archives of Pharmacal Research, 2019, 42, 543-548.	2.7	72
705	Systems immunology: Integrating multi-omics data to infer regulatory networks and hidden drivers of immunity. Current Opinion in Systems Biology, 2019, 15, 19-29.	1.3	32
706	A Practical Guide to Genome Editing Using Targeted Nuclease Technologies. , 2019, 9, 665-714.		7
707	Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond. World Journal of Gastroenterology, 2019, 25, 789-807.	1.4	135
708	Therapeutic targeting of trained immunity. Nature Reviews Drug Discovery, 2019, 18, 553-566.	21.5	287

#	Article	IF	Citations
709	Immune expression in children with Wilms tumor: a pilot study. Journal of Pediatric Urology, 2019, 15, 441.e1-441.e8.	0.6	19
710	Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5â^'/â^' mice. Nature Communications, 2019, 10, 1492.	5.8	114
711	Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy. Thyroid, 2019, 29, 979-992.	2.4	71
713	T helper 17 (Th17) cells and interleukin-17 (IL-17) in cancer. Archives of Pharmacal Research, 2019, 42, 549-559.	2.7	82
714	Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy. Advanced Healthcare Materials, 2019, 8, e1801320.	3.9	43
715	Immunotherapy-based combination strategies for treatment of gastrointestinal cancers: current status and future prospects. Frontiers of Medicine, 2019, 13, 12-23.	1.5	14
716	Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors. , 2019, 7, 53.		59
717	Therapeutic modulation of autophagy: which disease comes first?. Cell Death and Differentiation, 2019, 26, 680-689.	5.0	48
718	Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy. Nature Communications, 2019, 10, 620.	5.8	60
719	Efficiency of CAR-T Therapy for Treatment of Solid Tumor in Clinical Trials: A Meta-Analysis. Disease Markers, 2019, 2019, 1-11.	0.6	81
720	Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment. Frontiers in Immunology, 2019, 10, 193.	2.2	105
721	Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy. Trends in Cell Biology, 2019, 29, 396-416.	3.6	66
722	Prognostic impact of CD8 and programmed death-ligand 1 expression in patients with resectable non-small cell lung cancer. British Journal of Cancer, 2019, 120, 547-554.	2.9	42
723	Cancer Cell Membrane Camouflaged Nanoparticles to Realize Starvation Therapy Together with Checkpoint Blockades for Enhancing Cancer Therapy. ACS Nano, 2019, 13, 2849-2857.	7.3	253
724	Cancer-induced inflammation and inflammation-induced cancer in colon: a role for S1P lyase. Oncogene, 2019, 38, 4788-4803.	2.6	27
725	Surgical Tumor-Derived Personalized Photothermal Vaccine Formulation for Cancer Immunotherapy. ACS Nano, 2019, 13, 2956-2968.	7.3	230
726	The pioneers behind immune checkpoint blockers awarded the Nobel Prize in physiology or medicine 2018. Acta OncolÃ³gica, 2019, 58, 1-8.	0.8	14
727	Epigenomics-Guided Drug Development: Recent Advances in Solving the Cancer Treatment â€œjigsaw puzzleâ€• OMICS A Journal of Integrative Biology, 2019, 23, 70-85.	1.0	23

#	Article	IF	Citations
728	PDâ€L1 expression levels on tumor cells affect their immunosuppressive activity. Oncology Letters, 2019, 18, 5399-5407.	0.8	54
729	New emerging targets in cancer immunotherapy: the role of neoantigens. ESMO Open, 2019, 4, e000684.	2.0	20
730	Introductory Chapter: Are We There Yet? The Long and Winding Road to Cancer Immunotherapy. , 2019, , .		0
731	Immunotherapy for Treatment of Cancer. , 2019, , .		4
732	The Effects of AHCCÂ®, a Standardized Extract of Cultured Lentinura edodes Mycelia, on Natural Killer and T Cells in Health and Disease: Reviews on Human and Animal Studies. Journal of Immunology Research, 2019, 2019, 1-7.	0.9	18
733	The application of single-cell sequencing technology in the diagnosis and treatment of hepatocellular carcinoma. Annals of Translational Medicine, 2019, 7, 790-790.	0.7	11
734	Fine-tuning immunotherapy in MMR-D/MSI-H colorectal cancer. Colorectal Cancer, 2019, 8, CRC12.	0.8	1
735	Angiopoietin 2 signal complexity in cardiovascular disease and cancer. Life Sciences, 2019, 239, 117080.	2.0	28
737	Highly multiplexed immunofluorescence images and single-cell data of immune markers in tonsil and lung cancer. Scientific Data, 2019, 6, 323.	2.4	39
738	High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer. , 2019, 7, 351.		39
739	Dendritic Cells Loaded with Heat Shock-Conditioned Ovarian Epithelial Carcinoma Cell Lysates Elicit T Cell-Dependent Antitumor Immune Responses In Vitro. Journal of Immunology Research, 2019, 2019, 1-12.	0.9	12
740	IL-17 inhibits CXCL9/10-mediated recruitment of CD8+ cytotoxic T cells and regulatory T cells to colorectal tumors. , 2019, 7, 324.		68
741	Differential impact of classical and non-canonical NF-Î²B pathway-related gene expression on the survival of breast cancer patients. Journal of Cancer, 2019, 10, 5191-5211.	1.2	11
742	Lack of detectable neoantigen depletion signals in the untreated cancer genome. Nature Genetics, 2019, 51, 1741-1748.	9.4	59
743	Immune induction strategies to enhance responses to PD-1 blockade: lessons from the TONIC trial. , 2019, 7, 318.		12
744	UVEITIS CAUSED BY TREATMENT FOR MALIGNANT MELANOMA: A CASE SERIES. Retinal Cases and Brief Reports, 2021, 15, 718-723.	0.3	6
745	Lymph Node Metastasis From Gastroesophageal Cancer Successfully Treated by Nivolumab: A Case Report of a Young Patient. Frontiers in Oncology, 2019, 9, 1375.	1.3	7
746	Targeting Approaches of Nanomedicines in Acute Myeloid Leukemia. Dose-Response, 2019, 17, 155932581988704.	0.7	14

#	Article	IF	Citations
747	Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies. Liver Cancer, 2019, 8, 413-426.	4.2	40
748	Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer. , 2019, 7, 346.		65
749	The pro-tumorigenic host response to cancer therapies. Nature Reviews Cancer, 2019, 19, 667-685.	12.8	135
750	VISTA Is Crucial for Corneal Allograft Survival and Maintenance of Immune Privilege. , 2019, 60, 4958.		10
751	Combing the Cancer Genome for Novel Kinase Drivers and New Therapeutic Targets. Cancers, 2019, 11, 1972.	1.7	8
752	Overexpressed ITGA2 promotes malignant tumor aggression by up-regulating PD-L1 expression through the activation of the STAT3 signaling pathway. Journal of Experimental and Clinical Cancer Research, 2019, 38, 485.	3.5	71
753	MRI of Cardiotoxicity. Cardiology Clinics, 2019, 37, 429-439.	0.9	7
754	Immunomodulators targeting the PDâ€1/PDâ€L1 proteinâ€protein interaction: From antibodies to small molecules. Medicinal Research Reviews, 2019, 39, 265-301.	5.0	128
755	Engineering Nanoparticles for Targeted Remodeling of the Tumor Microenvironment to Improve Cancer Immunotherapy. Theranostics, 2019, 9, 126-151.	4.6	128
756	Ushering in Integrated T Cell Repertoire Profiling in Cancer. Trends in Cancer, 2019, 5, 85-94.	3.8	19
757	Functional Nanomaterials Optimized to Circumvent Tumor Immunological Tolerance. Advanced Functional Materials, 2019, 29, 1806087.	7.8	21
758	Genomic and transcriptional Profiling of tumor infiltrated CD8⁺ T cells revealed functional heterogeneity of antitumor immunity in hepatocellular carcinoma. OncoImmunology, 2019, 8, e1538436.	2.1	17
759	Molecular phenotype of kidney transplant indication biopsies with inflammation in scarred areas. American Journal of Transplantation, 2019, 19, 1356-1370.	2.6	41
760	Enhancing Anti-PD-1/PD-L1 Immune Checkpoint Inhibitory Cancer Therapy by CD276-Targeted Photodynamic Ablation of Tumor Cells and Tumor Vasculature. Molecular Pharmaceutics, 2019, 16, 339-348.	2.3	66
761	Improving Cancer Vaccine Efficiency by Nanomedicine. Advanced Biology, 2019, 3, e1800287.	3.0	22
762	Improving cancerâ€specific outcomes in solid organ transplant recipients: Where to begin?. Cancer, 2019, 125, 838-842.	2.0	3
763	Cancer Epigenomics on Precision Medicine and Immunotherapy. , 2019, , 483-503.		0
764	Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 1692-1697.	3.3	237

#	Article	IF	Citations
765	Rationale for combination of radiation therapy and immune checkpoint blockers to improve cancer treatment. Acta OncolÃ³gica, 2019, 58, 9-20.	0.8	8
766	Development and validation of a UPLC-MS/MS method for determination of motesanib in plasma: Application to metabolic stability and pharmacokinetic studies in rats. Journal of Pharmaceutical and Biomedical Analysis, 2019, 166, 244-251.	1.4	6
767	The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors. Clinical Cancer Research, 2019, 25, 2144-2154.	3.2	134
768	Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study. Clinical Cancer Research, 2019, 25, 515-523.	3.2	354
769	A SERS microfluidic platform for targeting multiple soluble immune checkpoints. Biosensors and Bioelectronics, 2019, 126, 178-186.	5.3	48
770	Exosomes: Isolation, Analysis, and Applications in Cancer Detection and Therapy. ChemBioChem, 2019, 20, 451-461.	1.3	92
771	The lung microenvironment: an important regulator of tumour growth and metastasis. Nature Reviews Cancer, 2019, 19, 9-31.	12.8	692
772	A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2). Gastric Cancer, 2019, 22, 344-354.	2.7	60
773	Blocking IL-1Î² reverses the immunosuppression in mouse breast cancer and synergizes with antiâ€“PD-1 for tumor abrogation. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 1361-1369.	3.3	302
774	Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy. Molecular Therapy, 2019, 27, 244-260.	3.7	67
775	Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-ÎºB Activation and PD-L1 Expression. Molecular Cell, 2019, 73, 22-35.e6.	4.5	174
776	Glioblastoma Therapy in the Age of Molecular Medicine. Trends in Cancer, 2019, 5, 46-65.	3.8	68
777	CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions. Cancer Immunology, Immunotherapy, 2019, 68, 365-377.	2.0	180
778	Metal Drugs and the Anticancer Immune Response. Chemical Reviews, 2019, 119, 1519-1624.	23.0	237
779	Forecasting of emerging therapeutic monoclonal antibodies patents based on a decision model. Technological Forecasting and Social Change, 2019, 139, 185-199.	6.2	31
780	Immune checkpoint blockade opens a new way to cancer immunotherapy. Journal of Cellular Physiology, 2019, 234, 8541-8549.	2.0	84
781	Xinjiang herbal tea exerts immunomodulatory activity via TLR2/4-mediated MAPK signaling pathways in RAW264.7 cells and prevents cyclophosphamide-induced immunosuppression in mice. Journal of Ethnopharmacology, 2019, 228, 179-187.	2.0	29
782	Stimulating T Cells Against Cancer With Agonist Immunostimulatory Monoclonal Antibodies. International Review of Cell and Molecular Biology, 2019, 342, 1-25.	1.6	22

#	Article	IF	Citations
783	Beyond the vicious cycle: The role of innate osteoimmunity, automimicry and tumor-inherent changes in dictating bone metastasis. Molecular Immunology, 2019, 110, 57-68.	1.0	21
784	The cell surface phenotype of human dendritic cells. Seminars in Cell and Developmental Biology, 2019, 86, 3-14.	2.3	45
785	Genomic and epigenomic perspectives of T-cell exhaustion in cancer. Briefings in Functional Genomics, 2019, 18, 113-118.	1.3	6
786	From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview. Antioxidants and Redox Signaling, 2019, 30, 2110-2153.	2.5	96
787	The safety and efficacy of anti-PD-1/anti-PD-L1 antibody therapy in the treatment of previously treated, advanced gastric or gastro-oesophageal junction cancer: A meta-analysis of prospective clinical trials. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 211-222.	0.7	13
788	Monitoring abscopal responses to radiation in mice. Methods in Enzymology, 2020, 635, 111-125.	0.4	2
789	The role of DNA-demethylating agents in cancer therapy. , 2020, 205, 107416.		26
790	Human macrophages and innate lymphoid cells: Tissue-resident innate immunity in humanized mice. Biochemical Pharmacology, 2020, 174, 113672.	2.0	10
791	Advances of functional nanomaterials for cancer immunotherapeutic applications. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2020, 12, e1574.	3.3	10
792	Pathology, Biomarkers, and Molecular Diagnostics. , 2020, , 225-253.e8.		4
793	Role of cell surface proteoglycans in cancer immunotherapy. Seminars in Cancer Biology, 2020, 62, 48-67.	4.3	59
794	Microparticles from tumors exposed to radiation promote immune evasion in part by PD-L1. Oncogene, 2020, 39, 187-203.	2.6	34
795	Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-Î³ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy. Cancer Biology and Therapy, 2020, 21, 130-138.	1.5	6
796	Immune checkpoint inhibitors: a promising anticancer therapy. Drug Discovery Today, 2020, 25, 223-229.	3.2	110
797	Simvastatin increases temozolomideâ€induced cell death by targeting the fusion of autophagosomes and lysosomes. FEBS Journal, 2020, 287, 1005-1034.	2.2	84
798	Dual-functional conjugates improving cancer immunochemotherapy by inhibiting tubulin polymerization and indoleamine-2,3-dioxygenase. European Journal of Medicinal Chemistry, 2020, 189, 112041.	2.6	11
799	Novel immunotherapy combinations for genitourinary cancers. Expert Opinion on Biological Therapy, 2020, 20, 253-262.	1.4	11
800	Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nature Medicine, 2020, 26, 39-46.	15.2	236

#	Article	IF	Citations
801	Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment. Cellular and Molecular Immunology, 2020, 17, 27-35.	4.8	168
802	Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors. BMC Genomics, 2020, 21, 2.	1.2	124
803	CTLA4 blockade promotes vessel normalization in breast tumors via the accumulation of eosinophils. International Journal of Cancer, 2020, 146, 1730-1740.	2.3	51
804	Neutrophils suppress tumorâ€infiltrating T cells in colon cancer via matrix metalloproteinaseâ€mediated activation of <scp>TGF</scp> Î². EMBO Molecular Medicine, 2020, 12, e10681.	3.3	100
805	Developments in anticancer vaccination: budding new adjuvants. Biological Chemistry, 2020, 401, 435-446.	1.2	2
806	Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma. Hepatology International, 2020, 14, 80-95.	1.9	15
807	Combining Doxorubicin-Loaded PEGylated Poly(Lactide-co-glycolide) Nanoparticles with Checkpoint Inhibition Safely Enhances Therapeutic Efficacy in a Melanoma Model. ACS Biomaterials Science and Engineering, 2020, 6, 2659-2667.	2.6	15
808	Peptide-Based Vaccines: Current Progress and Future Challenges. Chemical Reviews, 2020, 120, 3210-3229.	23.0	352
809	Targeting citrate as a novel therapeutic strategy in cancer treatment. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1873, 188332.	3.3	36
810	Targeting Tumor Microenvironment by Small-Molecule Inhibitors. Translational Oncology, 2020, 13, 57-69.	1.7	82
811	Comparative evaluation of bolus and fractionated administration modalities for two antibody-cytokine fusions in immunocompetent tumor-bearing mice. Journal of Controlled Release, 2020, 317, 282-290.	4.8	3
812	The Etiology of Cancer. , 2020, , 1-35.		1
813	Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity. Theranostics, 2020, 10, 1033-1045.	4.6	27
814	Characterization of the prognostic and oncologic values of ITGB superfamily members in pancreatic cancer. Journal of Cellular and Molecular Medicine, 2020, 24, 13481-13493.	1.6	44
815	ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models. PLoS ONE, 2020, 15, e0239595.	1.1	21
816	Dendritic cell tracking and modulation. Nature Materials, 2020, 19, 1134-1135.	13.3	2
817	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives. Cancers, 2020, 12, 3025.	1.7	55
818	Present and Future of Anti-Glioblastoma Therapies: A Deep Look into Molecular Dependencies/Features. Molecules, 2020, 25, 4641.	1.7	7

#	Article	IF	Citations
819	CDK5 Inhibition Abrogates TNBC Stemâ€Cell Property and Enhances Antiâ€PDâ€1 Therapy. Advanced Science, 2020, 7, 2001417.	5.6	24
820	Predictive molecular markers in the era of immunotherapy. Journal of Pancreatology, 2020, 3, 132-138.	0.3	5
821	Recent advances in targeted nanomedicine as promising antitumor therapeutics. Drug Discovery Today, 2020, 25, 2227-2244.	3.2	71
822	Kidney Cancer. Urologic Clinics of North America, 2020, 47, 419-431.	0.8	84
823	Tailoring Viruslike Mesoporous FeSe₂ Hedgehogs for Controlled Drug Delivery and Synergistic Tumor Suppression. ACS Applied Materials & Interfaces, 2020, 12, 47197-47207.	4.0	19
824	A heat-shocked melanoma cell lysate vaccine enhances tumor infiltration by prototypic effector T cells inhibiting tumor growth. , 2020, 8, e000999.		19
825	Correlation of MET and PD-L1 Expression in Malignant Melanoma. Cancers, 2020, 12, 1847.	1.7	8
826	The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells. Cell Communication and Signaling, 2020, 18, 112.	2.7	62
827	Combinatorial Immunotherapies for Metastatic Colorectal Cancer. Cancers, 2020, 12, 1875.	1.7	19
828	Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. IScience, 2020, 23, 101201.	1.9	18
829	Nanovaccineâ€™s rapid induction of anti-tumor immunity significantly improves malignant cancer immunotherapy. Nano Today, 2020, 35, 100923.	6.2	31
830	Immunotherapies and Combination Strategies for Immuno-Oncology. International Journal of Molecular Sciences, 2020, 21, 5009.	1.8	63
831	Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy. Pharmaceutics, 2020, 12, 663.	2.0	24
832	Necroptoticâ€susceptible dendritic cells exhibit enhanced antitumor activities in mice. Immunity, Inflammation and Disease, 2020, 8, 468-479.	1.3	3
833	Rationally Designed Redox-Active Au(I) N-Heterocyclic Carbene: An Immunogenic Cell Death Inducer. Journal of the American Chemical Society, 2020, 142, 20536-20541.	6.6	59
834	PBRM1 and the glycosylphosphatidylinositol biosynthetic pathway promote tumor killing mediated by MHC-unrestricted cytotoxic lymphocytes. Science Advances, 2020, 6, .	4.7	8
835	Targeting the myeloid checkpoint receptor SIRPÎ± potentiates innate and adaptive immune responses to promote anti-tumor activity. Journal of Hematology and Oncology, 2020, 13, 160.	6.9	40
836	Photoâ€Enhanced CRISPR/Cas9 System Enables Robust PDâ€L1 Gene Disruption in Cancer Cells and Cancer Stemâ€Like Cells for Efficient Cancer Immunotherapy. Small, 2020, 16, e2004879.	5.2	21

#	Article	IF	Citations
837	Immune checkpoints and their inhibitors: Reappraisal of a novel diagnostic and therapeutic dimension in the urologic malignancies. Seminars in Oncology, 2020, 47, 367-379.	0.8	6
838	Combination of Photodynamic Therapy and a Flagellin-Adjuvanted Cancer Vaccine Potentiated the Anti-PD-1-Mediated Melanoma Suppression. Cells, 2020, 9, 2432.	1.8	34
839	Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?. International Journal of Molecular Sciences, 2020, 21, 8305.	1.8	58
840	Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitorâ€“Associated Myocarditis. Journal of the American Heart Association, 2020, 9, e018306.	1.6	38
841	Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors. Archivum Immunologiae Et Therapiae Experimentalis, 2020, 68, 36.	1.0	26
842	Multivalent, Soluble Nano-Self Peptides Increase Phagocytosis of Antibody-Opsonized Targets while Suppressing â€œSelfâ€•Signaling. ACS Nano, 2020, 14, 15083-15093.	7.3	12
843	Emerging Therapies in Thoracic Malignanciesâ€”Immunotherapy, Targeted Therapy, and T-Cell Therapy in Nonâ€“Small Cell Lung Cancer. Surgical Oncology Clinics of North America, 2020, 29, 555-569.	0.6	6
844	Trial Watch: experimental TLR7/TLR8 agonists for oncological indications. OncoImmunology, 2020, 9, 1796002.	2.1	63
845	The chemical biology of IL-12 productionviathe non-canonical NFkB pathway. RSC Chemical Biology, 2020, 1, 166-176.	2.0	11
846	Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. Journal of Autoimmunity, 2020, 114, 102514.	3.0	37
847	Single-Sample Node Entropy for Molecular Transition in Pre-deterioration Stage of Cancer. Frontiers in Bioengineering and Biotechnology, 2020, 8, 809.	2.0	7
848	Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy. Theranostics, 2020, 10, 8382-8399.	4.6	42
849	Network-principled deep generative models for designing drug combinations as graph sets. Bioinformatics, 2020, 36, i445-i454.	1.8	24
850	Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors. Pharmacology, 2021, 106, 123-136.	0.9	24
851	Deep learning-based image analysis methods for brightfield-acquired multiplex immunohistochemistry images. Diagnostic Pathology, 2020, 15, 100.	0.9	35
852	Small molecules as antagonists of co-inhibitory pathways for cancer immunotherapy: a patent review (2018-2019). Expert Opinion on Therapeutic Patents, 2020, 30, 677-694.	2.4	6
853	Wild simulated ginseng activates mouse macrophage, RAW264.7Âcells through TRL2/4-dependent activation of MAPK, NF-ÎºB and PI3K/AKT pathways. Journal of Ethnopharmacology, 2020, 263, 113218.	2.0	25
854	The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nature Reviews Cancer, 2020, 20, 662-680.	12.8	860

#	Article	IF	Citations
855	PTEN Function at the Interface between Cancer and Tumor Microenvironment: Implications for Response to Immunotherapy. International Journal of Molecular Sciences, 2020, 21, 5337.	1.8	26
856	Harnessing the Therapeutic Potential of Dendritic Cells. , 2020, , 489-505.		0
857	Dianhydrogalactitol synergizes with topoisomerase poisons to overcome DNA repair activity in tumor cells. Cell Death and Disease, 2020, 11, 577.	2.7	3
858	Targeting the immune milieu in gastrointestinal cancers. Journal of Gastroenterology, 2020, 55, 909-926.	2.3	7
859	Investigating the Role of the N-Terminal Loop of PD-1 in Binding Process Between PD-1 and Nivolumab via Molecular Dynamics Simulation. Frontiers in Molecular Biosciences, 2020, 7, 574759.	1.6	6
860	The tumor microenvironment of colorectal cancer metastases: opportunities in cancer immunotherapy. Immunotherapy, 2020, 12, 1083-1100.	1.0	27
861	Listeria monocytogenes as a Vector for Cancer Immunotherapy. Vaccines, 2020, 8, 439.	2.1	5
862	Conjunctival Melanoma: Update on Genetics, Epigenetics and Targeted Molecular and Immune-Based Therapies . Clinical Ophthalmology, 2020, Volume 14, 3137-3152.	0.9	12
863	Liothyronine could block the programmed death-ligand 1 (PDL1) activity: an e-Pharmacophore modeling and virtual screening study. Journal of Receptor and Signal Transduction Research, 2020, , 1-9.	1.3	10
864	A Phase I, Open-label, Dose-escalation, and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With AdGMCA9 (DC-AdGMCAIX) in Patients With Metastatic Renal Cell Carcinoma. Journal of Immunotherapy, 2020, 43, 273-282.	1.2	11
865	Chemokine biology on immune checkpointâ€“targeted therapies. European Journal of Cancer, 2020, 137, 260-271.	1.3	13
866	A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs. Scientific Reports, 2020, 10, 18311.	1.6	61
867	Targeting TANK-binding kinase 1 (TBK1) in cancer. Expert Opinion on Therapeutic Targets, 2020, 24, 1065-1078.	1.5	26
868	Conserved Interferon-Î³ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer Cell, 2020, 38, 500-515.e3.	7.7	203
869	The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy. Cell Communication and Signaling, 2020, 18, 134.	2.7	28
870	Emerging Roles of 1D Vertical Nanostructures in Orchestrating Immune Cell Functions. Advanced Materials, 2020, 32, e2001668.	11.1	45
871	Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity. , 2020, 8, e001182.		38
872	Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies. Cancers, 2020, 12, 2392.	1.7	171

#	Article	IF	Citations
873	Cellular Uptake of siRNA-Loaded Nanocarriers to Knockdown PD-L1: Strategies to Improve T-cell Functions. Cells, 2020, 9, 2043.	1.8	7
874	Cancer Immunotherapy via Targeting Cancer Stem Cells Using Vaccine Nanodiscs. Nano Letters, 2020, 20, 7783-7792.	4.5	55
875	Black phosphorus-based photothermal therapy with aCD47-mediated immune checkpoint blockade for enhanced cancer immunotherapy. Light: Science and Applications, 2020, 9, 161.	7.7	145
876	The immunocytokine L19-TNF eradicates sarcomas in combination with chemotherapy agents or with immune check-point inhibitors. Anti-Cancer Drugs, 2020, 31, 799-805.	0.7	13
877	Voluntary wheel running can lead to modulation of immune checkpoint molecule expression. Acta OncolÃ³gica, 2020, 59, 1447-1454.	0.8	18
878	Cancers from Novel Pole-Mutant Mouse Models Provide Insights into Polymerase-Mediated Hypermutagenesis and Immune Checkpoint Blockade. Cancer Research, 2020, 80, 5606-5618.	0.4	14
879	A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 23684-23694.	3.3	32
880	Modeling Immune Checkpoint Inhibitor Efficacy in Syngeneic Mouse Tumors in an Ex Vivo Immuno-Oncology Dynamic Environment. International Journal of Molecular Sciences, 2020, 21, 6478.	1.8	7
881	Leveraging the Modularity of Biomaterial Carriers to Tune Immune Responses. Advanced Functional Materials, 2020, 30, 2004119.	7.8	13
882	Cross-reactivity between tumor MHC class Iâ€“restricted antigens and an enterococcal bacteriophage. Science, 2020, 369, 936-942.	6.0	217
883	Targeting Prostate Cancer Using Intratumoral Cytotopically Modified Interleukin-15 Immunotherapy in a Syngeneic Murine Model . ImmunoTargets and Therapy, 2020, Volume 9, 115-130.	2.7	13
884	Systems Immunology Analysis Reveals an Immunomodulatory Effect of Snail-p53 Binding on Neutrophil- and T Cell-Mediated Immunity in KRAS Mutant Non-Small Cell Lung Cancer. Frontiers in Immunology, 2020, 11, 569671.	2.2	6
885	Immune Adaptation of Colorectal Cancer Stem Cells and Their Interaction With the Tumor Microenvironment. Frontiers in Oncology, 2020, 10, 588542.	1.3	15
886	Immune Escape in Prostate Cancer. Urologic Clinics of North America, 2020, 47, e9-e16.	0.8	7
887	Genomic investigation of co-targeting tumor immune microenvironment and immune checkpoints in pan-cancer immunotherapy. Npj Precision Oncology, 2020, 4, 29.	2.3	11
888	Quantitative MRI cell tracking of immune cell recruitment to tumors and draining lymph nodes in response to anti-PD-1 and a DPX-based immunotherapy. OncoImmunology, 2020, 9, 1851539.	2.1	6
889	The Dichotomous Role of Bone Marrow Derived Cells in the Chemotherapy-Treated Tumor Microenvironment. Journal of Clinical Medicine, 2020, 9, 3912.	1.0	6
890	Interrogating Cellular Communication in Cancer with Genetically Encoded Imaging Reporters. Radiology Imaging Cancer, 2020, 2, e190053.	0.7	5

#	Article	IF	Citations
891	Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas. , 2020, 8, e001355.		55
892	T cell factor 1: A master regulator of the T cell response in disease. Science Immunology, 2020, 5, .	5.6	85
893	Case Report: Low-Dose Decitabine Plus Anti-PD-1 Inhibitor Camrelizumab for Previously Treated Advanced Metastatic Non-Small Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 558572.	1.3	12
894	The identification and functional analysis of CD8+PD-1+CD161+ T cells in hepatocellular carcinoma. Npj Precision Oncology, 2020, 4, 28.	2.3	19
895	Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer. BMC Cancer, 2020, 20, 445.	1.1	11
896	The algal polysaccharide ulvan suppresses growth of hepatoma cells. Food Frontiers, 2020, 1, 83-101.	3.7	32
897	Productive screening of single aptamers with ddPCR. Analyst, The, 2020, 145, 4130-4137.	1.7	10
898	Therapeutic ISCOMATRIXâ„¢ adjuvant vaccine elicits effective anti-tumor immunity in the TRAMP-C1 mouse model of prostate cancer. Cancer Immunology, Immunotherapy, 2020, 69, 1959-1972.	2.0	7
899	Macrophage checkpoint blockade: results from initial clinical trials, binding analyses, and CD47-SIRPÎ± structureâ€“function. Antibody Therapeutics, 2020, 3, 80-94.	1.2	73
900	CD40 agonist-induced IL-12p40 potentiates hepatotoxicity. , 2020, 8, e000624.		12
901	Immune Checkpoints Contribute Corneal Immune Privilege: Implications for Dry Eye Associated with Checkpoint Inhibitors. International Journal of Molecular Sciences, 2020, 21, 3962.	1.8	18
902	Mesothelial cells regulate immune responses in health and disease: role for immunotherapy in malignant mesothelioma. Current Opinion in Immunology, 2020, 64, 88-109.	2.4	14
903	Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts. Scientific Reports, 2020, 10, 8867.	1.6	13
904	Nanoparticle delivery of immunostimulatory oligonucleotides enhances response to checkpoint inhibitor therapeutics. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 13428-13436.	3.3	51
905	Efficacy of immune checkpoint inhibitors and age in cancer patients. Immunotherapy, 2020, 12, 587-603.	1.0	21
906	CAR T cell therapy: newer approaches to counter resistance and cost. Heliyon, 2020, 6, e03779.	1.4	19
907	Mimetic Heat Shock Protein Mediated Immune Process to Enhance Cancer Immunotherapy. Nano Letters, 2020, 20, 4454-4463.	4.5	58
908	Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection. BMC Medical Research Methodology, 2020, 20, 103.	1.4	10

#	Article	IF	Citations
909	Engineered IL-21 Cytokine Muteins Fused to Anti-PD-1 Antibodies Can Improve CD8+ T Cell Function and Anti-tumor Immunity. Frontiers in Immunology, 2020, 11, 832.	2.2	35
910	Current status of immune checkpoint inhibitors for gastric cancer. Gastric Cancer, 2020, 23, 565-578.	2.7	133
911	Identification of Tumor Antigens in the HLA Peptidome of Patient-derived Xenograft Tumors in Mouse. Molecular and Cellular Proteomics, 2020, 19, 1360-1374.	2.5	12
912	Radiotherapy Cooperates with IL15 to Induce Antitumor Immune Responses. Cancer Immunology Research, 2020, 8, 1054-1063.	1.6	31
913	Triple Immunotherapy Overcomes Immune Evasion by Tumor in a Melanoma Mouse Model. Frontiers in Oncology, 2020, 10, 839.	1.3	7
914	Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors. Cancers, 2020, 12, 1502.	1.7	145
915	Inosine is an alternative carbon source for CD8+-T-cell function under glucose restriction. Nature Metabolism, 2020, 2, 635-647.	5.1	150
916	Immune checkpoint inhibitors-induced autoimmunity: The impact of gender. Autoimmunity Reviews, 2020, 19, 102590.	2.5	37
917	RNA binding protein PCBP1 is an intracellular immune checkpoint for shaping T cell responses in cancer immunity. Science Advances, 2020, 6, eaaz3865.	4.7	32
918	Assessment of Luminal and Basal Phenotypes in Bladder Cancer. Scientific Reports, 2020, 10, 9743.	1.6	83
919	Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy. British Journal of Clinical Pharmacology, 2020, 86, 1778-1789.	1.1	34
920	The potentials of immune checkpoints for the treatment of blood malignancies. Critical Reviews in Oncology/Hematology, 2020, 153, 103031.	2.0	4
921	Ligand-receptor interaction atlas within and between tumor cells and T cells in lung adenocarcinoma. International Journal of Biological Sciences, 2020, 16, 2205-2219.	2.6	42
922	Biomaterial-based strategies to prime dendritic cell-mediated anti-cancer immune responses. International Materials Reviews, 2020, 65, 445-462.	9.4	16
923	Regulation of Cancer Immune Checkpoints. Advances in Experimental Medicine and Biology, 2020, , .	0.8	7
924	Self-Assembled Multivalent Aptamer Nanoparticles with Potential CAR-like Characteristics Could Activate T Cells and Inhibit Melanoma Growth. Molecular Therapy - Oncolytics, 2020, 17, 9-20.	2.0	27
925	A critical evaluation of pembrolizumab in addition to lenalidomide and dexamethasone for the treatment of multiple myeloma. Expert Review of Hematology, 2020, 13, 435-445.	1.0	5
926	Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 6640-6650.	3.3	141

#	Article	IF	Citations
927	Valproic acid attenuates CCR2-dependent tumor infiltration of monocytic myeloid-derived suppressor cells, limiting tumor progression. OncoImmunology, 2020, 9, 1734268.	2.1	24
928	Augmenting Peptide Flexibility by Inserting Gamma-Aminobutyric Acid (GABA) in Their Sequence. International Journal of Peptide Research and Therapeutics, 2020, 26, 2633-2640.	0.9	4
929	CXCL-10: a new candidate for melanoma therapy?. Cellular Oncology (Dordrecht), 2020, 43, 353-365.	2.1	37
930	Targeting Toll-like receptor 3 in dendritic cells for cancer immunotherapy. Expert Opinion on Biological Therapy, 2020, 20, 937-946.	1.4	19
931	Identification of immune cells and mRNA associated with prognosis of gastric cancer. BMC Cancer, 2020, 20, 206.	1.1	37
932	T cell costimulation, checkpoint inhibitors and anti-tumor therapy. Journal of Biosciences, 2020, 45, 1.	0.5	24
933	Unanticipated Myocarditis in a Surgical Patient Treated With Pembrolizumab: A Case Report. A&A Practice, 2020, 14, e01177.	0.2	8
934	Nanotechnologies for enhancing cancer immunotherapy. Nano Research, 2020, 13, 2595-2616.	5.8	22
935	Multifunctional Nanomodulators Regulate Multiple Pathways To Enhance Antitumor Immunity. ACS Applied Bio Materials, 2020, 3, 4635-4642.	2.3	15
936	Discovery of AB680: A Potent and Selective Inhibitor of CD73. Journal of Medicinal Chemistry, 2020, 63, 11448-11468.	2.9	52
937	The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cellular and Molecular Immunology, 2020, 17, 807-821.	4.8	1,136
938	Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs. Pharmaceutics, 2020, 12, 595.	2.0	7
939	Genomic and single cell sequencing facilitate the dissection of heterogeneity of pancreatic tumors. BMC Medicine, 2020, 18, 177.	2.3	2
940	Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy. Cancers, 2020, 12, 1757.	1.7	17
941	Competition NMR for Detection of Hit/Lead Inhibitors of Proteinâ€“Protein Interactions. Molecules, 2020, 25, 3017.	1.7	11
942	Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process. Cancers, 2020, 12, 1660.	1.7	29
943	Molecular mechanism of the recognition of bacterially cleaved immunoglobulin by the immune regulatory receptor LILRA2. Journal of Biological Chemistry, 2020, 295, 9531-9541.	1.6	8
944	Hyperprogressive disease in patients with advanced renal cell carcinoma: a new pattern of post-treatment cancer behavior. Immunologic Research, 2020, 68, 204-212.	1.3	5

#	Article	IF	Citations
945	Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5. Acta Pharmaceutica Sinica B, 2020, 10, 2299-2312.	5.7	94
946	A Cu9S5 nanoparticle-based CpG delivery system for synergistic photothermal-, photodynamic- and immunotherapy. Communications Biology, 2020, 3, 343.	2.0	29
947	The impact of PD-L1â€‰N-linked glycosylation on cancer therapy and clinical diagnosis. Journal of Biomedical Science, 2020, 27, 77.	2.6	89
948	B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine. Future Oncology, 2020, 16, 1767-1791.	1.1	16
949	Transdermal cold atmospheric plasma-mediated immune checkpoint blockade therapy. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 3687-3692.	3.3	163
950	Non-coding RNAs in GI cancers: from cancer hallmarks to clinical utility. Gut, 2020, 69, 748-763.	6.1	152
951	PD-L1 expression in bladder primary in situ urothelial carcinoma: evaluation in BCG-unresponsive patients and BCG responders. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 269-277.	1.4	13
952	Glial TIM-3 Modulates Immune Responses in the Brain Tumor Microenvironment. Cancer Research, 2020, 80, 1833-1845.	0.4	18
953	Impact of Immune Checkpoint Inhibitors with or without a Combination of Tyrosine Kinase Inhibitors on Organ-Specific Efficacy and Macrovascular Invasion in Advanced Hepatocellular Carcinoma. Oncology Research and Treatment, 2020, 43, 211-220.	0.8	20
954	The abscopal effect 67 years later: from a side story to center stage. British Journal of Radiology, 2020, 93, 20200042.	1.0	73
955	Kinetics of pHâ€dependent interactions between PDâ€1 and PDâ€L1 immune checkpoint proteins from molecular dynamics. Proteins: Structure, Function and Bioinformatics, 2020, 88, 1162-1168.	1.5	4
956	Synergic effect of PD-1 blockade and endostar on the PI3K/AKT/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model. Biomedicine and Pharmacotherapy, 2020, 125, 109746.	2.5	57
957	Tumor-targeting oncolytic virus elicits potent immunotherapeutic vaccine responses to tumor antigens. OncoImmunology, 2020, 9, 1726168.	2.1	9
958	PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models. OncoImmunology, 2020, 9, 1721810.	2.1	79
959	Enzyme-instructed assembly of a cholesterol conjugate promotes pro-inflammatory macrophages and induces apoptosis of cancer cells. Biomaterials Science, 2020, 8, 2007-2017.	2.6	10
960	Nanotherapeutics for Immuno-Oncology: A Crossroad for New Paradigms. Trends in Cancer, 2020, 6, 288-298.	3.8	27
961	Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy. Cells, 2020, 9, 400.	1.8	59
962	Origin and functional heterogeneity of fibroblasts. FASEB Journal, 2020, 34, 3519-3536.	0.2	145

#	Article	IF	Citations
963	CD73 Blockade Promotes Dendritic Cell Infiltration of Irradiated Tumors and Tumor Rejection. Cancer Immunology Research, 2020, 8, 465-478.	1.6	87
964	Oncological outcomes of addition of anti-PD1/PD-L1 to chemotherapy in the therapy of patients with advanced gastric or gastro-oesophageal junction cancer. Medicine (United States), 2020, 99, e18332.	0.4	1
965	PDâ€1/PDâ€L1â€dependent immune response in colorectal cancer. Journal of Cellular Physiology, 2020, 235, 5461-5475.	2.0	86
966	Cytokines as potential combination agents with PDâ€1/PDâ€L1 blockade for cancer treatment. Journal of Cellular Physiology, 2020, 235, 5449-5460.	2.0	42
967	Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-Analysis. International Journal of Molecular Sciences, 2020, 21, 448.	1.8	6
968	Plastic antibodies for cancer therapy?. Nature Chemistry, 2020, 12, 111-112.	6.6	25
969	Sequential delivery of synergistic drugs by silica nanocarriers for enhanced tumour treatment. Journal of Materials Chemistry B, 2020, 8, 1472-1480.	2.9	7
970	Nuclear-localized costimulatory molecule 4-1BBL promotes colon cancer cell proliferation and migration by regulating nuclear Gsk3Î². and is linked to the poor outcomes associated with colon cancer. Cell Cycle, 2020, 19, 577-591.	1.3	4
971	Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody. Molecular Therapy, 2020, 28, 794-804.	3.7	42
972	PD-1 Blockade Reinvigorates Bone Marrow CD8+ T Cells from Patients with Multiple Myeloma in the Presence of TGFÎ² Inhibitors. Clinical Cancer Research, 2020, 26, 1644-1655.	3.2	25
973	Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response. Journal of Clinical Medicine, 2020, 9, 286.	1.0	50
974	Potential role of the PD-L1 expression and tumor-infiltrating lymphocytes on neuroblastoma. Pediatric Surgery International, 2020, 36, 137-143.	0.6	14
975	Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. OncoImmunology, 2020, 9, 1703449.	2.1	156
977	Rational targeting of immunosuppressive neutrophils in cancer. , 2020, 212, 107556.		36
978	Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities. Frontiers in Oncology, 2020, 10, 636.	1.3	24
979	Unravelling the heterogeneity and dynamic relationships of tumorâ€infiltrating T cells by singleâ€cell RNA sequencing analysis. Journal of Leukocyte Biology, 2020, 107, 917-932.	1.5	21
980	Biomaterials for cancer immunotherapy. , 2020, , 499-526.		5
981	Problems with using stability, specificity, and proportionality as criteria for evaluating strength of scientific causal explanations: commentary on Lynch et al. (2019). Biology and Philosophy, 2020, 35, 1.	0.7	5

#	Article	IF	Citations
982	Reverse immune suppressive microenvironment in tumor draining lymph nodes to enhance anti-PD1 immunotherapy via nanovaccine complexed microneedle. Nano Research, 2020, 13, 1509-1518.	5.8	36
983	Utilizing Automated Breast Cancer Detection to Identify Spatial Distributions of Tumor-Infiltrating Lymphocytes in Invasive Breast Cancer. American Journal of Pathology, 2020, 190, 1491-1504.	1.9	66
984	Advancing Cancer Research and Medicine with Single-Cell Genomics. Cancer Cell, 2020, 37, 456-470.	7.7	187
985	Antibodies specific for disease-associated antigens (DAA) expressed in non-malignant diseases reveal potential new tumor-associated antigens (TAA) for immunotherapy or immunoprevention. Seminars in Immunology, 2020, 47, 101394.	2.7	8
986	Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project. , 2020, 8, e000147.		329
987	CD244 represents a new therapeutic target in head and neck squamous cell carcinoma. , 2020, 8, e000245.		28
988	Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials. , 2020, 8, e000492.		55
989	Lifting the innate immune barriers to antitumor immunity. , 2020, 8, e000695.		50
990	The Biogenesis, Biology, and Clinical Significance of Exosomal PD-L1 in Cancer. Frontiers in Immunology, 2020, 11, 604.	2.2	51
991	TCMIO: A Comprehensive Database of Traditional Chinese Medicine on Immuno-Oncology. Frontiers in Pharmacology, 2020, 11, 439.	1.6	34
992	Bladder cancer therapy without toxicityâ€"A doseâ€escalation study of alpha1â€oleate. International Journal of Cancer, 2020, 147, 2479-2492.	2.3	11
993	Changing Technologies of RNA Sequencing and Their Applications in Clinical Oncology. Frontiers in Oncology, 2020, 10, 447.	1.3	72
994	Exendin-4 Promotes Schwann Cell Proliferation and Migration via Activating the Jak-STAT Pathway after Peripheral Nerve Injury. Neuroscience, 2020, 437, 1-10.	1.1	9
996	Immunotherapy in Lung Cancer: From a Minor God to the Olympus. Advances in Experimental Medicine and Biology, 2020, 1244, 69-92.	0.8	15
997	Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. Clinical Cancer Research, 2020, 26, 487-504.	3.2	355
998	Induced Tumor Heterogeneity Reveals Factors Informing Radiation and Immunotherapy Combinations. Clinical Cancer Research, 2020, 26, 2972-2985.	3.2	9
999	A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy. Liver Cancer, 2020, 9, 119-137.	4.2	45
1000	Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment. Cancer Biology and Medicine, 2020, 17, 32-43.	1.4	51

#	Article	IF	Citations
1001	Differential Targeting of Gr-MDSCs, T Cells and Prostate Cancer Cells by Dactolisib and Dasatinib. International Journal of Molecular Sciences, 2020, 21, 2337.	1.8	10
1002	Glucocorticoids and the cytokines IL-12, IL-15, and IL-18 present in the tumor microenvironment induce PD-1 expression on human natural killer cells. Journal of Allergy and Clinical Immunology, 2021, 147, 349-360.	1.5	65
1003	Microbiome and host crosstalk: A new paradigm to cancer therapy. Seminars in Cancer Biology, 2021, 70, 71-84.	4.3	18
1004	Current developments of targeting the p53 signaling pathway for cancer treatment. , 2021, 220, 107720.		70
1005	A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia. American Journal of Hematology, 2021, 96, E46-E50.	2.0	16
1006	Non-coding RNA derived from extracellular vesicles in cancer immune escape: Biological functions and potential clinical applications. Cancer Letters, 2021, 501, 234-246.	3.2	20
1007	Narcissistic T cells: reactivity to self makes a difference. FEBS Journal, 2021, 288, 1778-1788.	2.2	7
1008	Artificial intelligence and the interplay between tumor and immunity. , 2021, , 211-235.		1
1009	Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy. Blood, 2021, 137, 216-231.	0.6	40
1010	Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer. British Journal of Cancer, 2021, 124, 414-424.	2.9	38
1011	Drug delivery systems based on CD44-targeted glycosaminoglycans for cancer therapy. Carbohydrate Polymers, 2021, 251, 117103.	5.1	69
1012	Spatiotemporal combination of thermosensitive polypeptide fused interferon and temozolomide for post-surgical glioblastoma immunochemotherapy. Biomaterials, 2021, 264, 120447.	5.7	19
1013	Axl and Mertk Receptors Cooperate to Promote Breast Cancer Progression by Combined Oncogenic Signaling and Evasion of Host Antitumor Immunity. Cancer Research, 2021, 81, 698-712.	0.4	37
1014	Corn-like Au/Ag nanorod-mediated NIR-II photothermal/photodynamic therapy potentiates immune checkpoint antibody efficacy by reprogramming the cold tumor microenvironment. Biomaterials, 2021, 268, 120582.	5.7	69
1015	Immunotherapeutic strategies for the treatment of ovarian cancer: current status and future direction. Journal of Industrial and Engineering Chemistry, 2021, 94, 62-77.	2.9	11
1016	Autophagy in the cancer-immunity dialogue. Advanced Drug Delivery Reviews, 2021, 169, 40-50.	6.6	46
1017	In situ activation of STING pathway with polymeric SN38 for cancer chemoimmunotherapy. Biomaterials, 2021, 268, 120542.	5.7	57
1018	Histone demethylase UTX/KDM6A enhances tumor immune cell recruitment, promotes differentiation and suppresses medulloblastoma. Cancer Letters, 2021, 499, 188-200.	3.2	21

#	Article	IF	Citations
1019	Chimeric antigen receptor (CAR) natural killer (NK)â€cell therapy: leveraging the power of innate immunity. British Journal of Haematology, 2021, 193, 216-230.	1.2	61
1020	Design, synthesis, evaluation, and SAR of 4-phenylindoline derivatives, a novel class of small-molecule inhibitors of the programmed cell death-1/ programmed cell death-ligand 1 (PD-1/PD-L1) interaction. European Journal of Medicinal Chemistry, 2021, 211, 113001.	2.6	27
1021	Distinct roles of programmed death ligand 1 alternative splicing isoforms in colorectal cancer. Cancer Science, 2021, 112, 178-193.	1.7	24
1022	Targeting MARCO and IL37R on Immunosuppressive Macrophages in Lung Cancer Blocks Regulatory T Cells and Supports Cytotoxic Lymphocyte Function. Cancer Research, 2021, 81, 956-967.	0.4	104
1023	PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells. Human Immunology, 2021, 82, 130-138.	1.2	25
1024	Comparative efficacy and tolerability of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis. European Journal of Cancer, 2021, 144, 49-60.	1.3	16
1025	Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1. Cell Death and Differentiation, 2021, 28, 1773-1789.	5.0	80
1026	Continuous inertial cavitation evokes massive ROS for reinforcing sonodynamic therapy and immunogenic cell death against breast carcinoma. Nano Today, 2021, 36, 101009.	6.2	140
1027	Tumor-targeting anti-EGFR x anti-PD1 bispecific antibody inhibits EGFR-overexpressing tumor growth by combining EGFR blockade and immune activation with direct tumor cell killing. Translational Oncology, 2021, 14, 100916.	1.7	21
1028	The synergistic antitumor activity of 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) and anti-PD-L1 antibody inducing immunogenic cell death. Drug Delivery, 2021, 28, 800-813.	2.5	7
1029	Metastatic cancer: How one can address the therapeutic challenge. , 2021, , 485-514.		0
1030	Effect of Prognostic Nutrition Index in Gastric or Gastro-oesophageal Junction Cancer Patients Undergoing Nivolumab Monotherapy. In Vivo, 2021, 35, 563-569.	0.6	13
1031	Predictive Systems Biomarkers of Response to Immune Checkpoint Inhibitors. SSRN Electronic Journal, 0, , .	0.4	0
1032	Efficacy and side effects of immune checkpoint inhibitors in the treatment of colorectal cancer. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110020.	1.4	11
1033	Supramolecular Assembled Programmable Nanomedicine As In Situ Cancer Vaccine for Cancer Immunotherapy. Advanced Materials, 2021, 33, e2007293.	11.1	106
1034	Expression of Immune Checkpoint Regulators, Cytotoxic T-Lymphocyte Antigen-4, and Programmed Death-Ligand 1 in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma. Applied Immunohistochemistry and Molecular Morphology, 2021, 29, 401-408.	0.6	9
1035	Malignant Melanoma: From Molecular Characterization to Targeted Therapies. , 2021, , .		0
1036	MPA/DMBA-driven mammary carcinomas. Methods in Cell Biology, 2021, 163, 1-19.	0.5	5

#	Article	IF	Citations
1037	Potential alteration of tumor microenvironments by Î²-mercaptoethanol. Future Oncology, 2021, 17, 315-331.	1.1	1
1038	Expression of immune checkpoint molecules in Iraqi acute myeloid leukemia patients. Iraqi Journal of Hematology, 2021, 10, 1.	0.0	2
1039	Current Advances in Black Phosphorusâ€Based Drug Delivery Systems for Cancer Therapy. Advanced Science, 2021, 8, 2003033.	5.6	70
1040	Resveratrol induces PD-L1 expression through snail-driven activation of Wnt pathway in lung cancer cells. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1101-1113.	1.2	37
1041	Nanomaterials for Protein Delivery in Anticancer Applications. Pharmaceutics, 2021, 13, 155.	2.0	34
1042	STING Activated Tumor-Intrinsic Type I Interferon Signaling Promotes CXCR3 Dependent Antitumor Immunity in Pancreatic Cancer. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 41-58.	2.3	35
1043	The Impact of Priming Effect of Immune Checkpoint Inhibitor Therapy for Advanced Stage Non-Small Cell Lung Cancer: A Meta-Epidemiological Study. SSRN Electronic Journal, 0, , .	0.4	0
1044	Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 590-606.	1.3	25
1045	Systems pharmacology dissection of Epimedium targeting tumor microenvironment to enhance cytotoxic T lymphocyte responses in lung cancer. Aging, 2021, 13, 2912-2940.	1.4	11
1046	Overview of Early Detection, Diagnosis, and Treatment of Head and Neck Cancers. , 2021, , 1-15.		0
1047	Holistic Fitness: Microbiomes are Part of the Holobiontâ€™s Fitness. The Microbiomes of Humans, Animals, Plants, and the Environment, 2021, , 101-160.	0.2	1
1048	Challenges and future prospects of nano-enabled cancer management. , 2021, , 229-233.		3
1049	Current and Futuristic Roadmap of Ovarian Cancer Management: An Overview. Advances in Experimental Medicine and Biology, 2021, 1330, 1-19.	0.8	1
1050	Lysosome activable polymeric vorinostat encapsulating PD-L1KD for a combination of HDACi and immunotherapy. Drug Delivery, 2021, 28, 963-972.	2.5	11
1051	The Emerging Role of the Interactions between Circular RNAs and RNA-binding Proteins in Common Human Cancers. Journal of Cancer, 2021, 12, 5206-5219.	1.2	15
1052	Therapeutic Approaches to Employ Monoclonal Antibody for Cancer Treatment. Advances in Medical Diagnosis, Treatment, and Care, 2021, , 42-88.	0.1	0
1053	Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody. MBio, 2021, 12, .	1.8	41
1054	Cancer Stem Cells in the Immune Microenvironment. Advances in Experimental Medicine and Biology, 2021, 1187, 245-266.	0.8	4

#	Article	IF	Citations
1055	Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy. , 2021, 9, e000832.		23
1056	Checkpoint-Inhibitoren. Springer Reference Medizin, 2021, , 1-11.	0.0	0
1057	Mapping the immune environment in clear cell renal carcinoma by single-cell genomics. Communications Biology, 2021, 4, 122.	2.0	139
1058	Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes. Journal of Hematology and Oncology, 2021, 14, 21.	6.9	51
1059	Unlocking the Mystery of the Therapeutic Effects of Chinese Medicine on Cancer. Frontiers in Pharmacology, 2020, 11, 601785.	1.6	18
1060	Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors. Current Oncology Reports, 2021, 23, 13.	1.8	38
1061	Immunotherapy and radiation therapy sequencing: State of the data on timing, efficacy, and safety. Cancer, 2021, 127, 1553-1567.	2.0	33
1062	A digital single-molecule nanopillar SERS platform for predicting and monitoring immune toxicities in immunotherapy. Nature Communications, 2021, 12, 1087.	5.8	62
1064	Mutations in the RAS/MAPK Pathway Drive Replication Repairâ€“Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition. Cancer Discovery, 2021, 11, 1454-1467.	7.7	19
1065	Prognostic values and immune suppression of the S100A family in pancreatic cancer. Journal of Cellular and Molecular Medicine, 2021, 25, 3006-3018.	1.6	26
1066	The MHC Class-I Transactivator NLRC5: Implications to Cancer Immunology and Potential Applications to Cancer Immunotherapy. International Journal of Molecular Sciences, 2021, 22, 1964.	1.8	27
1067	Polypyrrole-Coated Mesoporous TiO₂ Nanocomposites Simultaneously Loading DOX and Aspirin Prodrugs for a Synergistic Theranostic and Anti-Inflammatory Effect. ACS Applied Bio Materials, 2021, 4, 1483-1492.	2.3	13
1068	Interaction Between MDSC and NK Cells in Solid and Hematological Malignancies: Impact on HSCT. Frontiers in Immunology, 2021, 12, 638841.	2.2	34
1069	Traditional Chinese medicine compound, Bu Sheng Hui Yang Fang, promotes the proliferation of lymphocytes in the immunosuppressed mice potentially by upregulating IL-4 signaling. Biomedicine and Pharmacotherapy, 2021, 134, 111107.	2.5	4
1071	Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduction and Targeted Therapy, 2021, 6, 72.	7.1	191
1072	Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial. Digestive and Liver Disease, 2021, 53, 318-323.	0.4	14
1073	Nanomedicine in Cancer Clinics: Are We There Yet?. Current Pathobiology Reports, 2021, 9, 43-55.	1.6	15
1074	Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling. Nature Communications, 2021, 12, 1426.	5.8	176

#	Article	IF	Citations
1075	Reprogramming lipid metabolism prevents effector T cell senescence and enhances tumor immunotherapy. Science Translational Medicine, 2021, 13, .	5.8	101
1076	Host response to immune checkpoint inhibitors contributes to tumor aggressiveness. , 2021, 9, e001996.		9
1077	A Survey of Survival Outcomes for Targeted Cancer Drugs Approved by the US Food and Drug Administration. Therapeutic Innovation and Regulatory Science, 2021, 55, 676-684.	0.8	5
1078	Epithelial Mutant p53 Promotes Resistance to Anti-PD-1-Mediated Oral Cancer Immunoprevention in Carcinogen-Induced Mouse Models. Cancers, 2021, 13, 1471.	1.7	6
1079	Mucins as anti-cancer targets: perspectives of the glycobiologist. Glycoconjugate Journal, 2021, 38, 459-474.	1.4	21
1080	Eliminating mesothelioma by AAV-vectored, PD1-based vaccination in the tumor microenvironment. Molecular Therapy - Oncolytics, 2021, 20, 373-386.	2.0	10
1081	Tumor-derived ILT4 induces T cell senescence and suppresses tumor immunity. , 2021, 9, e001536.		23
1082	Higher postoperative plasma EV PD-L1 predicts poor survival in patients with gastric cancer. , 2021, 9, e002218.		9
1083	Wnt Inhibition Sensitizes PD-L1 Blockade Therapy by Overcoming Bone Marrow-Derived Myofibroblasts-Mediated Immune Resistance in Tumors. Frontiers in Immunology, 2021, 12, 619209.	2.2	13
1084	Melanoma-reactive T cells take up residence. Nature Cancer, 2021, 2, 253-255.	5.7	1
1085	Recent advances in preclinical models for lung squamous cell carcinoma. Oncogene, 2021, 40, 2817-2829.	2.6	26
1086	Tertiary Lymphoid Structure-B Cells Narrow Regulatory T Cells Impact in Lung Cancer Patients. Frontiers in Immunology, 2021, 12, 626776.	2.2	39
1087	Tumor Microenvironment in Metastatic Colorectal Cancer: The Arbitrator in Patientsâ€™ Outcome. Cancers, 2021, 13, 1130.	1.7	15
1088	Lactobacillus rhamnosus GG induces cGAS/STING- dependent type I interferon and improves response to immune checkpoint blockade. Gut, 2022, 71, 521-533.	6.1	108
1089	Characteristics of T-Cell Receptor Repertoire and Correlation With EGFR Mutations in All Stages of Lung Cancer. Frontiers in Oncology, 2021, 11, 537735.	1.3	5
1090	Singleâ€cell transcriptomics reveal the intratumoral landscape of infiltrated Tâ€cell subpopulations in oral squamous cell carcinoma. Molecular Oncology, 2021, 15, 866-886.	2.1	25
1091	CD47 expression and CD163+ macrophages correlated with prognosis of pancreatic neuroendocrine tumor. BMC Cancer, 2021, 21, 320.	1.1	16
1092	Immune Modulation Plus Tumor Ablation: Adjuvants and Antibodies to Prime and Boost Anti-Tumor Immunity In Situ. Frontiers in Immunology, 2021, 12, 617365.	2.2	21

#	Article	IF	Citations
1093	Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment. Frontiers in Immunology, 2021, 12, 633685.	2.2	4
1094	The inflammatory pathogenesis of colorectal cancer. Nature Reviews Immunology, 2021, 21, 653-667.	10.6	270
1095	Vector engineering, strategies and targets in cancer gene therapy. Cancer Gene Therapy, 2022, 29, 402-417.	2.2	18
1096	The PARP Enzyme Family and the Hallmarks of Cancer Part 2: Hallmarks Related to Cancer Host Interactions. Cancers, 2021, 13, 2057.	1.7	16
1097	Increased incidence of venous thromboembolism with cancer immunotherapy. Med, 2021, 2, 423-434.e3.	2.2	46
1098	Development of Immunotherapy Combination Strategies in Cancer. Cancer Discovery, 2021, 11, 1368-1397.	7.7	130
1099	Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel?. Hepatobiliary Surgery and Nutrition, 2021, 10, 180-192.	0.7	47
1100	CD8+ T cells inhibit metastasis and CXCL4 regulates its function. British Journal of Cancer, 2021, 125, 176-189.	2.9	21
1101	Immunotherapy for the Breast Cancer treatment: Current Evidence and Therapeutic Options. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2021, 21, .	0.6	2
1102	Palmoplantar Pustulosis Caused by Immune-Checkpoint Inhibitors. Clinical Lung Cancer, 2021, 22, e829-e832.	1.1	3
1103	A pilot study on EORTC or PERCIST for the prediction of progression-free survival with nivolumab therapy in advanced or metastatic gastric cancers. Medicine (United States), 2021, 100, e25494.	0.4	1
1104	Multimodal Molecular Imaging Detects Early Responses to Immune Checkpoint Blockade. Cancer Research, 2021, 81, 3693-3705.	0.4	15
1105	The Next Decade of Immune Checkpoint Therapy. Cancer Discovery, 2021, 11, 838-857.	7.7	363
1107	Manipulation des cellules Natural KillerÂen immunothÃ©rapie des cancers. Bulletin De L'Academie Nationale De Medecine, 2021, 205, 350-353.	0.0	0
1108	Leveraging Single-Cell Approaches in Cancer Precision Medicine. Trends in Cancer, 2021, 7, 359-372.	3.8	18
1109	Immune Checkpoints, Inhibitors and Radionuclides in Prostate Cancer: Promising Combinatorial Therapy Approach. International Journal of Molecular Sciences, 2021, 22, 4109.	1.8	15
1110	Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy. Journal of Hematology and Oncology, 2021, 14, 68.	6.9	153
1111	Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets. Nature Biomedical Engineering, 2021, 5, 1038-1047.	11.6	164

#	Article	IF	Citations
1112	Recent Progress in the Design and Medical Application of In Situ Self-Assembled Polypeptide Materials. Pharmaceutics, 2021, 13, 753.	2.0	17
1113	The role of exosomal PD-L1 in tumor immunotherapy. Translational Oncology, 2021, 14, 101047.	1.7	31
1114	Emerging concepts in PD-1 checkpoint biology. Seminars in Immunology, 2021, 52, 101480.	2.7	84
1115	Progress for Immunotherapy in Inflammatory Breast Cancer and Emerging Barriers to Therapeutic Efficacy. Cancers, 2021, 13, 2543.	1.7	4
1116	Animal Models in Pharmacology: A Brief History Awarding the Nobel Prizes for Physiology or Medicine. Pharmacology, 2021, 106, 356-368.	0.9	15
1117	Strategies for the Improvement of Metal-Based Chemotherapeutic Treatments. Biomedicines, 2021, 9, 504.	1.4	35
1118	Zeb1 induces immune checkpoints to form an immunosuppressive envelope around invading cancer cells. Science Advances, 2021, 7, .	4.7	53
1119	Characterizing the tumor microenvironment of metastatic ovarian cancer by single-cell transcriptomics. Cell Reports, 2021, 35, 109165.	2.9	75
1120	An Antibody-like Polymeric Nanoparticle Removes Intratumoral Galectin-1 to Enhance Antitumor T-Cell Responses in Cancer Immunotherapy. ACS Applied Materials & Interfaces, 2021, 13, 22159-22168.	4.0	14
1121	Hitchhiking on Controlled-Release Drug Delivery Systems: Opportunities and Challenges for Cancer Vaccines. Frontiers in Pharmacology, 2021, 12, 679602.	1.6	15
1122	LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy. Journal of Experimental Medicine, 2021, 218, .	4.2	53
1123	Current Prospects for Treatment of Solid Tumors via Photodynamic, Photothermal, or Ionizing Radiation Therapies Combined with Immune Checkpoint Inhibition (A Review). Pharmaceuticals, 2021, 14, 447.	1.7	32
1124	Mitochondrial ATP fuels ABC transporter-mediated drug efflux in cancer chemoresistance. Nature Communications, 2021, 12, 2804.	5.8	77
1125	Immunotherapy for Breast Cancer Treatment. Iranian Biomedical Journal, 2021, 25, 140-156.	0.4	2
1126	Nanotechnology synergized immunoengineering for cancer. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 163, 72-101.	2.0	8
1127	Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40. Nature Communications, 2021, 12, 3424.	5.8	74
1128	Bladder cancer therapy using a conformationally fluid tumoricidal peptide complex. Nature Communications, 2021, 12, 3427.	5.8	14
1129	An orally available PD-1/PD-L1 blocking peptide OPBP-1-loaded trimethyl chitosan hydrogel for cancer immunotherapy. Journal of Controlled Release, 2021, 334, 376-388.	4.8	38

#	Article	IF	Citations
1130	Comments on the ambiguity of selected surface markers, signaling pathways and omics profiles hampering the identification of myeloid-derived suppressor cells. Cellular Immunology, 2021, 364, 104347.	1.4	4
1131	Extracellular vesicles as antigen carriers for novel vaccination avenues. Advanced Drug Delivery Reviews, 2021, 173, 164-180.	6.6	49
1132	Precision Medicine in Lung Cancer: Challenges and Opportunities in Diagnostic and Therapeutic Purposes. , 0, , .		0
1133	Natural products targeting cancer cell dependency. Journal of Antibiotics, 2021, 74, 677-686.	1.0	7
1134	Drugâ€induced immuneâ€mediated thrombocytopenia secondary to durvalumab use. Clinical Case Reports (discontinued), 2021, 9, e04227.	0.2	5
1135	Successful Conversion Surgery for Stage IV Gastric Cancer after Nivolumab Monotherapy as Third-Line Chemotherapy. Case Reports in Gastroenterology, 2021, 15, 562-567.	0.3	5
1136	Increased TIGIT expressing NK cells with dysfunctional phenotype in AML patients correlated with poor prognosis. Cancer Immunology, Immunotherapy, 2022, 71, 277-287.	2.0	27
1137	Exosomes in hepatocellular carcinoma microenvironment and their potential clinical application value. Biomedicine and Pharmacotherapy, 2021, 138, 111529.	2.5	16
1138	Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers. Pharmacology Research and Perspectives, 2021, 9, e00808.	1.1	6
1139	Multidiscipline Immunotherapy-Based Rational Combinations for Robust and Durable Efficacy in Brain Metastases from Renal Cell Carcinoma. International Journal of Molecular Sciences, 2021, 22, 6290.	1.8	4
1140	Diversity of Dominant Peripheral T Cell Receptor Clone and Soluble Immune Checkpoint Proteins Associated With Clinical Outcomes Following Immune Checkpoint Inhibitor Treatment in Advanced Cancers. Frontiers in Immunology, 2021, 12, 649343.	2.2	4
1141	T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma. Cancer Immunology, Immunotherapy, 2022, 71, 339-352.	2.0	2
1142	In vitro and in vivo degradation of programmed cell death ligand 1 (PD-L1) by a proteolysis targeting chimera (PROTAC). Bioorganic Chemistry, 2021, 111, 104833.	2.0	37
1143	Biomimetic nanotherapy: coreâ€“shell structured nanocomplexes based on the neutrophil membrane for targeted therapy of lymphoma. Journal of Nanobiotechnology, 2021, 19, 179.	4.2	18
1144	Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cellâ€“Mediated Antitumor Immunity Through PDâ€L1. Hepatology Communications, 2022, 6, 178-193.	2.0	16
1145	Recent development and optimization of pseudomonas aeruginosa exotoxin immunotoxins in cancer therapeutic applications. International Immunopharmacology, 2021, 96, 107759.	1.7	20
1146	Local Destruction of Tumors and Systemic Immune Effects. Frontiers in Oncology, 2021, 11, 708810.	1.3	8
1147	A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer. BMC Cancer, 2021, 21, 877.	1.1	10

#	Article	IF	Citations
1148	Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial. Clinical and Translational Medicine, 2021, 11, e491.	1.7	26
1149	A TLR4 agonist improves immune checkpoint blockade treatment by increasing the ratio of effector to regulatory cells within the tumor microenvironment. Scientific Reports, 2021, 11, 15406.	1.6	12
1150	Research status on immunotherapy trials of gastric cancer. World Journal of Clinical Cases, 2021, 9, 5782-5793.	0.3	5
1151	Recent progress and application of boronate affinity materials in bioanalysis. TrAC - Trends in Analytical Chemistry, 2021, 140, 116271.	5.8	39
1152	Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy. , 2021, 9, e002256.		18
1153	Submicron particle docetaxel intratumoral injection in combination with anti-mCTLA-4 into 4T1-Luc orthotopic implants reduces primary tumor and metastatic pulmonary lesions. Medical Oncology, 2021, 38, 106.	1.2	8
1154	Leveraging NKG2D Ligands in Immuno-Oncology. Frontiers in Immunology, 2021, 12, 713158.	2.2	56
1155	The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma. BMC Cancer, 2021, 21, 761.	1.1	12
1156	Immunity beyond cancer cells: perspective from tumor tissue. Trends in Cancer, 2021, 7, 1010-1019.	3.8	24
1157	Orchestration of myeloid-derived suppressor cells in the tumor microenvironment by ubiquitous cellular protein TCTP released by tumor cells. Nature Immunology, 2021, 22, 947-957.	7.0	37
1158	Dissecting immune cell stat regulation network reveals biomarkers to predict ICB therapy responders in melanoma. Journal of Translational Medicine, 2021, 19, 296.	1.8	4
1159	Immune checkpoints and cancer development: Therapeutic implications and future directions. Pathology Research and Practice, 2021, 223, 153485.	1.0	29
1160	Sialidase-Conjugated â€œNanoNicheâ€•for Efficient Immune Checkpoint Blockade Therapy. ACS Applied Bio Materials, 2021, 4, 5735-5741.	2.3	8
1161	Complete pathological response with diabetic ketoacidosis to the combination of sintilimab and anlotinib in an unresectable hepatocellular carcinoma patient. Anti-Cancer Drugs, 2021, Publish Ahead of Print, .	0.7	4
1162	Identification of a class of non-conventional ER-stress-response-derived immunogenic peptides. Cell Reports, 2021, 36, 109312.	2.9	13
1163	Identification of vitamin B6 as a PD-L1 suppressor and an adjuvant for cancer immunotherapy. Biochemical and Biophysical Research Communications, 2021, 561, 187-194.	1.0	11
1164	The loss of RNA N6-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8+ TÂcell dysfunction and tumor growth. Cancer Cell, 2021, 39, 945-957.e10.	7.7	124
1165	Poor Prognosis and Therapeutic Responses in LILRB1-Expressing M2 Macrophages-Enriched Gastric Cancer Patients. Frontiers in Oncology, 2021, 11, 668707.	1.3	5

#	Article	IF	Citations
1166	Anaphylactic shock in a small cell lung cancer patient receiving atezolizumab therapy: a rare but potentially fatal complication. Investigational New Drugs, 2021, , 1.	1.2	3
1167	DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application. Clinical Epigenetics, 2021, 13, 166.	1.8	85
1168	In Vivo Cell Tracking Using PET: Opportunities and Challenges for Clinical Translation in Oncology. Cancers, 2021, 13, 4042.	1.7	11
1169	Advances in immune therapies for the treatment of microsatellite instabilityâ€'high/deficient mismatch repair metastatic colorectal cancer (Review). International Journal of Oncology, 2021, 59, .	1.4	4
1170	Immune cell infiltration-associated signature in colon cancer and its prognostic implications. Aging, 2021, 13, 19696-19709.	1.4	15
1171	Interpretable systems biomarkers predict response to immune-checkpoint inhibitors. Patterns, 2021, 2, 100293.	3.1	47
1172	Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal. Journal of Nanobiotechnology, 2021, 19, 243.	4.2	14
1173	Targeting AXL in NSCLC. Lung Cancer: Targets and Therapy, 2021, Volume 12, 67-79.	1.3	8
1174	The inhibitory effect of Agrimonia Pilosa methanolic extract on matrix metalloproteinases in HT1080 cells. Journal of Food Biochemistry, 2021, 45, e13894.	1.2	8
1175	The antioncogenic effect of Beclin-1 and FOXP3 is associated with SKP2 expression in gastric adenocarcinoma. Medicine (United States), 2021, 100, e26951.	0.4	4
1176	Epitranscriptomic Approach: To Improve the Efficacy of ICB Therapy by Co-Targeting Intracellular Checkpoint CISH. Cells, 2021, 10, 2250.	1.8	6
1178	Overexpression of CD73 in pancreatic ductal adenocarcinoma is associated with immunosuppressive tumor microenvironment and poor survival. Pancreatology, 2021, 21, 942-949.	0.5	16
1179	Melanoma medicine in the new millennium. British Journal of Dermatology, 2021, 185, 239-240.	1.4	0
1180	STING agonist and IDO inhibitor combination therapy inhibits tumor progression in murine models of colorectal cancer. Cellular Immunology, 2021, 366, 104384.	1.4	26
1181	The Potential of Tissue-Resident Memory T Cells for Adoptive Immunotherapy against Cancer. Cells, 2021, 10, 2234.	1.8	10
1182	TLR4 expression and functionality are downregulated in glioblastoma cells and in tumor-associated macrophages: A new mechanism of immune evasion?. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166155.	1.8	9
1183	Identification of active small-molecule modulators targeting the novel immune checkpoint VISTA. BMC Immunology, 2021, 22, 55.	0.9	11
1184	Single-cell transcriptomic landscape reveals tumor specific innate lymphoid cells associated with colorectal cancer progression. Cell Reports Medicine, 2021, 2, 100353.	3.3	44

#	Article	IF	Citations
1185	Damage-associated molecular patterns and Toll-like receptors in the tumor immune microenvironment. International Immunology, 2021, 33, 841-846.	1.8	7
1186	Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial. , 2021, 9, e002804.		5
1187	PD-L1-Mediated Immunosuppression in Oral Squamous Cell Carcinoma: Relationship With Macrophage Infiltration and Epithelial to Mesenchymal Transition Markers. Frontiers in Immunology, 2021, 12, 693881.	2.2	20
1188	Cancer immunotherapy: Classification, therapeutic mechanisms, and nanomaterial-based synergistic therapy. Applied Materials Today, 2021, 24, 101149.	2.3	7
1189	Radiation-activated secretory proteins of Scgb1a1+ club cells increase the efficacy of immune checkpoint blockade in lung cancer. Nature Cancer, 2021, 2, 919-931.	5.7	26
1190	circHMGCS1â€“016 reshapes immune environment by sponging miR-1236-3p to regulate CD73 and GAL-8 expression in intrahepatic cholangiocarcinoma. Journal of Experimental and Clinical Cancer Research, 2021, 40, 290.	3.5	30
1191	Tumor eradicated by combination of imiquimod and OX40 agonist for in situ vaccination. Cancer Science, 2021, 112, 4490-4500.	1.7	8
1192	A Redoxâ€Responsive Nanovaccine Combined with A2A Receptor Antagonist for Cancer Immunotherapy. Advanced Healthcare Materials, 2021, 10, e2101222.	3.9	23
1193	Conjugated Polymers: Optical Toolbox for Bioimaging and Cancer Therapy. Small, 2021, 17, e2103127.	5.2	31
1194	Integrating Immunotherapy with Chemotherapy: A New Approach to Drug Repurposing. , 0, , .		10
1195	Highlights on the Role of KRAS Mutations in Reshaping the Microenvironment of Pancreatic Adenocarcinoma. International Journal of Molecular Sciences, 2021, 22, 10219.	1.8	14
1196	Cytotoxic T cells are able to efficiently eliminate cancer cells by additive cytotoxicity. Nature Communications, 2021, 12, 5217.	5.8	99
1197	Doxorubicin-Near infrared dye conjugate induces immunogenic cell death to enhance cancer immunotherapy. International Journal of Pharmaceutics, 2021, 607, 121027.	2.6	9
1198	Combination Immunotherapies to Overcome Intrinsic Resistance to Checkpoint Blockade in Microsatellite Stable Colorectal Cancer. Cancers, 2021, 13, 4906.	1.7	18
1199	Multiple-therapy strategies via polysaccharides-based nano-systems in fighting cancer. Carbohydrate Polymers, 2021, 269, 118323.	5.1	19
1200	Immune checkpoint therapy modeling of PD-1/PD-L1 blockades reveals subtle difference in their response dynamics and potential synergy in combination. ImmunoInformatics, 2021, 1-2, 100004.	1.2	1
1201	Viral infections and the efficacy of PD-(L)1 inhibitors in virus-related cancers: Head and neck squamous cell carcinoma and hepatocellular carcinoma. International Immunopharmacology, 2021, 100, 108128.	1.7	13
1202	Anti-PD1 antibody enhances the anti-tumor efficacy of MUC1-MBP fusion protein vaccine via increasing Th1, Tc1 activity and decreasing the proportion of MDSC in the B16-MUC1 melanoma mouse model. International Immunopharmacology, 2021, 101, 108173.	1.7	6

#	Article	IF	Citations
1203	Intrinsic and acquired cancer immunotherapy resistance. , 2022, , 463-497.		0
1204	Implantable and long-lasting drug delivery systems for cancer treatment. , 2022, , 129-162.		2
1205	Polymeric scaffolds for antitumor immune cell priming. , 2022, , 63-95.		2
1206	Mesothelial Cells. , 2022, , 58-66.		0
1207	Intratumoral and Oncoviral Immunotherapy. Digestive Disease Interventions, 2021, 05, 050-054.	0.3	3
1208	Role of immunotherapy in stage IIIA non-small cell lung cancer: a narrative review. Current Challenges in Thoracic Surgery, 0, .	0.2	2
1209	Full Spectrum Flow Cytometry as a Powerful Technology for Cancer Immunotherapy Research. Frontiers in Molecular Biosciences, 2020, 7, 612801.	1.6	52
1210	Introduction: specific disease areas. , 2021, , 43-262.		0
1211	The Unusual Immune System of the Naked Mole-Rat. Advances in Experimental Medicine and Biology, 2021, 1319, 315-327.	0.8	13
1212	Role of Nanomedicine for Cancer Immunotherapy. , 2021, , 115-132.		0
1213	Targeting ubiquitin signaling for cancer immunotherapy. Signal Transduction and Targeted Therapy, 2021, 6, 16.	7.1	34
1214	Contribution of resident and circulating precursors to tumor-infiltrating CD8 ⁺ T cell populations in lung cancer. Science Immunology, 2021, 6, .	5.6	82
1215	Identification of an epigenetic prognostic signature for patients with lowerâ€grade gliomas. CNS Neuroscience and Therapeutics, 2021, 27, 470-483.	1.9	16
1217	Basophils in Tumor Microenvironment and Surroundings. Advances in Experimental Medicine and Biology, 2020, 1224, 21-34.	0.8	30
1218	Immune-Related Adverse Events: Pneumonitis. Advances in Experimental Medicine and Biology, 2020, 1244, 255-269.	0.8	38
1219	Current Landscape of Immunotherapy in Genitourinary Malignancies. Advances in Experimental Medicine and Biology, 2020, 1244, 107-147.	0.8	3
1220	Discovery of New Immune Checkpoints: Family Grows Up. Advances in Experimental Medicine and Biology, 2020, 1248, 61-82.	0.8	20
1221	Mechanisms of Resistance to Checkpoint Blockade Therapy. Advances in Experimental Medicine and Biology, 2020, 1248, 83-117.	0.8	22

#	Article	IF	Citations
1222	Rational Discovery of Response Biomarkers: Candidate Prognostic Factors and Biomarkers for Checkpoint Inhibitor-Based Immunotherapy. Advances in Experimental Medicine and Biology, 2020, 1248, 143-166.	0.8	3
1223	Abdominal CT manifestations of adverse events to immunotherapy: a primer for radiologists. Abdominal Radiology, 2020, 45, 2624-2636.	1.0	8
1224	Drugs repurposed to potentiate immunotherapy for cancer treatment. , 2020, , 311-334.		1
1225	Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist. British Journal of Anaesthesia, 2020, 124, 251-260.	1.5	35
1226	Functional Genomics for Cancer Drug Target Discovery. Cancer Cell, 2020, 38, 31-43.	7.7	46
1227	COVID-19 and Cancer: Current Challenges and Perspectives. Cancer Cell, 2020, 38, 629-646.	7.7	196
1228	Challenges and Chances in the Preclinical to Clinical Translation of Anticancer Metallodrugs. 2-Oxoglutarate-Dependent Oxygenases, 2019, , 308-347.	0.8	14
1229	Arginine metabolism: a potential target in pancreatic cancer therapy. Chinese Medical Journal, 2021, 134, 28-37.	0.9	27
1230	Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors. Current Opinion in Hematology, 2018, 25, 136-145.	1.2	73
1231	PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer. Annals of Surgery, 2019, 269, 471-478.	2.1	135
1240	Enhanced Antitumor Immunity via Endocrine Therapy Prevents Mammary Tumor Relapse and Increases Immune Checkpoint Blockade Sensitivity. Cancer Research, 2021, 81, 1375-1387.	0.4	17
1241	Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. Journal of Clinical Investigation, 2018, 128, 4912-4923.	3.9	214
1242	Cancer neoantigens targeted by adoptive T cell transfer: private no more. Journal of Clinical Investigation, 2019, 129, 949-951.	3.9	5
1243	Senescent T cells within suppressive tumor microenvironments: emerging target for tumor immunotherapy. Journal of Clinical Investigation, 2020, 130, 1073-1083.	3.9	53
1244	TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors. Journal of Clinical Investigation, 2016, 126, 784-794.	3.9	60
1245	The fibrotic tumor stroma. Journal of Clinical Investigation, 2018, 128, 16-25.	3.9	189
1246	Immunogenic Chemotherapy Sensitizes Renal Cancer to Immune Checkpoint Blockade Therapy in Preclinical Models. Medical Science Monitor, 2017, 23, 3360-3366.	0.5	35
1247	Epigenetics in Cancer: A Hematological Perspective. PLoS Genetics, 2016, 12, e1006193.	1.5	77

#	Article	IF	Citations
1248	A Peptide Mimetic of 5-Acetylneuraminic Acid-Galactose Binds with High Avidity to Siglecs and NKG2D. PLoS ONE, 2015, 10, e0130532.	1.1	7
1249	Senolytics and Senostatics: A Two-Pronged Approach to Target Cellular Senescence for Delaying Aging and Age-Related Diseases. Molecules and Cells, 2019, 42, 821-827.	1.0	61
1250	Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies. Critical Reviews in Oncogenesis, 2017, 22, 527-557.	0.2	1
1251	Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma. Aging, 2020, 12, 11466-11484.	1.4	27
1252	How to target small cell lung cancer. Oncoscience, 2015, 2, 684-692.	0.9	11
1253	Cancer cell-binding peptide fused Fc domain activates immune effector cells and blocks tumor growth. Oncotarget, 2016, 7, 75940-75953.	0.8	6
1254	microRNA-210-3p depletion by CRISPR/Cas9 promoted tumorigenesis through revival of TWIST1 in renal cell carcinoma. Oncotarget, 2017, 8, 20881-20894.	0.8	57
1255	Antiproliferative effect of ZSTK474 alone or in combination with chemotherapeutic drugs on HL60 and HL60/ADR cells. Oncotarget, 2017, 8, 39064-39076.	0.8	12
1256	Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein. Oncotarget, 2017, 8, 67439-67456.	0.8	15
1257	Distinct mobilization of leukocytes and hematopoietic stem cells by CXCR4 peptide antagonist LY2510924 and monoclonal antibody LY2624587. Oncotarget, 2017, 8, 94619-94634.	0.8	21
1258	Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting. Oncotarget, 2018, 9, 3576-3589.	0.8	19
1259	An NFÎºB-dependent mechanism of tumor cell plasticity and lateral transmission of aggressive features. Oncotarget, 2018, 9, 26679-26700.	0.8	14
1260	Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette-Guerin. Oncotarget, 2018, 9, 34066-34078.	0.8	45
1261	Epstein-Barr virus: From kisses to cancer, an ingenious immune evader. Oncotarget, 2018, 9, 36411-36412.	0.8	8
1262	Using lymph node swelling as a potential biomarker for successful vaccination. Oncotarget, 2016, 7, 35655-35669.	0.8	11
1263	A novelCBL-Bflox/floxmouse model allows tissue-selective fully conditionalCBL/CBL-Bdouble-knockout: CD4-Cre mediatedCBL/CBL-Bdeletion occurs in both T-cells and hematopoietic stem cells. Oncotarget, 2016, 7, 51107-51123.	0.8	14
1264	Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies. , 2019, 2, 980-993.		9
1265	Gut microbiota: a new player in regulating immune- and chemo-therapy efficacy. , 2020, 3, 356-370.		15

#	Article	IF	Citations
1266	Current Molecular Targeted Agents for Advanced Gastric Cancer . OncoTargets and Therapy, 2020, Volume 13, 4075-4088.	1.0	17
1267	THE ROLE OF TUMOR-ASSOCIATED MACROPHAGES IN THE PATHOGENESIS OF ORAL SQUAMOUS CELL CARCINOMA CORRELATED WITH THE CLINICOPATHOLOGICAL PARAMETERS. Alexandria Dental Journal: ADJ, 2020, .	0.1	1
1268	Cancer Stem Cells and Combination Therapies to Eradicate Them. Current Pharmaceutical Design, 2020, 26, 1994-2008.	0.9	6
1269	Human Papillomavirus Induced Cervical and Oropharyngeal Cancers: From Mechanisms to Potential Immuno-therapeutic Strategies. Current Drug Metabolism, 2020, 21, 167-177.	0.7	4
1270	Can Combined Therapy Benefit Immune Checkpoint Blockade Response in Hepatocellular Carcinoma?. Anti-Cancer Agents in Medicinal Chemistry, 2019, 19, 222-228.	0.9	4
1271	Monoclonal Antibodies for the Treatment of Cancer. Anticancer Research, 2017, 37, 5935-5939.	0.5	79
1272	Detecting and Filtering Immune-Related Adverse Events Signal Based on Text Mining and Observational Health Data Sciences and Informatics Common Data Model: Framework Development Study. JMIR Medical Informatics, 2020, 8, e17353.	1.3	6
1273	Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged. Cancers, 2021, 13, 32.	1.7	27
1274	Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma. Cancers, 2021, 13, 90.	1.7	21
1275	Immunotherapy in human colorectal cancer: Challenges and prospective. World Journal of Gastroenterology, 2016, 22, 6362.	1.4	41
1276	Role of Pentacyclic Triterpenoids in Chemoprevention and Anticancer Treatment: An Overview on Targets and Underling Mechanisms. Journal of Pharmacopuncture, 2019, 22, 55-67.	0.4	72
1277	Rheumatic complications in cancer patients treated with immune checkpoint inhibitors. Korean Journal of Internal Medicine, 2019, 34, 1197-1209.	0.7	11
1278	Immunotherapy a New Hope for Cancer Treatment: A Review. Pakistan Journal of Biological Sciences, 2018, 21, 135-150.	0.2	21
1279	Tumour Regression via Integrative Regulation of Neurological, Inflammatory, and Hypoxic Tumour Microenvironment. Biomolecules and Therapeutics, 2020, 28, 119-130.	1.1	13
1280	Coalition Forces of Immunologists and Oncologists for Defeating Cancer. Immune Network, 2020, 20, e1.	1.6	4
1281	Dynamics of Soluble Programmed Death-Ligand 1 (sPDL1) during Chemotherapy and Its Prognostic Implications in Cancer Patients: Biomarker Development in Immuno-oncology. Cancer Research and Treatment, 2019, 51, 832-840.	1.3	11
1282	PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs. Cancer Research and Treatment, 2020, 52, 661-670.	1.3	72
1283	Why Don't Immune Checkpoint Inhibitors Work in Colorectal Cancer?. Journal of Cancer Science and Research, 0, s2, .	0.1	1

#	Article	IF	Citations
1284	Treatment After First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non- Small-Cell Lung Cancer. Turkish Thoracic Journal, 2017, 18, 66-71.	0.2	7
1285	Prognostic value of programmed cell death ligand-1 expression in ovarian cancer: an updated meta-analysis. Obstetrics and Gynecology Science, 2020, 63, 346-356.	0.6	11
1286	A primer on tumour immunology and prostate cancer immunotherapy. Canadian Urological Association Journal, 2016, 10, 60.	0.3	10
1287	Domain-swapped T cell receptors improve the safety of TCR gene therapy. ELife, 2016, 5, .	2.8	48
1288	Topography of cancer-associated immune cells in human solid tumors. ELife, 2018, 7, .	2.8	206
1289	Inhibitory Effects of 4T1 Breast Tumor Transplantation on Mouse Peripheral Blood Immune Cell Populations. Biotechnology Journal International, 2017, 19, 1-12.	0.2	4
1290	Construction of a competing endogenous RNA network related to the prognosis of cholangiocarcinoma and comprehensive analysis of the immunological correlation. Journal of Gastrointestinal Oncology, 2021, 12, 2287-2309.	0.6	3
1291	Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell, 2021, 39, 1578-1593.e8.	7.7	275
1292	Exploiting Canonical TGFÎ² Signaling in Cancer Treatment. Molecular Cancer Therapeutics, 2022, 21, 16-24.	1.9	10
1293	Improved Immunotherapy Efficacy by Vascular Modulation. Cancers, 2021, 13, 5207.	1.7	12
1294	Gastrointestinal cancer organoidsâ€”applications in basic and translational cancer research. Experimental and Molecular Medicine, 2021, 53, 1459-1470.	3.2	15
1295	Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment. BMC Cancer, 2021, 21, 1134.	1.1	7
1297	Novel Cancer Therapeutics and Implications for Rehabilitation. Current Physical Medicine and Rehabilitation Reports, 2021, 9, 224-229.	0.3	0
1298	Mast Cells as Important Regulators in Autoimmunity and Cancer Development. Frontiers in Cell and Developmental Biology, 2021, 9, 752350.	1.8	15
1299	Rational Design of Potent Peptide Inhibitors of the PD-1:PD-L1 Interaction for Cancer Immunotherapy. Journal of the American Chemical Society, 2021, 143, 18536-18547.	6.6	22
1300	A Different Facet of p53 Function: Regulation of Immunity and Inflammation During Tumor Development. Frontiers in Cell and Developmental Biology, 2021, 9, 762651.	1.8	36
1301	PENTOXIFYLLINE ENHANCES IN VITRO T-CELL ANTITUMOR RESPONSE IN BREAST CANCER PATIENTS. Medical Immunology (Russia), 2021, 23, 785-790.	0.1	0
1302	Lung cancer cells expressing a shortened CDK16 3â€²UTR escape senescence through impaired miRâ€485â€5p targeting. Molecular Oncology, 2022, 16, 1347-1364.	2.1	8

#	Article	IF	Citations
1304	Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis. Biomedicines, 2021, 9, 1484.	1.4	10
1305	Abscopal effect in the radio and immunotherapy. Radiation Oncology Journal, 2021, 39, 247-253.	0.7	15
1306	A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+â€‰tumors in hPD-1 transgenic mouse model and contributes immune memory formation. Breast Cancer Research and Treatment, 2022, 191, 51-61.	1.1	24
1307	Single-cell sequencing reveals antitumor characteristics of intratumoral immune cells in old mice. , 2021, 9, e002809.		11
1308	Identification of Novel Modalities Through Bibliometric Analysis for Timely Development of Regulatory Guidance: A Case Study of T Cell Immunity. Frontiers in Medicine, 2021, 8, 756870.	1.2	2
1309	The Era of Personalized Cancer Treatments. Juntendo Medical Journal, 2016, 62, 2-6.	0.1	0
1310	Advances in lung cancer with a focus on ATS 2016 updates. Journal of Thoracic Disease, 2016, 8, S566-S568.	0.6	0
1311	Cancer Epigenomics on Precision Medicine and Immunotherapy. , 2017, , 1-21.		0
1312	Immunotherapy and Targeted Therapies in Advanced Castration Resistant Prostate Cancer. , 2017, , 357-377.		1
1314	Programmed death-1 (PD-1) ligand 1 and PD-1 ligand 2 expressions and their clinical relevance in colorectal cancer. Korean Journal of Clinical Oncology, 2017, 13, 131-137.	0.1	0
1315	Surrogate Role of CD85k on Monocytic Lineage Involved Leukemogenesis Biology and Clinical Aspect. Open Journal of Blood Diseases, 2018, 08, 61-73.	0.1	0
1316	The Effects of Checkpoint Blockade and a CD40 Agonist on Tindependent and T-dependent Antibody Responses in Mice: Implications for Optimization of Vaccination Strategies in Patients Receiving Immunotherapies. Journal of Cancer Research and Immuno-Oncology, 2018, 04, .	0.0	0
1317	PDL1 is Expressed in the Islets of People With Type 1 Diabetes and is Up-regulated by Interferons-- and--. SSRN Electronic Journal, 0, , .	0.4	0
1318	Voluntary Wheel Running Regulates Tumor Immunogenicity and Response to Immune Checkpoint Therapy. SSRN Electronic Journal, 0, , .	0.4	0
1319	Novel Options in Metastatic and Non-surgically Curable Bladder Cancer. European Oncology and Haematology, 2018, 14, 87.	0.0	0
1320	Predicting hepatocellular carcinoma through cross-talk genes identified by risk pathways. Oncotarget, 2018, 9, 21259-21267.	0.8	0
1323	Systemische Therapie: Grundlagen. Springer Reference Medizin, 2019, , 1-7.	0.0	0
1324	Emerging Immune Context. , 2019, , 269-329.		0

#	Article	IF	Citations
1325	Immunotherapy with mRNA vaccination and immunomodulation nanomedicine for cancer therapy. , 2019, , 551-600.		0
1326	Microbial-Based Cancer Therapy: Diagnostic Tools and Therapeutic Strategies. Microorganisms for Sustainability, 2019, , 53-82.	0.4	0
1328	Cancer Therapy. , 2019, , 7-76.		0
1329	Germline variants in cancer therapy. , 2019, 2, 18-30.		3
1331	Treatment Effect of Tuftsin and Antigen Peptide Combined with Immune Cells on Colorectal Cancer. Medical Science Monitor, 2019, 25, 5465-5472.	0.5	3
1335	iDeBlurInfo: An Assessment and Evaluation Study of Image Deblurring Techniques. , 2019, , .		0
1338	Correlation of Programmed Death Ligand-1 (PD-L1) Expression with Clinicopathological Features in Non-Small Cell Lung Carcinoma: Experience from a Tertiary Cancer Care Center in India. Journal of Cancer Therapy, 2020, 11, 172-187.	0.1	1
1342	Cancer vaccines from cryogenically silicified tumour cells functionalized with pathogen-associated molecular patterns. Nature Biomedical Engineering, 2022, 6, 19-31.	11.6	50
1343	Engineering a variant of IL-17RA with high binding affinity to IL-17A for optimized immunotherapy. Biotechnology Reports (Amsterdam, Netherlands), 2021, 32, e00682.	2.1	1
1344	Gene modification strategies using AOâ€mediated exon skipping and CRISPR/Cas9 as potential therapies for Duchenne muscular dystrophy patients. Engineering Biology, 2020, 4, 37-42.	0.8	0
1345	Immunotherapy and prevention of breast cancer. Muthanna Medical Journal, 2020, 7, 58-70.	0.0	0
1346	Wnt signaling pathway in cancer immunotherapy. Cancer Letters, 2022, 525, 84-96.	3.2	60
1347	Perspectives on the Role of T Cell Negative Immune Checkpoint Receptors in Health and Disease. , 2020, , 297-318.		0
1348	Higher Post-Operative Plasma EV PD-L1 Predicts Poor Survival in Gastric Cancer Patients. SSRN Electronic Journal, 0, , .	0.4	0
1349	Current Perspectives on Cancer Immunotherapy in Bone. , 2020, , 421-437.		0
1350	Integrative molecular characterization of Chinese prostate cancer specimens. Asian Journal of Andrology, 2020, 22, 162.	0.8	7
1352	Higher Expression of WT1 With Lower CD58 Expression may be Biomarkers for Risk Stratification of Patients With Cytogenetically Normal Acute Myeloid Leukemia. Technology in Cancer Research and Treatment, 2021, 20, 153303382110521.	0.8	6
1353	Surgery After Conversion Therapy With PD-1 Inhibitors Plus Tyrosine Kinase Inhibitors Are Effective and Safe for Advanced Hepatocellular Carcinoma: A Pilot Study of Ten Patients. Frontiers in Oncology, 2021, 11, 747950.	1.3	33

#	Article	IF	Citations
1354	Cancer-cell-biomimetic nanoparticles systemically eliminate hypoxia tumors by synergistic chemotherapy and checkpoint blockade immunotherapy. Acta Pharmaceutica Sinica B, 2022, 12, 2103-2119.	5.7	24
1355	The roles of exosomal immune checkpoint proteins in tumors. Military Medical Research, 2021, 8, 56.	1.9	12
1356	Prostate cancer research in the 21st century; report from the 2021 Coffeyâ€Holden prostate cancer academy meeting. Prostate, 2021, , .	1.2	2
1357	Genetically Programmable Fusion Cellular Vesicles for Cancer Immunotherapy. Angewandte Chemie - International Edition, 2021, 60, 26320-26326.	7.2	55
1359	Current Perspectives on the Immunosuppressive Niche and Role of Fibrosis in Hepatocellular Carcinoma and the Development of Antitumor Immunity. Journal of Histochemistry and Cytochemistry, 2022, 70, 53-81.	1.3	6
1360	Genetically Programmable Fusion Cellular Vesicles for Cancer Immunotherapy. Angewandte Chemie, 2021, 133, 26524-26530.	1.6	2
1362	Acute liver injury associated with rechallenge with a different type of immune checkpoint inhibitor in a patient with a history of severe immune-related adverse events. Acta Hepatologica Japonica, 2020, 61, 572-581.	0.0	2
1363	Therapeutic Monoclonal Antibodies in Clinical Practice against Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2020, 20, 1895-1907.	0.9	2
1364	Artificial T Cell Mimetics to Combat Melanoma Tumor Growth. American Journal of Advanced Drug Delivery, 2018, 6, 21-32.	0.1	2
1366	Overexpression of B7-H3 as an opportunity for targeted therapy in head and neck cancers. American Journal of Translational Research (discontinued), 2019, 11, 5183-5196.	0.0	6
1367	Conditionally reprogrammed colorectal cancer cells combined with mouse avatars identify synergy between EGFR and MEK or CDK4/6 inhibitors. American Journal of Cancer Research, 2020, 10, 249-262.	1.4	7
1368	Heterogeneous responses in hepatocellular carcinoma: the achilles heel of immune checkpoint inhibitors. American Journal of Cancer Research, 2020, 10, 1085-1102.	1.4	2
1369	Novel genetic variants of and involved in immunoregulatory interactions are associated with non-small cell lung cancer survival. American Journal of Cancer Research, 2020, 10, 1770-1784.	1.4	2
1370	Immune checkpoint targeting TIGIT in hepatocellular carcinoma. American Journal of Translational Research (discontinued), 2020, 12, 3212-3224.	0.0	12
1371	Personalised Medicine: implication and perspectives in the field of occupational health. Medicina Del Lavoro, 2020, 111, 425-444.	0.3	7
1372	Prognostic impact of sarcopenia on immune-related adverse events in malignancies received immune checkpoint inhibitors: a systematic review and meta-analysis. Translational Cancer Research, 2021, 10, 5150-5158.	0.4	6
1373	Bridging Radiotherapy to Immunotherapy: The IFNâ€“JAKâ€“STAT Axis. International Journal of Molecular Sciences, 2021, 22, 12295.	1.8	13
1374	Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Nonâ€“Small Cell Lung Cancer. JAMA Network Open, 2021, 4, e2134299.	2.8	13

#	Article	IF	Citations
1375	Expression of nonâ€'homologous end joining factor, Ku80, is negatively correlated with PDâ€'L1 expression in cancer cells after Xâ€'ray irradiation. Oncology Letters, 2021, 23, 29.	0.8	7
1376	IgA Nephropathy Secondary to Ipilimumab Use. Case Reports in Nephrology and Dialysis, 2022, 11, 327-333.	0.3	3
1377	Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer. OncoTargets and Therapy, 2021, Volume 14, 5275-5291.	1.0	5
1378	STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors. Molecular Cancer Therapeutics, 2022, 21, 282-293.	1.9	6
1379	Cancer Treatment Evolution from Traditional Methods to Stem Cells and Gene Therapy. Current Gene Therapy, 2022, 22, 368-385.	0.9	10
1380	Vitamin C, From Supplement to Treatment: A Re-Emerging Adjunct for Cancer Immunotherapy?. Frontiers in Immunology, 2021, 12, 765906.	2.2	12
1381	Surgical Conversion for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Using a Triple Combination of Angiogenesis Inhibitors, Anti-PD-1 Antibodies, and Hepatic Arterial Infusion Chemotherapy: A Retrospective Study. Frontiers in Oncology, 2021, 11, 729764.	1.3	28
1382	Combination of epigenetic regulation with gene therapy-mediated immune checkpoint blockade induces anti-tumour effects and immune response in vivo. Nature Communications, 2021, 12, 6742.	5.8	45
1383	Radioimaging of Activated T Cells in Preclinical and Clinical Cancer Investigations. , 2022, , 61-101.		0
1384	A newly intervention strategy in preeclampsia: Targeting PDâ€1/Timâ€3 signaling pathways to modulate the polarization of decidual macrophages. FASEB Journal, 2022, 36, e22073.	0.2	11
1385	Oncolytic adenovirus inhibits malignant ascites of advanced ovarian cancer by reprogramming the ascitic immune microenvironment. Molecular Therapy - Oncolytics, 2021, 23, 488-500.	2.0	4
1386	Modulating undruggable targets to overcome cancer therapy resistance. Drug Resistance Updates, 2022, 60, 100788.	6.5	15
1387	Immune Checkpoint Therapy. Urological Science, 2020, 31, 1-2.	0.2	0
1388	Landscape of Immunotherapy in Genitourinary Malignancies. Advances in Experimental Medicine and Biology, 2021, 1342, 143-192.	0.8	2
1389	External stimuli-responsive nanomedicine for cancer immunotherapy. , 2021, , .		0
1390	Pulmonary Toxicities of Immunotherapy. Advances in Experimental Medicine and Biology, 2021, 1342, 357-375.	0.8	4
1391	BDNF expression in GISTs predicts poor prognosis when associated with PD-L1 positive tumor-infiltrating lymphocytes. OncoImmunology, 2021, 10, 2003956.	2.1	3
1392	Nanomaterials with changeable physicochemical property for boosting cancer immunotherapy. Journal of Controlled Release, 2022, 342, 210-227.	4.8	16

#	Article	IF	Citations
1393	A PD1 targeted nano-delivery system based on epigenetic alterations of TÂcell responses in the treatment of gastric cancer. Molecular Therapy - Oncolytics, 2022, 24, 148-159.	2.0	14
1394	The anti-programmed cell death 1 antibody immunotherapy: A paradigm shift in the treatment of nonsmall-cell lung cancer. Nigerian Journal of Cardiovascular & Thoracic Surgery, 2020, 5, 29.	0.1	0
1395	Overlapping NMDA-R and GFAP Antibody Autoimmune Encephalitis After Nivolumab Therapy. Neurology: Clinical Practice, 2021, 11, e913-e915.	0.8	0
1396	Autoimmune and Inflammatory Encephalopathies as Complications of Cancer. , 2022, , 430-459.		0
1397	A Novel Immune-Related ceRNA Network and Relative Potential Therapeutic Drug Prediction in ccRCC. Frontiers in Genetics, 2021, 12, 755706.	1.1	5
1398	LCVM infection generates tumor antigen-specific immunity and inhibits growth of nonviral tumors. OncoImmunology, 2022, 11, 2029083.	2.1	3
1399	Targeting Oncogenic Pathways in the Era of Personalized Oncology: A Systemic Analysis Reveals Highly Mutated Signaling Pathways in Cancer Patients and Potential Therapeutic Targets. Cancers, 2022, 14, 664.	1.7	7
1400	Cellular architecture of human brain metastases. Cell, 2022, 185, 729-745.e20.	13.5	69
1401	Soluble Expression of a Neo2/15-Conjugated Single Chain Fv against PD-L1 in Escherichia coli. Current Issues in Molecular Biology, 2022, 44, 301-308.	1.0	1
1402	Monoclonal Antibodies Generation: Updates and Protocols on Hybridoma Technology. Methods in Molecular Biology, 2022, 2435, 73-93.	0.4	3
1403	Differential expression of inhibitory receptor NKG2A distinguishes diseaseâ€specific exhausted CD8 + T cells. MedComm, 2022, 3, e111.	3.1	2
1404	New Therapeutic Approaches for Conjunctival Melanomaâ€"What We Know So Far and Where Therapy Is Potentially Heading: Focus on Lymphatic Vessels and Dendritic Cells. International Journal of Molecular Sciences, 2022, 23, 1478.	1.8	4
1405	Enhancing the therapeutic efficacy of programmed death ligand 1 antibody for metastasized liver cancer by overcoming hepatic immunotolerance in mice. Hepatology, 2022, 76, 630-645.	3.6	13
1406	Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3KÎ±/Î²/Î´ treatment. Nature Communications, 2022, 13, 182.	5.8	40
1407	Childhood Medulloblastoma: An Overview. Methods in Molecular Biology, 2022, 2423, 1-12.	0.4	5
1408	Single-Cell Technologies to Decipher the Immune Microenvironment in Myeloid Neoplasms: Perspectives and Opportunities. Frontiers in Oncology, 2021, 11, 796477.	1.3	0
1409	Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy. , 2022, 235, 108114.		13
1410	The radiobiology of TGFÎ². Seminars in Cancer Biology, 2022, 86, 857-867.	4.3	15

#	Article	IF	Citations
1411	Immune Checkpoint Blockade Augments Changes Within Oncolytic Virus-induced Cancer MHC-I Peptidome, Creating Novel Antitumor CD8 T Cell Reactivities. Molecular and Cellular Proteomics, 2022, 21, 100182.	2.5	3
1412	NIR-II laser-mediated photo-Fenton-like reaction via plasmonic Cu9S8 for immunotherapy enhancement. Nano Today, 2022, 43, 101397.	6.2	33
1413	A pH-sensitive nanomedicine incorporating catalase gene and photosensitizer augments photodynamic therapy and activates antitumor immunity. Nano Today, 2022, 43, 101390.	6.2	32
1414	Antibodyâ€incorporated Nanomedicines for Cancer Therapy. Advanced Materials, 2022, 34, e2109210.	11.1	32
1415	Leveraging self-assembled nanobiomaterials for improved cancer immunotherapy. Cancer Cell, 2022, 40, 255-276.	7.7	45
1416	Core-shell structured nanoparticles for photodynamic therapy-based cancer treatment and related imaging. Coordination Chemistry Reviews, 2022, 458, 214427.	9.5	30
1417	T cell costimulation, checkpoint inhibitors and anti-tumor therapy. Journal of Biosciences, 2020, 45, .	0.5	6
1418	NIR-II Laser-Mediated Photo-Fenton-Like Reaction <i>Via</i> Plasmonic Cu ₉S ₈ for Immunotherapy Enhancement. SSRN Electronic Journal, 0, , .	0.4	0
1419	Molecular imprinting of glycoproteins: From preparation to cancer theranostics. Theranostics, 2022, 12, 2406-2426.	4.6	18
1420	Patient-derived functional organoids as a personalized approach for drug screening against hepatobiliary cancers. Advances in Cancer Research, 2022, , 319-341.	1.9	2
1421	Targeting Myeloid Suppressive Cells Revives Cytotoxic Anti-Tumor Responses in Pancreatic Cancer. SSRN Electronic Journal, 0, , .	0.4	0
1422	Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents. Trends in Cancer, 2022, 8, 426-444.	3.8	13
1423	New Developments in T Cell Immunometabolism and Implications for Cancer Immunotherapy. Cells, 2022, 11, 708.	1.8	8
1424	Cell membrane coated-nanoparticles for cancer immunotherapy. Acta Pharmaceutica Sinica B, 2022, 12, 3233-3254.	5.7	61
1425	Gut Microbiota: A Promising Milestone in Enhancing the Efficacy of PD1/PD-L1 Blockade Therapy. Frontiers in Oncology, 2022, 12, 847350.	1.3	6
1426	The tumor immune-microenvironment in gastric cancer. Tumori, 2022, 108, 541-551.	0.6	12
1427	Enhanced antitumor chemoâ€immunotherapy by local coâ€delivery of chemotherapeutics, immune checkpoint blocking antibody and <scp>IDO</scp> inhibitor using an injectable polypeptide hydrogel. Journal of Polymer Science, 2022, 60, 1595-1609.	2.0	9
1428	PTPN2 elicits cell autonomous and nonâ€“cell autonomous effects on antitumor immunity in triple-negative breast cancer. Science Advances, 2022, 8, eabk3338.	4.7	22

#	Article	IF	Citations
1429	Immune Infiltration in Gastric Cancer Microenvironment and Its Clinical Significance. Frontiers in Cell and Developmental Biology, 2021, 9, 762029.	1.8	10
1430	Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic Melanoma. American Journal of Clinical Dermatology, 2022, 23, 331-338.	3.3	16
1431	Fluence rate differences in photodynamic therapy efficacy and activation of immune checkpoints of murine colorectal cancer. , 2022, , .		0
1432	1Î±,25(OH)₂D₃reverses exhaustion and enhances antitumor immunity of human cytotoxic T cells. , 2022, 10, e003477.		17
1433	Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study. Cancer Immunology, Immunotherapy, 2022, 71, 2597-2608.	2.0	25
1434	Recent advances in overcoming barriers to cellâ€based delivery systems for cancer immunotherapy. Exploration, 2022, 2, .	5.4	68
1435	Thermosensitive hydrogel releasing nitric oxide donor and anti-CTLA-4 micelles for anti-tumor immunotherapy. Nature Communications, 2022, 13, 1479.	5.8	61
1437	Immunotherapy and Transarterial therapy of <scp>HCC</scp>: What the interventional radiologist needs to know about the changing landscape of <scp>HCC</scp> treatment?. Journal of Medical Imaging and Radiation Oncology, 2022, 66, 478-482.	0.9	10
1438	Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events. Frontiers in Immunology, 2022, 13, 804597.	2.2	27
1440	Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies. Cancers, 2022, 14, 1732.	1.7	185
1441	Metal-Organic Framework-Based Nanotherapeutics With Tumor Hypoxia-Relieving Ability for Synergistic Sonodynamic/Chemo-therapy. Frontiers in Materials, 2022, 9, .	1.2	8
1442	Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses. Journal of Hematology and Oncology, 2022, 15, 37.	6.9	23
1443	Development and Validation of Ferroptosis-Related LncRNA Biomarker in Bladder Carcinoma. Frontiers in Cell and Developmental Biology, 2022, 10, 809747.	1.8	5
1444	Bispecific Antibodies Progression in Malignant Melanoma. Frontiers in Pharmacology, 2022, 13, 837889.	1.6	0
1445	Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy. Molecular Cancer, 2022, 21, 64.	7.9	45
1446	Microbiota-dependent activation of the myeloid calcineurin-NFAT pathway inhibits B7H3- and B7H4-dependent anti-tumor immunity in colorectal cancer. Immunity, 2022, 55, 701-717.e7.	6.6	16
1447	Single-Cell RNA Sequencing with Spatial Transcriptomics of Cancer Tissues. International Journal of Molecular Sciences, 2022, 23, 3042.	1.8	28
1448	Adapted to Survive: Targeting Cancer Cells with BH3 Mimetics. Cancer Discovery, 2022, 12, 1217-1232.	7.7	16

#	Article	IF	Citations
1449	RNA and RNA derivatives: light and dark sides in cancer immunotherapy. Antioxidants and Redox Signaling, 2022, , .	2.5	0
1450	Epithelialâ€“Mesenchymal Plasticity in Tumor Immune Evasion. Cancer Research, 2022, 82, 2329-2343.	0.4	23
1451	Exosomal circGSE1 promotes immune escape of hepatocellular carcinoma by inducing the expansion of regulatory T cells. Cancer Science, 2022, 113, 1968-1983.	1.7	38
1452	Therapeutic targeting of TANK-binding kinase signaling towards anticancer drug development: Challenges and opportunities. International Journal of Biological Macromolecules, 2022, 207, 1022-1037.	3.6	9
1453	Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response. Translational Oncology, 2022, 20, 101405.	1.7	25
1454	Natural killer cell therapy: A new frontier for obesity-associated cancer. Cancer Letters, 2022, 535, 215620.	3.2	17
1455	Sulfisoxazole Elicits Robust Antitumour Immune Response Along with Immune Checkpoint Therapy by Inhibiting Exosomal PDâ€Ł1. Advanced Science, 2022, 9, e2103245.	5.6	22
1456	Lipid-loaded tumor-associated macrophages sustain tumor growth and invasiveness in prostate cancer. Journal of Experimental Medicine, 2022, 219, .	4.2	53
1457	Depletion of central memory CD8+ T cells might impede the antitumor therapeutic effect of Mogamulizumab. Nature Communications, 2021, 12, 7280.	5.8	11
1458	Epsteinâ€“Barr Virus Epithelial Cancersâ€”A Comprehensive Understanding to Drive Novel Therapies. Frontiers in Immunology, 2021, 12, 734293.	2.2	24
1459	Discovery of Spiro-azaindoline Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1). ACS Medicinal Chemistry Letters, 2022, 13, 84-91.	1.3	17
1460	Chemokines in the Landscape of Cancer Immunotherapy: How They and Their Receptors Can Be Used to Turn Cold Tumors into Hot Ones?. Cancers, 2021, 13, 6317.	1.7	17
1461	Conversion therapy with an immune checkpoint inhibitor and an antiangiogenic drug for advanced hepatocellular carcinoma: A review. BioScience Trends, 2022, 16, 130-141.	1.1	14
1462	Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nature Communications, 2022, 13, 1970.	5.8	34
1463	Emerging therapies for glioblastoma: current state and future directions. Journal of Experimental and Clinical Cancer Research, 2022, 41, 142.	3.5	103
1464	AHCCÂ®, a Standardized Extract of Cultured Lentinula Edodes Mycelia, Promotes the Anti-Tumor Effect of Dual Immune Checkpoint Blockade Effect in Murine Colon Cancer. Frontiers in Immunology, 2022, 13, 875872.	2.2	5
1465	T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor Reactivity. Cancers, 2022, 14, 1998.	1.7	9
1466	Sialic acids: An Avenue to Target Cancer Progression, Metastasis, and Resistance to Therapy. Forum of Clinical Oncology, 2021, 12, 40-48.	0.1	2

#	Article	IF	Citations
1468	Prognostic factors of recurrent intrahepatic cholangiocarcinoma after hepatectomy: A retrospective study. World Journal of Gastroenterology, 2022, 28, 1574-1587.	1.4	1
1469	Dissecting the Role of Immune Checkpoint Regulation Patterns in Tumor Microenvironment and Prognosis of Gastric Cancer. Frontiers in Genetics, 2022, 13, 853648.	1.1	5
1470	Evaluation of Prognostic Factors for Unresectable or Recurrent Gastric Cancer Treated with Nivolumab. Journal of Gastrointestinal Cancer, 2023, 54, 485-491.	0.6	3
1505	Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial. Journal of Cancer Research and Clinical Oncology, 2023, 149, 779-789.	1.2	10
1506	Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy. Science Advances, 2022, 8, eabl9171.	4.7	30
1507	IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatinâ€“paclitaxel, with or without bevacizumab in patients with advanced cancer. , 2022, 10, e003924.		8
1512	New paradigm in combination therapy of siRNA with chemotherapeutic drugs for effective cancer therapy. Current Research in Pharmacology and Drug Discovery, 2022, 3, 100103.	1.7	12
1513	Preclinical Development of Seriniquinones as Selective Dermcidin Modulators for the Treatment of Melanoma. Marine Drugs, 2022, 20, 301.	2.2	2
1514	Anti-Tumoral Effect and Action Mechanism of Exosomes Derived From Toxoplasma gondii-Infected Dendritic Cells in Mice Colorectal Cancer. Frontiers in Oncology, 2022, 12, .	1.3	4
1515	Cell surfaceâ€“tethered IL-12 repolarizes the tumor immune microenvironment to enhance the efficacy of adoptive T cell therapy. Science Advances, 2022, 8, eabi8075.	4.7	21
1516	Bifunctional Pdots-Based Novel ECL Nanoprobe with Qualitative and Quantitative Dual Signal Amplification Characteristics for Trace Cytokine Analysis. Analytical Chemistry, 2022, 94, 7115-7122.	3.2	5
1517	Pharmacological targeting of the tumorâ€“immune symbiosis in glioblastoma. Trends in Pharmacological Sciences, 2022, 43, 686-700.	4.0	15
1518	An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors. Clinical Cancer Research, 2022, 28, 3053-3065.	3.2	26
1519	NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer. , 2022, 10, e004569.		5
1520	Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies. Wiener Klinische Wochenschrift, 2022, 134, 654-674.	1.0	7
1521	Role of CD68 in tumor immunity and prognosis prediction in pan-cancer. Scientific Reports, 2022, 12, 7844.	1.6	22
1522	Altered glycosylation in pancreatic cancer and beyond. Journal of Experimental Medicine, 2022, 219, .	4.2	27
1523	Advancements on Small Molecule PROTACs Containing an Indole/Spiro-fused Oxoindole Scaffolds: An Emerging Degrader Targeting Cancers. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, .	0.9	0

#	Article	IF	Citations
1524	Intratumoral delivery of a novel oncolytic adenovirus encoding human antibody against PD-1 elicits enhanced antitumor efficacy. Molecular Therapy - Oncolytics, 2022, 25, 236-248.	2.0	9
1525	Nanomedicine as a magic bullet for combating lymphoma. Journal of Controlled Release, 2022, 347, 211-236.	4.8	6
1526	Engineered bacterial membrane vesicles are promising carriers for vaccine design and tumor immunotherapy. Advanced Drug Delivery Reviews, 2022, 186, 114321.	6.6	36
1527	Optochemical Control of Immune Checkpoint Blockade via Lightâ€Triggered PDâ€L1 Dimerization. Advanced NanoBiomed Research, 2022, 2, .	1.7	4
1528	Advances in the study of <scp>CD47</scp>â€based bispecific antibody in cancer immunotherapy. Immunology, 2022, 167, 15-27.	2.0	15
1529	Synergy of a STING agonist and an IL-2 superkine in cancer immunotherapy against MHC Iâ€“deficient and MHC I ⁺ tumors. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2200568119.	3.3	20
1530	Cancer Immunoediting in the Era of Immuno-oncology. Clinical Cancer Research, 2022, 28, 3917-3928.	3.2	31
1531	Cytotoxic innate lymphoid cells sense cancer cell-expressed interleukin-15 to suppress human and murine malignancies. Nature Immunology, 2022, 23, 904-915.	7.0	39
1532	Research progress of photothermal-mediated immunotherapy in the prevention of tumor recurrence and metastases. Journal of Nanoparticle Research, 2022, 24, .	0.8	1
1533	Overcoming immunotherapeutic resistance in PDAC: SIRPÎ±-CD47 blockade. Pharmacological Research, 2022, 181, 106264.	3.1	4
1534	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. , 2022, 10, e003956.		16
1535	Uroplakin II as a single marker for luminal versus basal molecular subtypes in muscle invasive urothelial carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 397-403.	1.4	2
1536	Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors. Nature Cancer, 2022, 3, 808-820.	5.7	21
1537	New Targets for Antiviral Therapy: Inhibitory Receptors and Immune Checkpoints on Myeloid Cells. Viruses, 2022, 14, 1144.	1.5	0
1538	Pathological Response and Immune Biomarker Assessment in Non-Small-Cell Lung Carcinoma Receiving Neoadjuvant Immune Checkpoint Inhibitors. Cancers, 2022, 14, 2775.	1.7	5
1540	Injectable DNA Hydrogel-Based Local Drug Delivery and Immunotherapy. Gels, 2022, 8, 400.	2.1	11
1541	Application and prospect of single-cell sequencing in cancer metastasis. Future Oncology, 2022, 18, 2723-2736.	1.1	2
1542	BHLHE22 Expression Is Associated with a Proinflammatory Immune Microenvironment and Confers a Favorable Prognosis in Endometrial Cancer. International Journal of Molecular Sciences, 2022, 23, 7158.	1.8	2

#	Article	IF	Citations
1543	Bv8 Blockade Sensitizes Anti-PD1 Therapy Resistant Tumors. Frontiers in Immunology, 0, 13, .	2.2	0
1544	Self-Assembly of a Multifunction DNA Tetrahedron for Effective Delivery of Aptamer PL1 and Pcsk9 siRNA Potentiate Immune Checkpoint Therapy for Colorectal Cancer. ACS Applied Materials & Interfaces, 2022, 14, 31634-31644.	4.0	23
1545	Research progress of <scp>PDâ€L1</scp> nonâ€glycosylation in cancer immunotherapy. Scandinavian Journal of Immunology, 2022, 96, .	1.3	2
1546	Recent Progress and Future Perspectives of Immunotherapy in Advanced Gastric Cancer. Frontiers in Immunology, 0, 13, .	2.2	27
1547	An M0 macrophage-related prognostic model for hepatocellular carcinoma. BMC Cancer, 2022, 22, .	1.1	24
1548	Aiphanol, a multi-targeting stilbenolignan, potently suppresses mouse lymphangiogenesis and lymphatic metastasis. Acta Pharmacologica Sinica, 0, , .	2.8	2
1549	Self-Activated Cascade Biocatalysis of Glucose Oxidaseâ€“Polycationâ€“Iron Nanoconjugates Augments Cancer Immunotherapy. ACS Applied Materials & Interfaces, 2022, 14, 32823-32835.	4.0	7
1550	Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression. Journal of Controlled Release, 2022, 348, 893-910.	4.8	41
1551	Myeloid derived suppressor cells and innate immune system interaction in tumor microenvironment. Life Sciences, 2022, 305, 120755.	2.0	11
1553	Human Variation in DNA Repair, Immune Function, and Cancer Risk. Frontiers in Immunology, 0, 13, .	2.2	4
1554	The expression pattern of Immune checkpoints after chemo/radiotherapy in the tumor microenvironment. Frontiers in Immunology, 0, 13, .	2.2	2
1555	The Role of HDACs in the Response of Cancer Cells to Cellular Stress and the Potential for Therapeutic Intervention. International Journal of Molecular Sciences, 2022, 23, 8141.	1.8	15
1556	The immunoregulation effect of tumor microenvironment in pancreatic ductal adenocarcinoma. Frontiers in Oncology, 0, 12, .	1.3	5
1557	<scp>ITGB1</scp> as a prognostic biomarker correlated with immune suppression in gastric cancer. Cancer Medicine, 2023, 12, 1520-1531.	1.3	12
1558	Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors. Hormone and Metabolic Research, 2022, 54, 795-812.	0.7	1
1560	A Fc-VEGF chimeric fusion enhances PD-L1 immunotherapy via inducing immune reprogramming and infiltration in the immunosuppressive tumor microenvironment. Cancer Immunology, Immunotherapy, 2023, 72, 351-369.	2.0	6
1561	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer. , 2022, 10, e004434.		14
1562	Single-cell atlas of diverse immune populations in the advanced biliary tract cancer microenvironment. Npj Precision Oncology, 2022, 6, .	2.3	5

#	Article	IF	Citations
1563	Lysosomal acid lipase, CSF1R, and PD-L1 determine functions of CD11c+ myeloid-derived suppressor cells. JCI Insight, 2022, 7, .	2.3	9
1564	Upregulated PD-1 signaling antagonizes glomerular health in aged kidneys and disease. Journal of Clinical Investigation, 2022, 132, .	3.9	20
1565	Highly Sensitive Detection of the Immune Checkpoint PD-L1-Positive Circulating Tumor Cells Based on Steric Hindrance. Analytical Chemistry, 2022, 94, 11767-11772.	3.2	7
1566	The nomogram for the prediction of overall survival in patients with metastatic lung adenocarcinoma undergoing primary site surgery: A retrospective population-based study. Frontiers in Oncology, 0, 12, .	1.3	2
1567	Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer. International Journal of Molecular Sciences, 2022, 23, 8878.	1.8	5
1568	Inhibition of Melanoma Cellâ€“Intrinsic Tim-3 Stimulates MAPK-Dependent Tumorigenesis. Cancer Research, 2022, 82, 3774-3784.	0.4	7
1569	Eosinophilâ€“lymphocyte interactions in the tumor microenvironment and cancer immunotherapy. Nature Immunology, 2022, 23, 1309-1316.	7.0	39
1570	Schweinfurthin induces ICD without ER stress and caspase activation. OncoImmunology, 2022, 11, .	2.1	5
1571	A Smart Silkâ€Based Microneedle for Cancer Stem Cell Synergistic Immunity/Hydrogen Therapy. Advanced Functional Materials, 2022, 32, .	7.8	18
1572	The emerging roles of HDACs and their therapeutic implications in cancer. European Journal of Pharmacology, 2022, 931, 175216.	1.7	27
1573	Intratumoral xenogeneic tissue-specific cell immunotherapy inhibits tumor growth by increasing antitumor immunity in murine triple negative breast and pancreatic tumor models. Cancer Letters, 2022, 545, 115478.	3.2	8
1574	A novel prognostic index of stomach adenocarcinoma based on immunogenomic landscape analysis and immunotherapy options. Experimental and Molecular Pathology, 2022, 128, 104832.	0.9	11
1575	Role of tumor cell sialylation in pancreatic cancer progression. Advances in Cancer Research, 2023, , 123-155.	1.9	6
1576	Epigenetic Mediated Regulation of Cancer-Testis/Germline Antigen and Its Implication in Cancer Immunotherapy: A Treasure Map for Future Anticipatory Medicine. Cognitive Systems Monographs, 2022, , 149-166.	0.1	0
1577	Impact of CTLA-4 checkpoint antibodies on ligand binding and Transendocytosis. Frontiers in Immunology, 0, 13, .	2.2	2
1578	Structural Basis of a Novel Agonistic Anti-OX40 Antibody. Biomolecules, 2022, 12, 1209.	1.8	2
1579	Bioinformatics analysis of immune infiltrates and tripartite motif (TRIM) family genes in hepatocellular carcinoma. Journal of Gastrointestinal Oncology, 2022, 13, 1942-1958.	0.6	5
1580	Cancer cell membrane-wrapped nanoparticles for cancer immunotherapy: A review of current developments. Frontiers in Immunology, 0, 13, .	2.2	6

#	Article	IF	Citations
1581	Local administration of large surface area microparticle docetaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects: preclinical and clinical studies. Drug Delivery and Translational Research, 2023, 13, 503-519.	3.0	5
1582	Immunotherapy in advanced kidney cancer: an alternative meta-analytic method using reconstructed survival data in case of proportional hazard assumption violation. Frontiers in Oncology, 0, 12, .	1.3	3
1584	Development and verification of an immune-related gene prognostic index for gastric cancer. Scientific Reports, 2022, 12, .	1.6	3
1585	Thyroid Hormone Induces Oral Cancer Growth via the PD-L1-Dependent Signaling Pathway. Cells, 2022, 11, 3050.	1.8	2
1586	Exploring the oncogenic roles of LINC00857 in pan-cancer. Frontiers in Pharmacology, 0, 13, .	1.6	0
1587	Identification of Novel Immunologic Checkpoint Gene Prognostic Markers for Ovarian Cancer. Journal of Oncology, 2022, 2022, 1-18.	0.6	2
1588	The new progress in cancer immunotherapy. Clinical and Experimental Medicine, 2023, 23, 553-567.	1.9	6
1589	Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma. Cancers, 2022, 14, 4616.	1.7	18
1590	Exploiting the Innate Plasticity of the Programmed Cell Deathâ€1 (PD1) Receptor to Design Pembrolizumab H3 Loop Mimics**. ChemBioChem, 2022, 23, .	1.3	4
1591	Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	33
1592	Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy. , 2022, 10, e005020.		12
1593	ACBP/DBI protein neutralization confers autophagy-dependent organ protection through inhibition of cell loss, inflammation, and fibrosis. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	13
1594	Immunotherapy-based novel nanoparticles in the treatment of gastrointestinal cancer: Trends and challenges. World Journal of Gastroenterology, 0, 28, 5403-5419.	1.4	4
1595	An improved cell line-derived xenograft humanized mouse model for evaluation of PD-1/PD-L1 blocker BMS202-induced immune responses in colorectal cancer. Acta Biochimica Et Biophysica Sinica, 2022, 54, 1497-1506.	0.9	2
1596	Molecular Taxonomy and Immune Checkpoint Therapy in Bladder Cancer. Surgical Pathology Clinics, 2022, 15, 681-694.	0.7	2
1598	Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy. Cancer Cell, 2022, 40, 1374-1391.e7.	7.7	41
1599	Tissueâ€resident CD69⁺CXCR6⁺ Natural Killer cells with exhausted phenotype accumulate in human nonâ€small cell lung cancer. European Journal of Immunology, 2022, 52, 1993-2005.	1.6	3
1600	Tumor-associated macrophages expressing the transcription factor IRF8 promote TÂcell exhaustion in cancer. Immunity, 2022, 55, 2044-2058.e5.	6.6	53

#	Article	IF	Citations
1601	Advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnology. Frontiers in Immunology, 0, 13, .	2.2	2
1602	Efficacy of PD-1/PD-L1 inhibitors in patients with advanced gastroesophageal cancer: An updated meta-analysis based on randomized controlled trials. Frontiers in Pharmacology, 0, 13, .	1.6	3
1603	Using machine learning and RNA to enhance the efficacy of anti-tumor immunotherapy. Evolutionary Intelligence, 0, , .	2.3	0
1604	Identification of a novel ceRNA network related to prognosis and immunity in HNSCC based on integrated bioinformatic investigation. Scientific Reports, 2022, 12, .	1.6	1
1605	Tumor microenvironment-mediated immune tolerance in development and treatment of gastric cancer. Frontiers in Immunology, 0, 13, .	2.2	23
1609	Leverage biomaterials to modulate immunity for type 1 diabetes. Frontiers in Immunology, 0, 13, .	2.2	1
1610	Metabolic activation of drugs by cytochrome P450 enzymes: Biochemical insights into mechanism-based inactivation by fibroblast growth factor receptor inhibitors and chemical approaches to attenuate reactive metabolite formation. Biochemical Pharmacology, 2022, 206, 115336.	2.0	3
1611	Targeting myeloid suppressive cells revives cytotoxic anti-tumor responses in pancreatic cancer. IScience, 2022, 25, 105317.	1.9	10
1612	Peripheral blood lymphocyte subsets are associated with the clinical outcomes of prostate cancer patients. International Immunopharmacology, 2022, 113, 109287.	1.7	6
1613	HDAC/JAK dual target inhibitors of cancer-related targets: The success of nonclearable linked pharmacophore mode. Bioorganic Chemistry, 2022, 129, 106181.	2.0	4
1614	Cancer-cell-intrinsic mechanisms shaping the immunosuppressive landscape of prostate cancer. Asian Journal of Andrology, 2023, 25, 171.	0.8	3
1615	High-level of intratumoral GITR+ CD4 TÂcells associate with poor prognosis in gastric cancer. IScience, 2022, 25, 105529.	1.9	4
1616	Cascade Immune Activation of Selfâ€Đelivery Biomedicine for Photodynamic Immunotherapy Against Metastatic Tumor. Small, 2023, 19, .	5.2	13
1617	Adjuvant therapy options in renal cell carcinoma â€" targeting the metastatic cascade. Nature Reviews Urology, 2023, 20, 179-193.	1.9	4
1618	Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors. Npj Breast Cancer, 2022, 8, .	2.3	30
1619	Blockade of the immunosuppressive KIR2DL5/PVR pathway elicits potent human NK cellâ€"mediated antitumor immunity. Journal of Clinical Investigation, 2022, 132, .	3.9	14
1620	The effect of neoadjuvant chemotherapy on the tumor immune microenvironment in gastrointestinal tumors. Frontiers in Oncology, 0, 12, .	1.3	1
1621	Aging tumour cells to cure cancer: â€œpro-senescenceâ€•therapy for cancer. Swiss Medical Weekly, 2017, 147, w14367.	0.8	22

#	Article	IF	Citations
1622	Estimation of Tumor Immune Signatures from Transcriptomics Data. Springer Handbooks of Computational Statistics, 2022, , 311-338.	0.2	0
1623	Interdisciplinary Approach in Genitourinary Cancers. , 2022, , .		0
1624	Nanoparticle-Delivered Transforming Growth Factor-Î²1 siRNA Induces PD-1 against Gastric Cancer by Transforming the Phenotype of the Tumor Immune Microenvironment. Pharmaceuticals, 2022, 15, 1487.	1.7	2
1625	Targeting PIM Kinases to Improve the Efficacy of Immunotherapy. Cells, 2022, 11, 3700.	1.8	4
1626	Coagulation- and fibrinolysis-related genes for predicting survival and immunotherapy efficacy in colorectal cancer. Frontiers in Immunology, 0, 13, .	2.2	5
1628	Discovery and Chemical Development of Uvelostinag (MK-1454): A Therapeutic Cyclic Dinucleotide Agonist of the Stimulator of Interferon Gene. ACS Symposium Series, 0, , 1-94.	0.5	0
1629	Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates. International Journal of Molecular Sciences, 2023, 24, 41.	1.8	6
1630	Mutant and non-mutant neoantigen-based cancer vaccines: recent advances and future promises. Exploration of Targeted Anti-tumor Therapy, 0, , 746-762.	0.5	0
1631	Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer. Journal of Clinical Medicine, 2022, 11, 7523.	1.0	1
1632	Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer. Cancers, 2022, 14, 6034.	1.7	6
1633	Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors. Journal of Immunotherapy and Precision Oncology, 2023, 6, 31-49.	0.6	1
1634	Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80. Nature Cancer, 2022, 3, 1513-1533.	5.7	20
1635	Tumor-intrinsic IRE1Î± signaling controls protective immunity in lung cancer. Nature Communications, 2023, 14, .	5.8	11
1636	Research Progress of LAG-3 in the Diagnosis and Treatment of Microsatellite Instability High-Frequency Colon Cancer. Advances in Clinical Medicine, 2022, 12, 12184-12190.	0.0	0
1637	Configuring Therapeutic Aspects of Immune Checkpoints in Lung Cancer. Cancers, 2023, 15, 543.	1.7	8
1638	Progress in the application of hydrogels in immunotherapy of gastrointestinal tumors. Drug Delivery, 2023, 30, .	2.5	5
1639	Phytochemical Constituents and Derivatives of Cannabis sativa; Bridging the Gap in Melanoma Treatment. International Journal of Molecular Sciences, 2023, 24, 859.	1.8	8
1640	TLR5 agonists enhance anti-tumor immunity and overcome resistance to immune checkpoint therapy. Communications Biology, 2023, 6, .	2.0	5

#	Article	IF	Citations
1641	Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy. Journal of Clinical Investigation, 2023, 133, .	3.9	57
1643	Preclinical Evaluation of a Novel Small Molecule LCC-21 to Suppress Colorectal Cancer Malignancy by Inhibiting Angiogenic and Metastatic Signatures. Cells, 2023, 12, 266.	1.8	0
1646	Passive Membrane Permeability of Sizable Acyclic Î²-Hairpin Peptides. ACS Medicinal Chemistry Letters, 2023, 14, 278-284.	1.3	1
1647	Yin and yang roles of B lymphocytes in solid tumors: Balance between antitumor immunity and immune tolerance/immunosuppression in tumor-draining lymph nodes. Frontiers in Oncology, 0, 13, .	1.3	2
1648	Biomaterials tools to modulate the tumour microenvironment in immunotherapy. , 2023, 1, 125-138.		34
1649	Construction of a novel TROP2/CD3 bispecific antibody with potent antitumor activity and reduced induction of Th1 cytokines. Protein Expression and Purification, 2023, 205, 106242.	0.6	1
1650	Role of nanotechnology in cancer therapies: recent advances, current issues, and approaches. , 2023, , 73-95.		0
1651	Synthesis, characterization, and investigation photophysicochemical properties of axially 2-hydroxymethyl-1,4-benzodioxan di-substituted Silicon(IV) phthalocyanine. Journal of Organometallic Chemistry, 2023, 990, 122661.	0.8	3
1652	â€œTo be or not to Beâ€• Regulatory T cells in melanoma. International Immunopharmacology, 2023, 118, 110093.	1.7	3
1653	Polysaccharides from marine resources exhibit great potential in the treatment of tumor: A review. Carbohydrate Polymer Technologies and Applications, 2023, 5, 100308.	1.6	1
1654	Acute inflammatory reaction during anti-angiogenesis therapy combined with immunotherapy as a possible indicator of the therapeutic effect: Three case reports and literature review. Frontiers in Oncology, 0, 13, .	1.3	0
1655	Autophagy Paradox: Strategizing Treatment Modality in Melanoma. Current Treatment Options in Oncology, 2023, 24, 130-145.	1.3	4
1656	Tumor Cell Nanovaccines Based on Genetically Engineered Antibodyâ€Anchored Membrane. Advanced Materials, 2023, 35, .	11.1	10
1657	Singleâ€Cell Landscape Highlights Heterogenous Microenvironment, Novel Immune Reaction Patterns, Potential Biomarkers and Unique Therapeutic Strategies of Cervical Squamous Carcinoma, Human Papillomavirusâ€Associated (HPVA) and Nonâ€HPVA Adenocarcinoma. Advanced Science, 2023, 10, .	5.6	6
1658	The <scp>CTLA</scp>â€4 immune checkpoint protein regulates <scp>PDâ€L1</scp>:<scp>PD</scp>â€1 interaction via transendocytosis of its ligand <scp>CD80</scp>. EMBO Journal, 2023, 42, .	3.5	7
1660	Engineering nanoparticles boost TNBC therapy by CD24 blockade and mitochondrial dynamics regulation. Journal of Controlled Release, 2023, 355, 211-227.	4.8	9
1661	Tumor-infiltrating lymphocytes for melanoma immunotherapy. OncoImmunology, 2023, 12, .	2.1	2
1662	Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis. BMC Cancer, 2023, 23, .	1.1	4

#	Article	IF	Citations
1663	Dual blockage of both PD-L1 and CD47 enhances the therapeutic effect of oxaliplatin and FOLFOX in CT-26 mice tumor model. Scientific Reports, 2023, 13, .	1.6	3
1664	Thermoâ€pHâ€Sensitive Polymer Conjugated Glucose Oxidase for Tumorâ€Selective Starvationâ€Oxidationâ€Immune Therapy. Advanced Materials, 2023, 35, .	11.1	7
1665	Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis. Frontiers in Pharmacology, 0, 14, .	1.6	0
1666	Immunoregulation by resveratrol; implications for normal tissue protection and tumour suppression. Clinical and Experimental Pharmacology and Physiology, 2023, 50, 353-368.	0.9	16
1667	Identification of CBPA as a New Inhibitor of PD-1/PD-L1 Interaction. International Journal of Molecular Sciences, 2023, 24, 3971.	1.8	4
1668	Systems Biology Approaches for the Improvement of Oncolytic Virus-Based Immunotherapies. Cancers, 2023, 15, 1297.	1.7	4
1669	Acquired radioresistance in EMT6 mouse mammary carcinoma cell line is mediated by CTLA-4 and PD-1 through JAK/STAT/PI3K pathway. Scientific Reports, 2023, 13, .	1.6	1
1670	Positive Correlation between PMS2 Deficiency and PD-L1 Expression in Pancreatic Cancer. Advances in Bioscience and Biotechnology (Print), 2023, 14, 74-90.	0.3	0
1671	Toward the establishment of guidelines for the treatment of steroidâ€refractory immuneâ€related hepatotoxicity. JGH Open, 2023, 7, 85-86.	0.7	0
1672	Mechanisms of Antitumor Invasion and Metastasis of the Marine Fungal Derivative Epi-Aszonalenin A in HT1080 Cells. Marine Drugs, 2023, 21, 156.	2.2	0
1673	Current and emerging therapeutic strategies in adult T-cell leukemiaâ€“lymphoma. International Journal of Hematology, 2023, 117, 512-522.	0.7	6
1674	Harnessing the power of memory-like NK cells to fight cancer. Clinical and Experimental Immunology, 2023, 212, 212-223.	1.1	1
1675	Co-delivery of PDL1-blocking scFv and chemotherapeutics using engineered exosomes for cancer therapy. Journal of Drug Delivery Science and Technology, 2023, 82, 104337.	1.4	3
1676	ICI efficacy information portal: a knowledgebase for responder prediction to immune checkpoint inhibitors. NAR Cancer, 2023, 5, .	1.6	0
1677	T cell effects and mechanisms in immunotherapy of head and neck tumors. Cell Communication and Signaling, 2023, 21, .	2.7	4
1678	Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort. JHEP Reports, 2023, 5, 100719.	2.6	10
1679	Defining the Emergence of New Immunotherapy Approaches in Breast Cancer: Role of Myeloid-Derived Suppressor Cells. International Journal of Molecular Sciences, 2023, 24, 5208.	1.8	4
1680	Bispecific GPC3/PDâ€1 CARâ€T cells for the treatment of HCC. International Journal of Oncology, 2023, 62, .	1.4	4

#	Article	IF	Citations
1681	LAL deficiency induced myeloid-derived suppressor cells as targets and biomarkers for lung cancer. , 2023, 11, e006272.		2
1682	Immune checkpoint inhibitors in metastatic NSCLC: challenges and future directions (CME article). International Journal of Cancer Care and Delivery, 2023, 3, .	0.0	0
1683	Exosome-derived circCCAR1 promotes CD8â€‰+â€‰T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma. Molecular Cancer, 2023, 22, .	7.9	47
1684	Immunotherapies for advanced hepatocellular carcinoma. Frontiers in Pharmacology, 0, 14, .	1.6	4
1685	The link between intracellular calcium signaling and exosomal PD-L1 in cancer progression and immunotherapy. Genes and Diseases, 2024, 11, 321-334.	1.5	5
1686	Visual analysis of global research on immunotherapy for gastric cancer: A literature mining from 2012 to 2022. Human Vaccines and Immunotherapeutics, 2023, 19, .	1.4	4
1687	Ferroptosis Signature Shapes the Immune Profiles to Enhance the Response to Immune Checkpoint Inhibitors in Head and Neck Cancer. Advanced Science, 2023, 10, .	5.6	7
1688	Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers. Advances in Anatomic Pathology, 2023, 30, 174-194.	2.4	0
1690	Immune Checkpoint Inhibitors and Long-term Survival of Patients With Metastatic Urothelial Cancer. JAMA Network Open, 2023, 6, e237444.	2.8	5
1692	Immune checkpoint therapyâ€”current perspectives and future directions. Cell, 2023, 186, 1652-1669.	13.5	114
1693	Targeting CXCL16 and STAT1 augments immune checkpoint blockade therapy in triple-negative breast cancer. Nature Communications, 2023, 14, .	5.8	6
1694	Current Medicinal Insights on Synthetic Small Molecules and Natural Origin Products as PD-1/PD-L1 Inhibitors. Current Topics in Medicinal Chemistry, 2023, 23, .	1.0	0
1695	MYC Induces Immunotherapy and IFNÎ³ Resistance Through Downregulation of JAK2. Cancer Immunology Research, 2023, 11, 909-924.	1.6	1
1700	The Changing Fortune of Cancer Immunotherapy. , 2017, , 97-125.		0
1738	Cancer Vaccines. , 2023, , 191-210.e9.		0
1765	Immune checkpoint targeting antibodies hold promise for combinatorial cancer therapeutics. Clinical and Experimental Medicine, 2023, 23, 4297-4322.	1.9	2
1771	Targeting immune checkpoints for cancer therapy. , 2023, , 95-134.		0
1803	Understanding immune checkpoints and PD-1/PD-L1-mediated immune resistance towards tumour immunotherapy. 3 Biotech, 2023, 13, .	1.1	0

#	Article	IF	Citations
1808	Effects of Chemotherapy on the Immune System: Implications for Cancer Treatment and Patient Outcomes. Naunyn-Schmiedeberg's Archives of Pharmacology, 0, , .	1.4	1
1826	Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks. Cell Death and Disease, 2024, 15, .	2.7	0
1846	Unlocking the â€˜ovaâ€™-coming power: immunotherapyâ€™s role in shaping the future of ovarian cancer treatment. , 2024, 41, .		0